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Abstract 
 
The NMDA receptor is a highly diverse receptor with many functions. In particular 
NMDA receptors present on postsynaptic spines mediate the effects of the synaptic 
neurotransmitter glutamate, whilst NMDA receptors present on presynaptic nerve 
terminals directly regulate the release of neurotransmitters. The aim of this thesis 
was to expand the characterisation of these two populations of NMDA receptors 
by examining the functional role of the co-agonist binding sites. NMDA receptors 
have been strongly implicated in mechanisms of cognition and also the 
pathophysiology epilepsy and so I have focused my study in the entorhinal cortex 
which is an area increasingly seen to be central to both of these phenomenon. 
  
Initial work focussed on the endogenous regulation of the presynaptic NMDA 
receptors. My results indicated that the co-agonist site of these receptors was 
activated by D-serine and that this ligand may come from astrocytes, in contrast to 
the observations that others have made for postsynaptic NMDA receptors. 
Following this, I then characterised the effects of partial agonists of the NMDA 
receptor co-agonist site at each of these populations of NMDA receptors and report 
differential effects for the function of these receptors. Finally I then examined the 
effects of the co-agonist site ligands on epileptiform activity as a simple form of 
emergent neuronal network activity. Results from my study of co-agonist site 
ligands provide important new insights into the relationship between NMDA 
receptors and neuronal synchrony and also the mechanism of cognitive 
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1.1 Synaptic Transmission 
 
In the late 19th century, Santiago Ramon y Cajal used the recently invented Golgi 
stain to demonstrate that whilst varying in shape, all neurones consist of a cell 
body (or ‘soma’) that contains the nucleus, an axon and dendrites. Neuronal 
membranes are perforated by ion pumps, exchangers and channels that maintain a 
difference in the concentration of the principal ions between the intracellular and 
extracellular environments. When activated, ligand-gated ion channels open 
allowing ions to flow through the channel pore according to their electrochemical 
gradient, producing a change in conductance and activation of second messenger 
pathways. Such changes in conductance can lead to an action potential, a large 
depolarisation which propagates throughout the neurone due to sequential opening 
of voltage gated sodium channels. 
 
Neurones can interact with each other directly by gap junctions but more 
commonly by synapses. When the action potential reaches a synapse, voltage-
gated calcium channels in the presynaptic terminal (the bouton or variscosity) are 
activated and calcium flows in triggering exocytosis of vesicles containing a 
neurotransmitter. The neurotransmitter then diffuses across the synaptic cleft and 
binds to receptors present on the spine of the postsynaptic cell to elicit an excitation 
or an inhibition. Released neurotransmitters also commonly act on receptors on 
the presynaptic terminal to produce a feedback loop and they are removed from 
the cleft either by degradation or by reuptake back into neurones or into glial cells. 
Typically, an action potential ignites at the excitable, initial portion of the axon 
and travels down the axon to signal other neurones and also ‘back-propagates’ to 
its own dendrites. Excitatory neurones or ‘principal cells’ are predominantly 
glutamatergic and exhibit diverse connectivity, inhibitory neurones or 
interneurones are predominantly GABAergic and typically have local 
connectivity, providing feedback and feedforward inhibition.  
 
In the 1950s, Katz and colleagues utilised intracellular recordings from muscle 
fibres at the neuromuscular junction in frogs observing that without nervous 
activity small depolarisations were observable, occurring at random but with a 
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constant probability. Interestingly when the calcium concentration was lowered 
the size of evoked synaptic responses decreased and the probability, but not size, 
of these spontaneous potentials decreased. Furthermore, the evoked responses 
were seen to increment in steps about the size of these spontaneous events further 
indicating that these events represent a minimum quantity of release, and these 
were termed ‘quanta’ (see Del Castillo and Katz, 1954). Later it was shown that a 
quantum corresponds to the neurotransmitter contained within one vesicle (Heuser 
et al, 1979).  
 
At synapses between neurones the situation is complicated by the amount of 
synapses occurring at varying positions and the smaller size of potentials which 
may not be separable from background noise. The lower access-resistance granted 
by patch clamp recording is useful to increase the signal to noise ratio and this 
technique also allows the neurone to be voltage clamped, allowing direct 
observation of spontaneous currents. The physiological function of these synaptic 
events remains unclear though it may be that they represent a synaptic noise which 
enhances transmission via stochastic resonance or that they are important for the 
development and maintenance of synapses (see Greenhill et al, 2014). Important 
here though, is that they provide a selective substrate for the investigation of 
transmitter release. 
  
1.2 The Entorhinal Cortex  
 
The brain consists of the brainstem (the medulla, pons, cerebellum and midbrain) 
the diencephalon (thalamus and hypothalamus) and the telencephalon (limbic 
system, basal and cerebral cortex). The cerebral cortex can be spatially divided 
broadly into four lobes – frontal, parietal, temporal and occipital and the functions 
of the cortex can be characterised as sensory, motor or associative. The cortex is 
made up mainly of layered neurones (lamina) and ninety percent of the cortex is 
neocortex, containing six layers (or having six layers during development) of 
which layer 4 is the main input layer and layer 5 is the main output layer. Neurones 
are also lined up with the neurones above and below forming functional columns. 
The entorhinal cortex (EC) is a non-neocortical region of the cortex located in the 
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temporal lobe curved around the rostral surface of the hippocampus (part of the 
limbic system; see. Fig. 1.2) and acts as the gateway to this structure. The EC can 
also be divided into 6 layers though it lacks a true cellular layer 4. The intrinsic 
connectivity and laminar differences in principal cell types are depicted in Fig. 1.1. 
Projections to the hippocampus originate predominantly from layers 2 and 3 whilst 
projections both to and from the neocortex are largely by layer 5 (see Van Strien 














Fig. 1.1. Connectivity of the EC. The above diagram depicts the extrinsic 
connectivity of the medial EC. Neocortical input is largely to the superficial layers 
and layers II and III project to the hippocampal trisynaptic loop whilst hippocampal 
input and neocortical output is largely through layer V. The below diagram 
indicates the different cell types and morphology of each layer of the medial EC, 
along with their intrinsic connectivity (from van Haeften et al., 2003). Principal 
cells are largely pyramidal in layers III and V and stellate in layer II and exhibit 
high interconnectivity whilst inhibitory control is more pronounced in the 
superficial layers 
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1.2.1 The EC in cognition 
 
Historically, two people were instrumental in linking the temporal lobe to memory. 
The first was Wilder Penfield, a surgeon who electrically stimulated parts of the 
cortex during brain surgery and found that when the temporal lobe was stimulated, 
patients described experiencing recollections of past experiences. The second is 
the famous patient H.M. who underwent a bilateral medial temporal lobe resection 
which resulted in extreme anterograde amnesia for declarative memory. This was 
significant in that H.M. retained all other cognitive functions, indicating that 
memory formation is a distinct process whilst the selective nature of his surgery 
indicated that declarative memory formation (but not long-term storage) is 
dependent on the temporal lobe. Imaging and lesion studies have subsequently 
indicated that the hippocampus and the associated cortical regions, particularly the 
EC, are the key elements of this memory system (Roof et al, 1993; Glasier et al, 
1995; Cho and Jaffard, 1995; Kopniczky et al, 2006; Ranganath et al, 2004; Zola-
Morgan et al, 1993; Maass et al, 2014). The EC is now believed to be highly 
important as the site of interaction with the hippocampus, directly mediating input-
output with the neocortex and it may provide pre- and post-hippocampal 
information processing through its intrinsic connectivity (Eichenbaum, 2001; 
Squire et al, 2004; Dickerson and Eichenbaum, 2010). 
 
Whilst technology has allowed cognition to be efficiently examined on the 
anatomical level, the functional understanding of cognition is highly limited, 
though some observable phenomena on both the synaptic and network levels are 
thought to be important. The neuronal network is a complex system and network 
activity is emergent. Emergence is a common but fascinating concept describing a 
new structure with new properties and organisation, arising from the self-
organisation of another and may also account for Newtonian physics (which 
govern the brain), social structures and possibly even the conscious mind (see 
Gazzaniga et al, 2008). In a neuronal ensemble, activity alternates between 
complex and oscillatory/’rhythmic’ behaviour. Rhythmic activity is highly 
dependent on principal cell-interneurone dynamics and can be of several possible 
frequency bands, which have a natural logarithmic ratio meaning they cannot 
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synchronise phases and undergo perpetual complex interactions. These 
oscillations can be correlated to different thinking states, and the frequency of an 
oscillation is thought to correspond to the length of a temporal processing window 
whereby information is integrated and/or propagated (see Buzsaki, 2006).  
 
On the synaptic level, the ability for the future strength of transmission to change 
in response to activity, termed synaptic plasticity, is thought to represent the 
cellular basis of memory. In 1949 Donald Hebb postulated that if synapses 
strengthened in response to strong activity then the original pattern of stimulated 
synapses would become auto-associated forming an ‘engram’ which could easily 
be re-iterated by a later stimulus. Broadly, Hebb’s mechanism represents a 
conceptually sound schematic and has been supported by studies demonstrating 
mutual molecular dependencies of synaptic plasticity and memory (see Bear et al, 
2007). However, the details of the engram and how it relates to computation by 
networks is unclear.  
 
Fig. 1.2. The medial temporal lobe memory system in monkeys and rats (from 
Dickerson and Eichenbaum, 2010). Information from areas of the neocortex (blue) 
flows to, and converging in, the perirhinal cortex (purple), the parahippocampal cortex 
(dark purple), and the entorhinal cortex (light purple). Information from these 
interconnected areas leaves for the hippocampus from the entorhinal cortex, this 
pathway is known as the perforant path. Information is processed in the hippocampus 
and flows to the neocortex in a reversed manner. The parahippocampal region is 
located in the temporal lobe in primates but beneath the cortex in rodents. 
 
Chapter One  Introduction 
7 
Co-agonist Regulation of Pre and Postsynaptic NMDA Receptors in the Entorhinal Cortex 
Recently, the hippocampus and EC have been focussed on for their role in spatial 
navigation, which was originally discovered by the observation of hippocampal 
place cell which fire when a rat enters a certain part of its environment (O’keefe, 
1978). Later, grid cells were identified in the EC, occurring predominantly in layer 
2 (Hafting et al, 2005). These cells fire according to location according to a 
triangular grid and in doing so have the capacity to collectively represent the 
environment as Euclidean space. Though many discuss these regions as being a 
solely memory or navigation system, it is likely that a novel way of thinking which 
encompasses both functions is needed (Millivojevic and Doeller, 2013; 
Eichenbaum and Cohen, 2014). In their review, Buzsaski and Moser (2013) 
discussed several parallels between declarative memory and navigation, indicating 
the possibility that these share a fundamental mechanism. It is reasoned that many 
animals achieve navigation with much simpler systems but that the 
representational capacity of this system may have provided a substrate for the 
evolution of memory. Furthermore the EC has also been implicated in disorders of 
cognition including Alzheimer’s disease (Stranahan and Mattson, 2010) and 
Schizophrenia (Prasad et al, 2004).  
 
1.2.2 The EC in epilepsy 
 
The EC also appears to be important in the pathology of epilepsy. Epilepsy is a 
clinically diverse disease characterised by recurrent and unprovoked seizures. It 
can be caused by genetic mutations, developmental disorders/ abnormalities or by 
an insult to the brain, mechanical or other, which is typically followed by a seizure 
free latent period before epilepsy develops. Seizures are periods of abnormal 
synchronous neuronal excitation and in epilepsy typically are of the scale of 
seconds or minutes or can be continuous in status epilepticus, and may or may not 
involve muscular convulsions. There is no known consistent mechanism for 
epilepsy apart from in the broadest sense that the normal balancing of neuronal 
excitation and inhibition is perturbed. Such perturbations could initiate on the level 
of ions, neurones, synapses or networks (Scharfman, 2007) but the diversity of 
epilepsy and its treatment, even within specific forms, suggests that unifying 
schematics may not be possible. Treatments for epilepsy typically act broadly to 
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redress the balance of excitation and inhibition. Whilst treatment is effective, in 
many cases seizures are drug refractory and so there is a clinical need for novel 
drugs which selectively target the underlying pathological mechanisms. 
 
Temporal lobe epilepsy (TLE) is the most common form of adult epilepsy and 
multiple lines of enquiry have implicated the EC as a key region in this condition. 
TLE can be treated surgically with a partial temporal lobectomy and removal of 
the EC is particularly important to the success of this surgery (Sperling et al, 1996; 
Siegel et al, 1990; Fried, 1993; Goldring et al, 1992; Goldring et al 1993). Then, 
animal studies in vivo and in vitro have observed that epileptiform activity in the 
temporal lobe is commonly traced back to the EC, implicating this structure as 
being the site of initiation for seizure activity (Ben-Ari et al, 1981; Collins et al, 
1983; Stringer, 1994; Du et al, 1995; Jones and Lambert, 1990; Avoli et al, 2002; 
Lopantsev and Avoli, 1998). Though the precise pathology of TLE is largely 
unclear, a common theory is that TLE represents a pathological replay of juvenile 
brain physiology which is inappropriate within the adult brain and that 
epileptogenesis in this condition represents the elicitation of these aberrant 
developmental mechanisms (see Scharfman, 2005). The development of new 
synapses producing abnormal connectivity is one such mechanism that may lead 
to enhanced synchronisation (Sloviter et al, 2006) another is the re-emergence of 
machinery that conveys the enhanced synaptic transmission and plasticity seen in 
the developing brain (Cohen et al, 2003).  
 
1.3 NMDA Receptors 
 
The amino acid glutamate is the primary excitatory neurotransmitter in the central 
nervous system acting at a family of receptors which can be broadly divided into 
ionotropic and metabotropic/G-protein coupled receptors. Ionotropic glutamate 
receptors are the NMDA, AMPA and kainate receptors and are heteromeric cation 
channels of which the AMPA and kainate receptors mediate fast excitatory 
transmission with low calcium permeability. This is in contrast to the slower 
responses and more complex action of the NMDA receptors (NMDAr), so named 
after its original specific agonist; N-methyl-D-aspartate. 
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1.3.1 Structure of NMDAr  
 
Ionotropic glutamate receptors are comprised of four subunits, each of which 
contains four domains (depicted in Fig. 1.3.A). These are the amino (or ‘N-’) 
terminal domain (ATD) and the ligand (or ‘agonist’) binding domain (LBD), 
which are large ‘clamshell-like’, extracellular structures, the transmembrane 
domain (TMD) which consists of 3 membrane spanning helices and a re-entrant 
‘P-loop’, and the intracellular C-terminal domain (CTD). The ATD is the site of 
binding for many allosteric NMDAr modulators including protons, ifenprodil and 
its analogues, zinc ions and polyamines, whilst the LBD is the site of binding for 
agonists. The TMD forms the ion channel whilst the CTD mediates interactions 
with intracellular proteins and is thereby thought to be important in receptor 
trafficking and signalling. The structure of NMDAr has been studied at the atomic 
level using X-ray crystallography of the isolated extracellular amino terminal 
domain and ligand binding domain regions (see Wyllie et al, 2013). Although the 
complete structure has not been elucidated, Sobolevsky et al (2009) have 











Fig. 1.3. Structure of ionotropic glutamate receptors. A – Linear structure and 
general schematic of an ionotropic glutamate receptor subunit. B – Model of the full 
NMDAr structure based on crystal structures from the GluN1 and GluN2A and GluA2 
subunits. Adapted from Wyllie et al (2013), panel B originally from Sobolevsky et al 
(2009). 
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the closely related GluA2 AMPA receptor subunit to produce a putative structural 
model of the full NMDAr (see Fig.1.3.B). 
 
Functional NMDAr are heterotetramers comprising two obligatory GluN1 
subunits and two GluN2 subunits. Additionally two GluN3 subunits have been 
cloned which may be important in early development though have low homology 
with other subunits, and appear to have a relatively muted prevalence. Initial 
evidence suggested that the quaternary arrangement of the subunits was non-
alternating (GluN1/GluN1/GluN2/GluN2) (Schorge and Colquhoun, 2003) but 
more recent studies utilising cysteine linking have indicated a ‘hetero-dimer’ 
arrangement (GluN1/GluN2/GluN1/GluN2) (Sobolevsky et al, 2009; Lee and 
Gouaux, 2011; Riou et al, 2012; Salussolia and Wollmuth, 2012). In the plasma 
membrane the NMDAr forms part of a large multiprotein complex which is 
thought to determine the precise signalling and downstream effects that follow ion 
permeation through the receptor pore. The NMDAr channel pore can pass both 
sodium and calcium ions into the cell, but relative calcium permeability is around 
tenfold higher than that of sodium (Mayer and Westbrook, 1987) and is thought to 
be the major intracellular signalling mechanism. 
 
1.3.2 Regulation of NMDAr  
 
One particularly fascinating aspect of the NMDA receptor is the large amount of 
endogenous regulation that it undergoes. Firstly, the NMDA receptor is unique in 
that it recognises both an agonist and a co-agonist, both of which are required for 
channel opening. GluN2 subunits contain the glutamate binding agonist site whilst 
co-agonist sites are located on GluN1 subunits and can be activated endogenously 
by glycine or D-serine. Secondly, at resting membrane potential the NMDAr 
channel is blocked by extracellular magnesium ions and this block is removed 
upon depolarisation and some synthetic compounds such as MK801, 
phencyclidine, memantine and ketamine also act to block the NMDAR channel 
producing a use-dependent and non-competitive inhibition. Extracellular zinc ions 
inhibit GluN2A and, at higher concentration, GluN2B containing receptors, some 
neurosteroids such as pregnanolone sulphate also inhibit NMDAr and the 
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polyamines spermine, spermidine and putrescine have complex and diverse 
modulatory effects on NMDAr activity (Paoletti, 2011). However, although there 
has been a strong interest in NMDAr regulation, the roles and interactions between 
the types of endogenous modulation of the NMDAr in the brain are currently 
unclear. 
 
1.3.3 Diversity of NMDAr 
 
There are four different GluN2 subunits which can be incorporated in NMDAr, 
termed A-D. Receptors can be diheteromeric, containing two GluN1 subunits and 
two GluN2 subunits of the same subtype, or triheteromeric, containing two GluN1 
subunits and two different GluN2 subtypes. Additionally there are eight, regulated 
isoforms of the NR1 subunit arising from different combinations of three splice 
variants and these can also influence receptor kinetics and some pharmacological 
properties of the receptor, most significantly the inhibition of the receptor by 




Fig. 1.4. Functional Influence of GluN2 Subunit Identity. Adapted from Wyllie et 
al, 2013. The function of the NMDAr is highly dependent on the GluN2 subtype 
present. Considering diheteromeric NMDA receptors, multiple properties are broadly 
separated by categorising as 2A/2B or 2C/2D containing receptors. 
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However, the largest determinant of NMDAr function is the subtypes of GluN2 
subunits which the receptor contains. Importantly, GluN2A and GluN2B 
containing receptors typically have higher conductance, calcium permeability and 
sensitivity to magnesium blockade than those containing GluN2C and GluN2D 
subunits Interestingly, Retchless et al (2012) have shown that all of these three 
differences in pore permeation/blockade between 2A/B and 2C/D are all mediated 
by a difference in a single amino acid residue located in the TMD. Different GluN2 
subunits have varying affinity for glutamate but interestingly the GluN2 subunit 
present can also determine the efficacy and affinity of ligands of the GluN1 
subunit, indicating an important coupling between the GluN1 and GluN2 subunits. 
In addition the GluN2B-selective inhibitors ifenprodil and Ro25-6981 etc., and 
polyamines are thought to bind at the interface between GluN1 and GluN2 subunit 
ATD’s, again emphasising the importance of the interaction between the GluN1 
and GluN2 subunits (Karakas et al, 2011, Mony et al, 2011).  
 
Receptor open probabilities can be calculated using single channel (microscopic) 
recording and are typically compared under conditions of saturating agonist 
concentrations. For recombinant diheteromeric NMDA receptors these values are 
typically 0.5 for GluN2A containing receptors, 0.1 for GluN2B and are very low 
(0.01-0.04) for GluN2C and GluN2D diheteromers (Wyllie et al, 2013). The 
deactivation of NMDA receptors is also highly dependent on subunit composition 
and this was extensively investigated by Vicini et al (1998), utilising whole cell 
patches and outside-out patches containing multiple receptors (macroscopic 
recordings). Here it was observed that the monoexponential decay times for 
diheteromeric NMDA receptor responses following brief application of a 
saturating glutamate concentration (synaptic like) were approximately 100ms for 
GluN2A, 250ms for GluN2B and GluN2C and 4s for GluN2D. Both Gielen et al 
(2009) and Yuan et al (2009) created and studied chimeric receptors to examine 
the source of these differences in NMDAr open probability and deactivation 
kinetics observing that both are controlled by the GluN2 ATD. This interesting 
finding has expanded the importance of the ATD as a key determinant in the 
functional properties of NMDAr subtypes.  
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Temporal changes in NMDAr composition are thought to be an important 
component of brain development, in particular is the well documented increase in 
GluN2A subunit expression beginning at postnatal week 2 reflecting a 
neurodevelopmental decrease in plasticity at this age (Sanz-Clemente, 2013, 
Paoletti et al, 2013). Spatial differences in NMDAr composition are seen on the 
subcellular, cellular (including neurones and glial cells) and brain region levels. 
Within the neuronal membrane, NMDA receptors can be divided spatially into 
three populations – presynaptic, postsynaptic and extrasynaptic. Extrasynaptic 
NMDAr (extraNMDAr) can be located on spine necks, dendritic shafts, or somas 
and may play a key role in regulating the excitability of these zones (Zhou et al, 
2014). Postsynaptic and Presynaptic NMDA receptors are discussed in detail later 
(sections 1.5 and 1.6 respectively). 
 
1.3.4 Clinical importance of NMDAr 
 
NMDAr have been repeatedly implicated in epileptic pathology and many studies 
have observed a pathologically increased NMDAr expression in brain tissue from 
patients and in animal models (Ghasemi and Schacter, 2011). In addition, many 
NMDAr ligands modulate seizures in animals and the NMDAr is one target of the 
clinically used anticonvulsant felbamate (Subramaniam et al, 1995). The 
importance of NMDAr in the function and regulation of synapses has also lead to 
a huge interest in these receptors with respect to cognition (Collingridge et al, 
2013). Interestingly, the only pharmacological treatment for Alzheimer’s disease 
besides the acetylcholine esterase inhibitors is the NMDAr blocker memantine. It 
is thought that the dysregulation of glutamatergic synapse in Alzheimer’s disease 
leads to constant low-level depolarisation, causing ‘noisy’ NMDAr activity. By 
virtue of its moderate potency, memantine is thought to counteract this noise whilst 
allowing normal transmission to take place, thereby redressing the NMDAr 
dysfunction (Parsons et al, 2013). The high-efficacy co-agonist site partial agonist 
D-cycloserine (DCS) has also been indicated to have cognitive enhancing 
properties. Cognitive enhancement by DCS has been demonstrated in many animal 
study paradigms (discussed later) and in humans though its precise effects at 
NMDAr in the brain are unknown, with many studies simply ascribing effects to 
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a pro-NMDAr action. Interestingly there is also some evidence that DCS can 
produce anticonvulsant effects (discussed later).  
 
1.4 Receptor Gating and Partial Agonism 
 
The ability of a drug to bind a receptor is termed affinity and the ability of the drug 
to activate the receptor when bound is termed efficacy. The term ‘intrinsic 
efficacy’ is in some instances more useful, as other factors such as receptor reserve 
can influence observed efficacies, though will not be used here. An agonist has 
100% efficacy and thus can elicit a full response. A partial agonist has a sub-
maximal efficacy and thus produces a sub-maximal response when all receptors 
are fully bound which for ion channels results in a sub-maximal receptor open 
probability (the probability of a bound receptor opening). These effects were 
classically described by the model of Del Castillo and Katz (1957) who were the 
first to give separate binding (affinity driven) and activation (efficacy driven) 
equilibria (Fig. 1.5). Under such a scheme the activation equilibrium would lie 





However, for some ion channels at least, the idea of a single activation equilibrium 
is obsolete. Several studies focussing particularly on the pentameric glycine and 






Fig. 1.5. Classical model of receptor activation. This simple model first described 
by Del Castillo and Katz (1957) was the first to distinguish between receptor binding 
and receptor activation. In the presence of an agonist the unbound (‘R’) and bound 
(‘A.R’) forms of the receptor are in an equilibrium referred to with rate constants k+1 
and k-1. The bound receptor is also in equilibrium with the bound, activated receptor 
(‘A.R*’) with rate constants termed α and β. 
Chapter One  Introduction 
15 
Co-agonist Regulation of Pre and Postsynaptic NMDA Receptors in the Entorhinal Cortex 
of this receptor changes through a number of sequential intermediate shut states 
before becoming open. Intermediate states can be detected using single-channel 
recording through observation of open and shut times (i.e. how long the channel 
stays open/closed in each instance) in the presence of different concentrations of a 
ligand. Such experimentation typically involves fitting the sequences of open and 
shut times (durations of open periods and shut periods) to a putative mechanism 
and calculation of the rate constants in the reaction scheme. How well the 
mechanism fits the data can be judged, for example, by the ability of the fit to 
describe the distribution of open and shut times and the change in channel open 
probability (overall fraction of time the channel spends open) with drug 
concentration (see Colquhoun et al, 2003).   
 
In this way, Lape et al (2008) described an intermediate agonist-bound, shut (or 
‘pre-open’) conformation known as the ‘flip’ from which the receptor channel 
opens rapidly irrespective of what agonist is bound. Their work indicates that 
contrary to previously thought, it is a shift in the resting-shut/flipped-shut 
equilibrium towards flipped-shut that produces partial agonism. This conclusion 
was largely informed through the observation of brief shuttings (typically 5-10µs) 
which are thought to be fluctuations between the flip and open state. These 
closures were of similar length in the presence of full agonists and partial agonists 
indicating that this step was not relevant to the difference in agonist efficacies. The 
opening of the channel itself is a very rapid process with an indeterminably fast 
rise time.  
 
The idea of the ‘flip’ state is also significant because an all-high affinity state 
allows for the appearance of cooperative binding via the Monod-Wyman-
Changeux scheme which, due to its simplicity, is able to account for the abundance 
of co-operative binding across many proteins.. However, it may be difficult to find 
a unifying model for every receptor because even if receptors did indeed share the 
same mechanism, which may seem unlikely, different receptors may spend no 
appreciable time in one step giving the appearance of a different mechanism 
(Colquhoun and Lape, 2012). Another problem lies in explicitly linking kinetic 
observations of intermediate states with structural conformation changes. 
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1.4.1 NMDAr gating and partial agonism 
 
Banke and Traynelis (2003) produced a kinetic model of NMDA receptor gating 
which suggested that GluN1 and GluN2 subunit undergo independent transitions 
and that partial agonists increase time spent in a single shut state associated with 
the bound subunit. However, the idea of independent GluN1 and GluN2 transitions 
may have been influenced by the idea of a non-alternating arrangement, which is 
no longer favoured. Alternatively, the more recent kinetic single channel analysis 
by Kussius and Popescu (2009) indicated the presence of five resolvable closed 
states and three/four open states in the gating of these receptors (Fig. 1.6). Partial 
agonists of both the glutamate and glycine site were seen to have broad effects on 
channel gating, increasing time spent in multiple closed states, in contrast to the 
more simple ‘flip’ based mechanism for partial agonists at nicotinic and glycine 
receptors. However, it was suggested that one of the closed states (‘C2’) could 
represent an all-high-affinity state which is arrived at in a concerted manner.  
 
 
C3 C2 C1 O
C5 C6
Fig. 1.6. Kinetic model of NMDAr gating (adapted from Kussius and Popescu, 
2009). The images depict speculative structures representing kinetically resolved 
gating stages. ‘C’ denotes ‘closed’ and ‘O’ denotes ‘open’. The C3 structure is the only 
stage in which binding and unbinding occurs and these are not shown. C5 and C6 are 
long lived bound-closed stages. Open stages are represented as a single aggregate. 
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Interestingly, partial agonists of NMDAr also alter the decay of NMDAr 
macroscopic currents. These properties were extensively studied by Priestley and 
Kemp (1994) who demonstrated that relative to a full agonist, partial agonists of 
either site decrease the decay time of synaptic currents in an extent proportional to 
their efficacy. Kussius and Popescu (2009) indicated that relative to a full agonist, 
a partial agonist such as DCS will increase time spent in multiple bound/closed 
states including (indirectly) long-lived bound/closed (i.e. ‘desensitized’) states. 
This model also accurately predicts that partial agonists accelerate the decay of 
macroscopic currents resulting from prolonged glutamate application, through 
increasing the time spent in bound/closed states which can also transition to long-
lived bound/closed (desensitized) states. More recently this scheme was seen to 
accurately predict changes in the decay time of synaptic-like macroscopic currents 
resulting from structural changes in NMDAr (Paganelli et al, 2013). In this way it 
appears that the sub-maximal decay time produced by NMDAr partial agonists 
result from the same broad reductions in channel gating efficiency that produce 
sub-maximal amplitude, providing a simple explanation of why the extent of both 
is determined by the compound’s efficacy.  
 
Some analyses have indicated that the NMDAr, alongside the AMPAr, can display 
different gating ‘modes’. For example, Popescu and Auerbach (2003) studied 
single channel activity of GluN2A NMDAr observing 3 distinct gating modes 
which were separable by characteristic open probabilities and mean open times. 
The usefulness of such a scheme was shown by Zhang et al (2008), who 
demonstrated that modal gating can account well not only for observed variation 
of receptor kinetics over time, but also for biphasic decays of macroscopic 
currents. Under such a scheme two different gating modes, with monoexponential 
decays of different time constants, superimpose to produce the biexponential 
macroscopic decay. Zhang et al (2008) observed that gating modes change over a 
minute timescale, thus changes could occur to alter the distribution of gating 
modes before but not during the synaptic response. Kussius and Popescu (2009) 
were unable to rule out the possibility that changes in the proportions of gating 
modes contribute to submaximal open probabilities, and ultimately the 
understanding of the mechanism of partial agonism at NMDAr is not certain. 
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1.5 Postsynaptic NMDA receptors 
 
The most well studied NMDAr are those located on the postsynaptic spine, due to 
their more obvious action and directly observable function. These are termed 
postsynaptic NMDA receptors (postNMDAr) and are well studied as having a 
central role in neuronal and network dynamics. PostNMDAr are thought to be 
highly important as ‘coincidence detectors’ becoming open and unblocked only 
when presynaptic glutamate release and back-propagation of an action potential to 
the dendrite are present (Bear et al, 2007). Calcium entry through the postNMDAr 
leads to changes in the strength of the signal at that synapse, particularly to increase 
the strength which is known as long-term potentiation (LTP). In the immediate 
period, one way in which this occurs is through autophosphorylation of 
calmodulin-dependent protein kinase II which can phosphorylate AMPAr, 
increasing their conductance. Also postNMDAr activation can lead to insertion of 
new AMPAr receptors into the plasma membrane.  
 
Following release, the glutamate concentration in the synaptic cleft rapidly peaks 
at saturating concentration (approximately 1 mM) and is then cleared quickly by 
reuptake with a time constant of around 1 ms (Clements et al, 1992). Synaptic 
glutamate binds to postNMDAr producing a current of amplitude which will be 
determined by the number of receptors being activated, the receptor open 
probability and the conductance of the open channels (Fig. 1.7). Glutamate 
rebinding does not occur indicating that the time course of synaptic NMDAr 
currents is determined only by receptor gating i.e. the transitioning between open-
bound, closed-bound and closed-unbound states (Lester et al, 1990). Native 
postsynaptic NMDA receptor mediated currents can be directly observed using 
whole cell patch clamp if all other receptors are blocked and magnesium blockade 
is relieved by use of a magnesium free solution or, more commonly, by holding 
the cell at a depolarised potential. 
 
Experimentation using pharmacological tools has indicated that postNMDAr are 
likely to be GluN2A containing, whilst extrasynaptic NMDA receptors are likely 
to be GluN2B containing which has led to a pervasive schematic of postsynaptic 
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GluN2A heterodimers and extrasynaptic GluN2B heterodimers. However, whilst 
appealing in its neatness much evidence indicates that this schematic is likely to 
be an oversimplification (Wyllie et al, 2013). In particular at layer V synapses in 
the EC, postsynaptic NMDAr currents have been shown to be highly susceptible 
to both GluN2A and GluN2B antagonism indicating the presence of triheteromeric 
receptors (Chamberlain et al, 2008). Further to this, two recent studies compared 
the hippocampal synapses of wildtype and GluN2A/GluN2B knockout mice in 
acute slices (Rauner and Kohr, 2011) and neuronal cultures (Tovar et al, 2013). In 
both of these studies it was seen that only a population with a GluN2A-GluN2B 
triheteromer majority could account for the properties of postsynaptic receptor 
responses in the wild type (Rauner and Kohr, 2011, Tovar et al, 2013).  
 
 
Methodology for reliably expressing the GluN2A-GluN2B triheteromer for direct 
study has recently been developed by Hansen et al, (2014) who observed the 
properties of this receptor using whole cell patch clamp of HEK cells and Xenopus 
Oocytes. In this study it was seen that the kinetics and pharmacological properties 
of this receptor appear to lie between those of the GluN2A and GluN2B 
diheteromers, but closer to the GluN2A diheteromer. Interestingly, the authors of 
this study suggest that this may have influenced previous indications of 
predominantly GluN2A diheteromeric postsynaptic NMDAr populations.  
Number of receptors activated
Receptor Gating (open probability)
Channel conductance 
Receptor gating
Fig. 1.7. A summary of the elements underlying the amplitude and time course of 
macroscopic postNMDAr evoked currents. 
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1.6 Presynaptic NMDA receptors 
 
Whilst the effects of a neurotransmitter can be altered through mechanisms 
affecting the recipient postsynaptic receptors, neurotransmitter release is regulated 
by the activity of auto or heteroreceptors on the presynaptic nerve terminal. 
Presynaptic GABA receptors were the first such receptors to be identified (Dudel 
and Kuffler, 1961; Eccles 1964), with many types of presynaptic metabotropic and 
ionotropic receptors following. The possibility of NMDAr located on presynaptic 
terminals was first implicated in studies examining the release of noradrenaline 
(Fink et al, 1990; Pittaluga et al, 1992) and dopamine (Johnson and Jeng, 1991; 
Krebs et al, 1991; Wang, 1991) from synaptosomes which indicated that a 
presynaptic NMDA receptor (preNMDAr) might be a heteroreceptor for these 
transmitters. Early electron microscopy studies then allowed NMDAr located on 
presynaptic terminals to be visualised in, for example, the spinal cord (Liu et al, 
 
 
Fig. 1.8. An electron micrograph of synapses in the hippocampal CA1 region with 
immunogold labelling for GluN2B subunits from Aoki et al (2009). Large arrows 
indicate postsynaptic labelling, medium arrows indicate presynaptic labelling and 
small arrows indicate labelling inside spines. Asterisks denote unlabelled post synaptic 
densities. Scale bar = 500nm. 
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1994) and hippocampus (Siegel et al, 1994). In particular, Aoki et al (1994) 
directly examined different neuronal locations of NR1 subunits in the visual cortex 
and observed a large degree of NR1 immunoreactivity in axon terminals, explicitly 
linking this to the suggested preNMDAr. A more recent, high quality electron 
micrograph produced by Aoki et al (2009) which indicates the different subcellular 
locations of NMDAr in the hippocampus is shown in Fig. 1.8.      
 
1.6.1 Regulation of glutamate release by preNMDAr 
 
As NMDAr are present at both sides of the synapse, targeting the presynaptic 
receptor selectively for functional study is inherently problematic. The 
development of the technique of using MK801, an NMDAr blocker, dialysed into 
cells by inclusion in intracellular patch clamp solution to block postNMDAr by 
Berreta and Jones (1996) allowed the first functional demonstration of preNMDAr 
to be made. Here it was seen that at glutamatergic synapses in layer II of the EC 
preNMDAr act as autoreceptors to facilitate glutamate release. These receptors 
were tonically active producing an increased baseline of glutamate release. In a 
subsequent paper by Woodhall et al (2001) this effect was also observed in layer 
V of the EC and it was seen that the preNMDAr are not fully active as application 
of the NMDAr agonist homoquinolic acid produces a large increase in the 
frequency of spontaneous activity. preNMDAr were also seen to mediate 
frequency dependent facilitation of evoked currents at 3Hz demonstrating a role in 
a very short term form of plasticity (Woodhall et al, 2001). 
 
In Woodhall et al, (2001) it was observed that the activity of preNMDAr was 
inhibited by cobalt ions indicating that these actions are mediated by calcium 
influx through the receptor pore supporting the findings of a previous calcium 
imaging study of the reticulospinal axons in the lamprey spinal cord (Cochilla and 
Alford, 1999).  More recent calcium imaging has also indicated this to be the case 
(McGuinness et al, 2010), although a recent study by Kunz et al (2013) found that 
lowering the concentration of sodium ions decreases preNMDAr activity 
indicating that the influx of sodium ions, which would act to depolarise the 
terminal, may also be important. Further investigation of the tonic and activity 
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dependent facilitations produced by the preNMDAr indicated that these receptors 
were fully sensitive to GluN2B antagonism suggesting a GluN2B diheteromeric 
composition (Woodhall et al, 2001). This is a common finding for preNMDAr 
(Jourdain et al, 2007, Brasier and Feldman, 2008 and Sjöström et al, 2003, DeBiasi 
et al, 1996, Li et al, 2009 and McGuinness et al, 2010) although GluN2A and 
Fig. 1.9. Functional observation of preNMDAr by whole cell patch clamp. A – 
Example traces taken from Berretta and Jones (1996), the first functional 
demonstration of preNMDAr activity. B – Illustration of the experimental paradigm 
developed by Berretta and Jones. In this study postNMDAr were blocked by the 
NMDAr channel blocker MK801 which was added to intracellular patch solution. 
Addition of the glutamate antagonist to the bath was seen to produce a decrease in the 
frequency of spontaneous excitatory events with no change in amplitude. This 
indicated that NMDAr on glutamatergic nerve terminals were acting to promote 
quantal transmitter release. 
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GluN3 subunit containing preNMDAr have also been reported (Suárez and Solís, 
2006, Larsen et al, 2011). 
 
Duguid and Smart (2004) have shown that preNMDAr also facilitate release at 
inhibitory synapses in the cerebellum and can again mediate a long-term 
potentiation which is elicited by retrograde glutamate. Duguid and Smart found 
that this form of plasticity requires CICR (calcium induced calcium release) 
indicating that it is mediated by interaction with presynaptic calcium stores, 
although Glitsch (2008) has shown that CICR is not required for the immediate 
facilitation of GABA release by preNMDAr. Fiszman et al (2005) also observed a 
similar effect on GABA release by preNMDAr at inhibitory terminals in primary 
neuronal cultures from the cerebellum. In this study the presence of NMDAr 
heteroreceptors on terminals was explicitly demonstrated by outside-out single 
channel patch clamp experiments from interneurone variscosities. Using this 
technique, preNMDAr currents were observed in 61% of the patches excised 
suggesting that preNMDAr expression is not ubiquitous but targeted.  
 
1.6.2 preNMDAr and synaptic plasticity 
  
In 2003, Sjostrom et al identified a mechanism of long-term depression (LTD) at 
excitatory synapses in layer 5 of the visual cortex which was mediated by 
preNMDAr indicating that these receptors, alongside their postsynaptic 
counterpart, are important as detectors/mechanisms for synaptic plasticity of the 
brain. Here, dual patch clamp was used to give control over presynaptic and 
postsynaptic cells and it was observed that timing dependent LTD (tLTD) 
generated by 0.1 Hz was conferred by the presynaptic cell and was dependent on 
preNMDAr. Although expressed presynaptically, tLTD requires postsynaptic 
(although not postNMDAr) activity and was also seen to require cannabinoid 
receptor activation indicating that endocannabinoids may act as a retrograde 
signalling molecule, which induce tLTD if tonic activation of preNMDAr is 
present. Subsequent studies have made similar observations at excitatory synapses 
in the somatosensory cortex (Bender et al. 2006; Nevian and Sakmann 2006; 
Rodriguez-Moreno and Paulsen 2008) whilst in the lateral amygdala cortical 
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afferents exhibit a presynaptic LTP at 30 Hz stimulation which is independent of 
postsynapc activity and mediated by preNMDAr (Humeau et al, 2003; Fourcaudot 
et al, 2008; Fourcaudot et al, 2009).  
 
Recently the function and locus of preNMDAr have been supported by studies 
using ‘caged’ NMDAr ligands which only become active following uncaging by 
photolysis and this can be done in a compartment-specific manner. Rodriguez-
Moreno et al (2011) synthesised a caged form of MK801 which could be internally 
dialysed and used this compound to investigate further tLTD in the somatosensory 
cortex observing that only uncaging in the axonal department abolished this effect. 
Additionally, by combining precise photolysis of a caged form of NMDA with 
calcium imaging, agonist-induced calcium influx has been observed both at 
interneurone and layer V pyramidal cell terminals in the cerebellum (Rossi et al, 
2012) and visual cortex (Buchanan et al, 2012), respectively. Interestingly, in the 
study by Buchanan et al (2012) it was seen that preNMDAr were present on 
synapses between pyramidal cells but not on those from pyramidal cells onto 
basket cell interneurones. Additionally, in the experiments of Rossi et al (2012), 
NMDA-induced calcium transients were observed in 30% of locations along 
individual axons. These results further indicate that preNMDAr expression is 
synapse-specific. Buchanan et al (2012) used a computational model to show that 
such targeted expression could serve as a mechanism to reroute signals in neuronal 
networks during high-frequency firing.  
 
1.6.3 preNMDAr mobility 
 
NMDAr are now known to exhibit mobility within the neuronal membrane and the 
high concentration of NMDAr at the postsynaptic density (PSD) appears to be 
related to transient interactions with scaffolding proteins present at this location 
(Choquet and Triller, 2003; Lau and Zukin, 2007). In their study of NMDAr in P0-
P1 mouse hippocampal cultures, Tovar and Westbrook (2002) set out a novel, 
pharmacological method of studying NMDAr using the irreversible, activity 
dependent NMDAr channel blocker MK801. Later, Yang et al (2008) adapted the 
methodology of Tovar and Westbrook to also examine preNMDAr mobility in 
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acute brain slices of the rat EC. Using recovery from MK801 blockade and 
preNMDAr mediated frequency-dependent facilitation of AMPA receptor 
currents, here preNMDAr were seen to be highly mobile compared to the 
postNMDAr. This could be related to predominance of NR2B over NR2A in 
preNMDAr which has been shown to confer higher mobility of NMDAr (Groc et 
al, 2006) in addition to a potentially decreased prevalence of anchoring proteins at 
the terminal compared to the PSD. 
 
The experiments of Yang et al (2008) indicated that short term regulation of 
preNMDAr is mediated by lateral diffusion within the neuronal membrane over 
exocytosis/internalisation and it appears likely that preNMDAr diffuse/are 
trafficked into the terminal following insertion (Aoki et al, 2003) similar to 
postNMDAr (Lau and Zukin, 2007).  PreNMDAr mobility also appears to be 
activity dependent with brief activation leading to down-regulation of activity and 
vice versa (Yang et al, 2008). Although the mechanism of this effect is yet to be 
determined, it could be that Ca2+ influx through preNMDAr leads to activation of 
protein kinase C, which increases NMDA mobility (Groc et al, 2004 and Fong et 
al, 2002), causing dispersion of preNMDAr from active sites in the terminal 
membrane. Given the role of preNMDAr as a mediator of plasticity, phenomena 
which alter preNMDAr activity, such as regulated mobility, could act as 
mechanisms of metaplasticity.  
 
1.6.4 Regulation of preNMDAr 
 
Therefore preNMDAr appear to mediate elevated levels of activity and plasticity 
and so may act to ‘tune’ neuronal networks in the developing brain. A role for 
preNMDAr in the adult brain has not been shown and preNMDAr appear to 
undergo a decline in activity during development (Corlew et al, 2007, Mameli et 
al, 2005, Yang et al, 2008). Using electron microscopy, Corlew et al (2007) 
observed that the developmental decline in preNMDAr activity was correlated to 
a (70-80%) decrease in the presence of GluN1 at presynaptic terminals suggesting 
that a redistribution of NMDAr or change in surface expression may contribute to 
developmental changes in preNMDAr activity. Using the methodology of Beretta 
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and Jones (1996), Yang et al (2006) found that the developmental decline in 
preNMDAr at excitatory synapses in the EC was not present in chronically 
epileptic rats indicating that this system may re-emerge in epileptic pathology, 
contributing to heightened excitability. Furthermore preNMDAr antagonism has 
been shown to be an action of the anticonvulsant felbamate (Yang et al, 2007) 
supporting a causal role for preNMDAr in seizure generation. 
 
Whilst it appears that ambient glutamate levels are sufficient for tonic activity of 
preNMDAr, it is less clear how the receptor is continually free from blockade by 
Mg2+, though it may be that local excitatory currents are sufficient to maintain 
frequent depolarisation of the nerve terminals due to the small size/high input 
resistance of this structure (Jourdain et al, 2007). Alternatively results from Larsen 
et al (2011) indicated that in the visual cortex, incorporation of GluN3 subunits 
may contribute in conferring insensitivity to voltage-dependent block by Mg2+ and 
that change in GluN3 expression may also contribute to developmental changes in 
preNMDAr. The co-agonist site of preNMDAr represents a potential area for 
selective targeting of these receptors. It has been shown that the co-agonist site of 
preNMDAr in the visual cortex is also tonically bound, contributing to the active 
state of preNMDAr although the endogenous ligand was not identified (Li and 
Han, 2007). A study by Papouin et al (2012) suggested that postNMDAr and 
extrasynaptic NMDAr were bound by D-serine and glycine, respectively and that 
this was due to their different subunit compositions and subsequent affinities for 
the two endogenous co-agonists. Furthermore it was suggested that the segregation 
of these receptors was due to differential inhibition of mobility by the two co-
agonists. Investigation of the co-agonist regulation of preNMDAr may therefore 
be important to both furthering the understanding of the physiological importance 
and regulation of these receptors and in pharmacologically targeting these 






Chapter One  Introduction 
27 
Co-agonist Regulation of Pre and Postsynaptic NMDA Receptors in the Entorhinal Cortex 
1.7 Astrocytes and the Tripartite Synapse 
 
Neurones and their connections are the most important elements of the brain, 
acting to encode changes in the environment, communicate with each other and to 
ultimately control the body’s response, though it is often noted that neurones only 
represent 10% of the cells in the brain. The remainder are the non-excitable cells 
termed ‘glia’ from the Greek for ‘glue’ which refers to their most noticeable 
function; sustaining the physical structure of the brain. The function of some glia 
is clear such as oligodendrocytes and Schwann cells which act to insulate neuronal 
axons with myelin, and microglia which are phagocytic immune cells. The most 
abundant glia are astrocytes, these cells reside between neurones and control 
homeostasis of the extracellular space and envelop synapses. The homeostatic 
functions of astrocytes include regulating the pH and potassium content of the 
extracellular fluid and producing and exporting numerous molecules for neuronal 
function and viability such as antioxidants, neurotrophic factors and sources of 
energy (Allaman et al, 2011). However, whilst the importance of these actions is 
patent, at synapses astrocytes have been shown to have the capacity to both detect 
and influence neuronal activity. This has led to the view of many synapses as being 
‘tripartite’ in the flow of information and has prompted the idea that astrocytes 
may have a direct involvement in biological computation and brain function (Perea 
et al, 2014). 
 
Whilst astrocytes lack the machinery necessary for electrical excitability, they still 
have the mechanics for intracellular calcium signalling. Cytosolic calcium 
concentration in astrocytes is generally observed to be oscillatory, alternating 
between periods of accumulation, from intracellular and extracellular sources, and 
clearance (Zorec et al, 2012). These oscillations can occur spontaneously 
indicating that it is an intrinsic property of these cells (Parri and Crunelli, 2003) 
but are also controlled by metabotropic and ionotropic receptors in the cell 
membrane (Zorec et al, 2012). Activation of these receptors by neurotransmitters 
provides the basis by which neuronal synaptic activity can trigger calcium waves 
(Perea and Araque, 2005; Araque et al, 2014). Calcium waves can also propagate 
between astrocytes, with several possible mechanisms such as the passage of 
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calcium and IP3 through gap junctions or glutamatergic/purinergic paracrine 
signalling, though the extent to which this occurs in vivo is currently unclear (De 
Bock et al, 2014).  
 
Interestingly, one of the receptors present on astrocytes is none other than the 
NMDAr. Functional demonstration of NMDAr on astrocytes was carried out in 
2006 by Lalo et al, who utilised somatosensory cortex brain slices from mice with 
GFP-labelled astrocytes and observed that these receptors were indeed active at 
the resting membrane potential of astrocytes (-80 mV). A subsequent study by 
Palygin et al (2010) indicated that the pharmacological properties of these NMDAr 
imply the presence of GluN2C or GluN2D subunits, but also reasoned that the lack 
of sensitivity to Mg2+ indicates the presence of GluN3 subunits and a 
triheteromeric structure was suggested. In the study by Lalo et al (2006) it was also 
observed that astrocytes exhibit glutamatergic miniature spontaneous events akin 
to those seen in neurones, further highlighting the close association of astrocytes 
with the synaptic terminal. Metabotropic glutamate receptors are another, key, 
receptor in astrocyte regulation, as well as AMPA glutamate receptors (Parpura 




Importantly, however, intracellular calcium signalling also provides a mechanism 
by which astrocytes can respond to neuronal synaptic activity. Transmitters 
released by astrocytes are termed gliotransmitters and include GABA, glutamate 
and prostaglandins, though the best studied are glutamate and ATP both of which 
are released by Ca2+ dependent exocytosis (Zorec et al, 2012). Glial ATP can act 
at presynaptic P2Y receptors to suppress glutamate release (Zhang et al, 2003) and 
can be rapidly converted to adenosine by ectonucleotidases in the extracellular 
space. This adenosine can act at presynaptic adenosine receptors to depress 
glutamate or GABA release via A1 receptors (Pascual et al., 2005; Serrano et al., 
2006) or facilitate glutamate release via A2A receptors (Panatier et al, 2011). Also, 
astrocytic activation of postsynaptic adenosine receptors has been shown to 
modulate the trafficking of postNMDAr (Deng et al, 2011). It is already clear then 
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that the effects of gliotransmission are highly complex and variable depending on 
the gliotransmitter(s) released and the properties of the synapse. 
 
1.7.2 Astrocytes and glutamate 
 
Astrocytes are the main source of reuptake in the removal of glutamate from the 
synaptic cleft, which occurs via excitatory amino acid transporters, a family of five 
sodium dependent glutamate transporters (Shigeri, 2004). Once inside, glutamate 
is converted back to the precursor glutamine by the glial enzyme glutamine 
synthase, and this is then transported out of the astrocyte for reuptake into 
terminals (Hertz et al, 1999). Though, as previously mentioned, astrocytes can also 
release glutamate. Multiple studies have demonstrated that astrocytic glutamate 
can activate extraNMDAr  (Angulo et al, 2004; Shigetomi et al, 2008; Fellin et al, 
2004) though one study has focussed on activation of preNMDAr (Jourdain et al, 
2007). 
 
In this study dual recordings of astrocytes and principal cells were made in the 
dentate gyrus and stimulation of astrocytes was seen to elicit an increase in the 
frequency of spontaneous excitatory currents in roughly one third of the pairs, with 
no effect on the amplitude of events. This effect was abolished by inhibition of 
exocytosis in the astrocytes and by bath application of an NMDAr antagonist but 
not by blockade of postNMDAr by dialysed MK801. This effect was also sensitive 
to GluN2B selective antagonism and electron microscopy with immunogold 
labelling for this protein yielded an interesting observation – that this subunit had 
a prevailing presynaptic distribution at sites of interaction between astrocytic and 
neuronal membranes (Fig. 1.10). These experiments indicate that astrocytes can 
activate preNMDAr by release of glutamate and may have an intimate association 
with these receptors. Further experiments implicated activation of purinergic P2Y 
receptors and metabotropic glutamate receptors as the mechanism for activation of 
the astrocytes in this system whilst a follow up study indicated that the cytokine 
tumour necrosis factor alpha was necessary for the glutamate release stage 
(Santello et al, 2011).  
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Other studies have indicated that astrocytic glutamate can also activate presynaptic 
metabotropic and kainate receptors (see Santello et al, 2012 and Perea et al, 2014). 
Furthermore, Nadkarni et al (2008) considered bidirectional astrocyte signalling at 
synapses by combining computational modelling of vesicular release from 
terminals with astrocyte calcium dynamics. Here it was demonstrated that 
mechanisms by which astrocytes influence presynaptic calcium may function to 
allow astrocytes to set an optimum probability of release in response to 
postsynaptic activity, sustaining effective synaptic transmission whilst avoiding 
neurotransmitter depletion.  
 
1.7.3 Astrocytes in disease 
 
The advancement in understanding of the role that astrocytes play in the 
maintenance and function of the brain has led to an increased focus on these cells 
in disease, particularly in neurodegenerative disorders but also in epilepsy. Tian et 
al (2005) studied in vitro epileptiform activity in rat hippocampal and 
Fig. 1.10. Electron micrographs depicting hippocampal synapses with immungold 
labelling for the GluN2B subunit (from Jourdain et al, 2007). Arrows highlight 
GluN2B labelling, ‘Ter’ denotes terminal, ‘Sp’ denotes spine, ‘Ast’ denotes astrocyte 
and scale bars are 100nm. Here GluN2B containing NMDAr are seen to be located 
opposite astrocytic processes containing vesicles suggesting a functional coupling 
between these elements. 
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somatosensory cortical slices and utilised an acetoxymethyl ester calcium 
indicator which is preferentially loaded into astrocytes. Here it was observed that 
epleptiform-inducing agents increase calcium signalling in astrocytes independent 
of synaptic activity and that 70-80% of interictal paroxysmal depolarisation shifts 
(PDSs) are non-synaptic. These PDSs could also be induced by stimulation of 
astrocytes by photolysis of caged calcium and blocked by AMPAr and NMDAr 
antagonism indicating that glutamate release from astrocytes contributes to 
epileptiform discharges.  Following this Gomez Gonzalo et al (2010) examined 
epileptiform activity in the EC and observed that Ca2+ elevations were present in 
astrocytes during ictal but not interictal events. Also, perturbation of astrocyte 
activity by intracellular application of a calcium chelator could reduce the area of 
ictal events triggered by focal application of NMDA suggesting that recurrent 
neurone-astrocyte signalling may support the recruitment of neurones into 
hypersynchonous activity in epilespy. 
 
Reactive gliosis is a neuroinflammatory response in which glia undergo metabolic 
and structural changes and new glial cells are generated. Gliosis can be induced by 
insults to the brain making it an interesting candidate mechanism for the initiation 
and mediation of epileptogenesis and gliosis is indeed a common feature of human 
temporal lobe epilepsy (Cohen-Gadol et al, 2004; Thom et al, 2010), including in 
the EC (Yilmazer-Hanke et al, 2000), and in pilocarpine-induced epilepsy in 
rodents (Borges et al, 2003; Borges et al, 2006; Shapiro et al, 2008). As well as the 
control over synaptic transmission, the roles of glia in regulating extracellular ion 
concentrations and neuronal growth may be highly relevant (Scharfman, 2007). 
However, it has not been established whether gliosis may represent an aberrant, 
causative mechanism or if it may represent a compensatory, beneficial process or 
indeed neither. Also, computational analyses have demonstrated that astrocytes 
could influence the ability of a network to transition between synchronous and 
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1.8 Endogenous Co-agonist Regulation of NMDA Receptors 
 
Recently several studies have focussed on the endogenous regulation of the 
postNMDAr co-agonist binding site. Although the co-agonist site is a full agonist 
site it appears to be tonically bound, meaning that glutamate binding effectively 
determines the activity of postNMDAr. Glycine is a part of multiple metabolic 
pathways and therefore has a complex synthesis and metabolism, following release 
it is removed from the synapse by well-characterised reuptake mechanisms (Bear 
et al, 2007). D-serine is formed from L-serine by serine racemase and is degraded 
by D-amino acid oxidase, though the details of these processes is currently highly 
controversial (see section 3.4.2 for a discussion). Glycine was previously assumed 
to be the endogenous co-agonist at all NMDAr as it is present at high concentration 
in cerebrospinal fluid, although recently multiple studies have provided in depth 
analysis of the endogenous co-agonist regulation of postNMDAr.   
 
Fossat et al (2012) used both recombinant yeast D-amino acid oxidase (DAAO) 
and bacterial glycine oxidase (GO) to remove D-serine and glycine in acute brain 
slices of the rat prefrontal cortex. In whole cell patch clamp recordings, removal 
of D-serine was seen to produce a partial decrease in the amplitude of postNMDAr 
mediated currents (in agreement with Panatier et al, 2006)) and this was reversed 
by application of exogenous D-serine. Inhibition of glial metabolism by 
fluoroacetate produced similar effects and was seen to reduce the concentration of 
D-serine in slices as measured by laser induced fluorescence. Despite glycine 
levels in the slices being higher than those of D-serine, GO was not seen to have 
an effect on postNMDAr currents but it did preclude a potentiating effect of the 
glycine transporter inhibitor, sarcosine. These results indicated that D-serine, 
produced by glia, was the main co-agonist binding these postNMDAr in part due 
to suppression of glycine at the synapse by transporters.  
 
The same group subsequently made similar findings at CA3-CA1 synapses in the 
hippocampus (Papouin et al, 2012). Here it was also observed that GluN2A 
antagonism by free zinc produced a partial decrease in the amplitude of 
postNMDAr responses but no effect was seen by the GluN2B antagonist Ro25-
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6981. Conversely, extraNMDAr responses (detected by ‘puff’ application of 
NMDA, or as tonic currents) were seen to be sensitive to glycine removal and 
Ro25-6981 but not zinc. Then using the ‘quantum dot’ approach to monitor 
receptor diffusion in the neuronal membrane. As previously observed (Groc et al, 
2007) GluN2A were seen to be less mobile but furthermore it was seen that glycine 
selectively slowed down GluN2A receptors whereas D-serine selectively slowed 
down GluN2B receptors. Glycine has an approximately 10-fold higher affinity for 
GluN2B-containing NMDAr, whereas D-serine has only a slight preference for 
GluN2A. Based on this and their results the authors make the suggestion “that D-
serine on GluN2B-NMDARs and glycine on GluN2A-NMDARs could prevent 
their diffusion in and out of synapses, respectively”, though intuitively the 
observations on inhibition of diffusion would indicate the opposite. 
 
This scheme was recently extended again (Le Bail et al, 2015). Here it was 
observed that at SC-CA1 synapses removal of D-serine reduced NMDAr-mediated 
field potentials by 84% and removal of glycine reduced these by 36% indicating 
that D-serine was the main co-agonist at postNMDAr here. Whereas at mPP-DG 
synapses removal of D-serine and glycine caused 26% and 60% reductions, 
respectively indicating that glycine was the dominant co-agonist at these synapses. 
This was not seen to be due to any difference in the availability of D-serine or 
glycine, though differences were seen in the effects of zinc and Ro25-6981. The 
effects of Ro-25-6981 were equal at both synapses (~15% inhibition) but zinc 
reduced the amplitude of SC-CA1 responses by 34% and mPP-DG responses by 
23%, which is interpreted as indicating that GluN2B have a larger role at mPP-DG 
synapses, which the authors link to the higher affinity of glycine for GluN2B 
subunits.  
 
This study then examines the developmental change from GluN2B to GluN2A, 
observing that the effects of zinc were constant but the effects of Ro25-6981 
decreased from 30-35% to 15% over the P9/10 and P90 in both areas. At SC-CA1 
this was paralleled by a proportional change in the co-agonist contribution from 
glycine to D-serine, though this was not seen at mPP-DG synapses. In SC-CA1 
levels of D-serine increased 96% over this period (changing the D-serine/glycine 
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ratio from 0.22 to 0.47) and this was linked to changes in DAAO. Also at these 
synapses it was observed that the gliotoxin fluroacetate reduced responses at 
mature but not immature synapses and that the glycine transporter inhibitor 
ALX5407 potentiated responses also only at mature synapses. Based on these 
results and their previous observations on trafficking, the authors suggest the 
ambitious schematic that developmental formation of tripartite synapses at SC-
CA1 promotes D-serine release and uptake of glycine and this then reduces 
retention of GluN2B containing NMDAr in the synapse leading to a greater 
GluN2A component. 
 
Thus there have recently been many insights given into the endogenous regulation 
of the NMDAr co-agonist site. However, such research has typically focussed on 
the postNMDAr and co-agonist binding of the preNMDAr is relatively 
unexplored. Li et al (2007) examined preNMDAr in the visual cortex by 
monitoring spontaneous glutamate release and observed that a co-agonist site 
antagonist was able to reduce the frequency of these events indicating that the 
preNMDAr co-agonist site was also tonically bound. Whilst this is a useful 
observation it is now possible to use novel tools to further understand the 
endogenous regulation of the preNMDAr co-agonist site. In light of the findings 
at postNMDAr, we are interested in the possibility that such investigation may 




There has been a very large amount of interest in the therapeutic potential of the 
NMDAr co-agonist site partial agonist (‘partial co-agonist’) D-cycloserine (DCS) 
for a range of CNS disorders. Whilst there have been many exciting results, the 
truth is that DCS has not been widely adopted as a treatment for any CNS disorder, 
despite having been in use as an antibiotic (DCS is also inhibits bacterial cell wall 
synthesis) for over 50 years. On the one hand it is possible that the focus on DCS 
may merely have been driven by its unique practicality, as DCS is licensed for use 
in humans and has a good pharmacokinetic profile including efficient CNS 
penetration. However, on the other hand it is possible that DCS has not progressed 
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as a treatment because it is already licensed and so there is no financial incentive 
to develop its use. On this note it is interesting that the pharmaceutical company 
Naurex has developed an antibody which mimics the effects of DCS and use this 
as a basis for justifying its therapeutic potential (Moskal et al, 2005; Burgdorf et 
al, 2011).  Alternatively it may that a lack of understanding over its mechanism 
may have contributed to confusion over how DCS should be best used. 
 
1.9.1 Anticonvulsant properties of DCS 
 
A handful of studies have observed an anticonvulsant action of DCS. Wlaz et al 
(1994) tested the effects of DCS at 5, 80 and 320 mg/kg s.c. and found that the 
higher doses produced an elevated current threshold for maximal electrovulsions 
in mice. A time course indicated that this effect was maximum at 60 minutes 
corresponding to peak concentration (860 µM brain tissue) in a pharmacokinetic 
analysis. Loscher et al (1994) examined the effects of 20-320 mg/kg (i.v.) and 
observed an anticonvulsant effect at higher doses in the amgydala-kindled rat 
model. Similar pharmacokinetic findings to the Wlaz study were observed 
although an anticonvulsant effect was seen to persist long after the drug had been 
cleared, suggesting that DCS may produce adaptive changes. Wlaz (1998) again 
observed an anticonvulsant effect of DCS on electroconvulsions in mice with an 
ED50 of 443 mg/kg (i.p.). De Sarro et al (2000) then observed that DCS (1-100 
mg/kg i.p.) did not produce an anticonvulsant effect on audiogenic seizures in mice 
but a low dose (2.5 mg/kg) potentiated the effects of several antiepileptic drugs. 
Finally, Wlaz and Poleszak (2011) again observed an anticonvulsant effect DCS 
on electroconvulsions in mice and interestingly reported that it was potentiated by 
pre-treatment with glycine. However, in contrast to this, seizures are the second 
most commonly reported adverse event for the treatment of tuberculosis with D-
cycloserine (Hwang et al, 2013) where it is typically given orally at 250 mg/day 
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1.9.2 Pro-cognitive properties of DCS 
 
In 1989, Monahan et al, reported that low doses of DCS (0.3-10 mg/kg i.p.) 
increased learning in rats using passive avoidance and place learning tasks 
presenting the first demonstration of a cognitive enhancing effect by DCS. Later, 
Flood et al (1992) examined the effects of DCS on learning in mice over a large 
dose range using a passive avoidance task. Here it was observed that DCS 
enhanced learning with a biphasic or ‘u-shaped’ dose response curve, with a 
maximal effect at 10-30 mg/kg (i.p.). Flood et al (1992) observed that DCS was 
effective when given immediately after training indicating that these effects were 
necessarily on memory. Quartermain et al (1994) presented similar observations 
of a biphasic enhancing effect on mice in a maze learning task. Subsequently many 
studies have found positive effects on learning using DCS at these established 
cognitive enhancing doses, particularly in extinction paradigms pertaining to drug 
addiction (see Tomek et al, 2013) and anxiety disorders (see Hofmann et al, 2013). 
These findings have also been reflected in humans with several clinical studies 
reporting beneficial effects in enhancing cue exposure psychotherapies for anxiety 
disorders (Rodrigues et al, 2014) and the treatment of addiction (Myers and 
Carlezon, 2012). Typically a low dose of around 50 mg is used for DCS in such 
human studies and there is evidence that higher doses are ineffective, again 
indicating a u-shaped dose response (Norberg et al, 2008; Rothbaum, 2008; 
Hofmann et al, 2006). However, unfortunately it is currently unclear what the 
cognitive enhancing doses of DCS represent in terms of cerebrospinal fluid 
concentration.  
 
Sheinin et al (2001) and Dravid et al (2010) have studied the pharmacology of 
DCS at recombinant NMDAr observing that although DCS acts at the GluN1 
subunit, the respective GluN2 subunit determines its efficacy. GluN2A, GluN2B 
and GluN2D containing NMDA receptors all have high sub-maximal DCS 
efficacies (90%, 65% and 94% respectively) whilst at GluN2C containing NMDA 
receptors, DCS has an efficacy 200% that of endogenous agonists. Also, DCS 
affinity varies somewhat between these receptor subtypes with EC50s of 19, 8.2, 
3.3 and 2.9 µM at GluN2A, GluN2B, GluN2C and GluN2D containing NMDA 
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receptors respectively. This has led to the suggestion that, in studies of DCS 
induced cognitive enhancement, efficacious doses represent concentrations which 
elicit a preferential, GluN2C mediated, cognitive enhancing effect and that at 
higher, non-efficacious doses effects at other receptor subtypes may interfere, 
removing the enhancement (Goff, 2012). Recent support for this idea comes from 
the ability of a GluN2C/GluN2D selective potentiator to produce DCS-like 
cognitive effects (Ogden et al, 2014). 
 
1.10 Aims of the project 
 
The overarching hypothesis of the current project was that the co-agonist sites of 
NMDAr are a key functional element in the physiology of the EC. 
 
 The aims of the current project were: 
 
1. To investigate the endogenous regulation of the preNMDAr co-agonist site 
at glutamatergic synapses in the EC in a way comparable to studies on the 
endogenous regulation of the postNMDAr co-agonist site. 
 
2. To establish whether the properties and regulation of the preNMDAr co-
agonist site may provide a basis for selective targeting of preNMDAr in 
the EC. 
 
3. Examine the actions of different co-agonist site partial agonists at 
preNMDAr and postNMDAr to investigate the functional role of the co-
agonist site in the activity of these two receptor populations.  
 
4. To examine the mechanism of DCS action at NMDAr at excitatory 
synapses in the EC and establish whether these receptors could be 
important to the therapeutic effects of DCS. 
 
5. To explore the functional role of the co-agonist sites of pre- and post-
NMDAr on emergent activity at the neuronal network level, with reference 
to epilepsy and cognition. 
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2.1 General Methods 
 
2.1.1 Ethics Statement 
 
The use of animals in medical research requires careful ethical consideration. At 
The University of Bath experiments are performed in accordance with the U.K 
Animals (Scientific Procedures) Act 1986, European Communities Council 
Directive 1986 (86/609/EEC) and are  subject to conformity with the University 
ethical review document. The normative basis of animal research is that the 
sacrifice of a low-salience animal has the potential to alleviate or remove suffering 
for humans produced by disease. During these experiments, this ethical basis was 
kept under consideration and informed the progression of the research towards 




Whole cell patch clamp is the ideal technique for the study of both preNMDAr and 
postNMDAr. A patch pipette is touched against the neuron soma and suction is 
applied, sealing the pipette and cell membrane. This seal is then ruptured by further 
suction producing a circuit with the whole cell membrane and allowing changes in 
conductance of the membrane produced by ion channels to be monitored. After 
gaining whole-cell access the intracellular contents of the cell are exchanged with 
the patch solution. In voltage clamp, the neuron is held at constant voltage and 
changes in conductance are monitored as changes in the current applied to 
maintain this voltage. Ion flow through a channel will then be determined by its 
permeability, the composition of the patch solution and the holding voltage. 
 
The methodology of Berretta and Jones (1996) is a highly suitable and practical 
means for studying the regulation of preNMDAr in the EC. Here a high 
concentration of the NMDAr channel blocker MK801 is included in the patch 
solution and this dialyses into the cell to produce a blockade of postNMDAr. The 
activity of preNMDAr at synapses onto the patched cell is then inferred by 
monitoring the frequency and characteristics of spontaneous events. Tetrodotoxin 
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(TTX) can also be used to block action potentials in the brain slice, removing the 
possibility that network activity and postNMDAr on other cells may influence the 
spontaneous activity. The activity of postNMDAr was examined by electrically 
evoking synaptic currents and isolating the NMDAr component of the response by 
inhibition of all other activated receptors. The influence of magnesium blockade 
is removed by holding neurons at a depolarised voltage. Later in this program we 
studied epileptiform activity in our EC slices and to achieve this extracellular 
recordings were made with slices in an ‘interface’, non-submerged recording 
chamber.  
 
2.2 Slice Preparation 
 
Acute brain slices represent a best-compromise between physiological relevance 
and pharmacological control. The preparation of combined EC-hippocampal slices 
was carried out according to the original description by Jones and Heinemann 
(1988). Male Wistar rats were used and with one exception in the fourth chapter, 
were of juvenile age (45-55g, approximately 15-25 days old) as this age is 
appropriate for the study of preNMDAr and suitable for the preparation of high 




Fig. 2.1. Schematic of the combined EC-hippocampal slice. The CA1, CA3, 
dentate gyrus of the hippocampus and the lateral and medial areas of the EC are 
labelled. 
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Following cervical dislocation, rats were decapitated and the brain was removed 
and immersed in ice-chilled, oxygenated aCSF (artificial cerebrospinal fluid). The 
brain was then prepared by removing the cerebellum, bisecting through the midline 
and removing a small end portion from the dorsal surface of the two brain sections. 
Using the now flat dorsal surface, the brain was attached to a Teflon block ventral 
side up using cyano-acrylate glue. The slicing block was then loaded into a slicing 
chamber filled with ice-chilled, oxygenated aCSF and this was in turn loaded onto 
a Campden Vibroslice (Campden Instruments). 
 
The Vibroslice utilises a vibrating blade horizontally aligned to the block and this 
is then moved slowly through the brain tissue. Vibration and movement speeds 
were adapted based on quality of slices and structural preservation of the brain. 
After each slice is made, the blade is lowered by 350/400uM resulting in slices 
with this thickness. When the ventral hippocampus and rhinal fissure are reached, 
the ventral half of the slices is cut away yielding the combined EC-hippocampus 
slice (Fig. 2.1). Up to twelve of these slices were transferred from the slicing 
chamber to a pre-chamber (BSC-PC, Warner Instruments) containing aCSF at 
room temperature. aCSF in the chamber is bubbled with carbogen producing a 
circular flow of oxygenated aCSF which sustains viability of the acute slices for 
several hours. Slices are stored at room temperature in the pre-chamber for at least 




The artificial cerebrospinal fluid (aCSF) used here contained as standard (in mM) 
NaCl (126), KCl (4), MgSO4 (1.25), NaH2PO4 (1.4), NaHCO3 (24), CaCl2 (2), D-
glucose (10), ascorbic acid (0.57), sodium pyruvate (5) and creatinine 
monohydrate (5). aCSF used for dissection and cutting additionally contained the 
NMDAr channel blocker ketamine (150µM), the nonsteroidal anti-inflammatory 
drug indomethacin (45µM), the anti-oxidant n-acetyl-cysteine (6µM), 
aminoguanidine (25 µM) and Coomassie Brilliant Blue (250 nM). In unpublished 
studies these additives have been shown to enhance slice viability. aCSF was 
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pH7.3 at recording temperature. The different combinations of additivies are 
summarised in table 2.1 
 
 









KCl 4mM 4mM 4mM 
MgSO4 1.25mM 1.25mM 1.25mM 
NaH2PO4 1.4mM 1.4mM 1.4mM 
NaHCO3 24mM 24mM 24mM 
CaCl2 2mM 2mM 2mM 
D-glucose 10mM 10mM 10mM 
Ascorbic acid 570µM 570µM 570µM 
Sodium Pyruvate 5mM 5mM 5mM 
Creatinine 
monohydrate 
5mM 5mM 5mM 
Indomethacin - 45µM 45µM 
N-acetyl-cysteine - 6µM 6µM 
Aminoguanidine - 25µM 25µM 
Coomaise 
brilliant blue 
- 250nM - 
Ketamine - 150µM - 
 
 
   
Table 2.1. Compositions of aCSF solutions used. Three different aCSF compositions 
were used, a standard composition and dissection and storage compositions which 
included additional compounds for slice preservation. 
 
 
2.4 Patch Clamp Recordings 
 
For patch clamp recording individual slices were transferred from storage to the 
recording chamber of an upright BX50WI Olympus microscope. The slices were 
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held in place using a slice anchor and were submerged in aCSF which was 
continuously circulated with a reservoir at a rate of 2ml/min. aCSF was oxygenated 
in the reservoir and heated to 31 ± 1 ºC using an inline heater (SH-27B, Warner 
Instruments) and feedback power supply (TC-324, Warner Instruments). Neurones 
were visualised using a CCD infrared video camera (KP-M1E/K, Hitachi Kokusai 
Electric Inc.) and were selected for whole cell patch clamp based on healthy 
appearance and observable pyramidal morphology. The entire circulating aCSF 
volume (including reservoir) was 10ml and the recording chamber volume was 
0.5-1.0ml. 
 
Whole cell patch-clamp pipettes with a 1–4 MΩ open tip resistance were pulled 
from borosilicate glass pipettes (PG120T, 1.2 mm O.D. x 0.93 mm I.D., Harvard 
Apparatus) using a Flaming/Brown microelectrode puller. Patch pipettes were 
filled with EPSC intracellular recording solution containing (in mM) D-gluconate 
(100), HEPES (40), QX-314 (1), ethylene glycol tetraacetic acid (0.6), NaCl (2), 
Mg-gluconate (5), tetraethylammonium-Cl (5), phosphocreatinine (10), ATP-Na 
(4), GTP-Na (0.3) which was adjusted to pH 7.3 with 1 mM CsOH solution and 
adjusted to 275-295 mOsm by dilution before use. Filled pipettes were then loaded 
onto a microelectrode holder and the two were connected electrically by a 
chlorinated silver wire. The microelectrode holder was then loaded onto the head 
stage of a 200B Axopatch amplifier in the voltage clamp configuration. A silver 
chloride pellet embedded on silver wire is placed in the aCSF of the recording 
chamber to ground the signal. 
 
Signals were filtered at 2 kHz and digitised at 50kHz using a 1200B Digidata 
(Axon Instruments). Data were recorded online to computer hard disk using 
AxoScope software. Access resistance was measured at 5-minute intervals 
throughout experimentation and recordings were not used if this was seem to vary 
by more than 15%. Access resistance was generally of the order of 10-30 MΩ and 
Input resistances for the neurones recorded in these studies were of the order 500-
700 MΩ. Series resistance compensation was not used and liquid junction 
potentials were not routinely compensated for.  
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Following patching, neurones were allowed to stabilise for 15-20 minutes before 
recording commenced and treatment conditions generally lasted 15 minutes. Drugs 
were applied by addition to the perfusion aCSF reservoir. For comparison of 
pooled data under different treatment conditions the mean was calculated for each 
parameter in each cell. These were used to calculate the grand mean for the data 
set and for significance testing with a two-tailed, paired Student’s t-test. Between-
slice changes were assessed using an unpaired, two-tailed Student’s t-test. 
Normalised values were also calculated as percentage change from control and 
these were used to calculate average percentage changes for concentration curves. 
Throughout this thesis error values refer to the standard error of the grand mean. 
 
2.5 Monitoring preNMDAr Activity 
 
Using this intracellular solution and when neurones are held at -60 mV, small 
random excitatory currents are observed due to spontaneous release of synaptic 
glutamate. These events are mediated by glutamatergic receptors present on the 
recording cell. To remove the influence of postNMDAr, MK801 (5mM) is added 
to the intracellular solution and this blocks the postNMDAr in the recording cell 
(Berretta and Jones, 1996; Woodhall et al., 2001; Yang et al., 2006, 2008). In this 
configuration only spontaneous AMPAr events are observed and the activity of 
preNMDAr can be monitored by examining changes in the frequency of quantal 
events. Spontaneous excitatory postsynaptic currents consist of a mixture of 
quantal and multi-quantal events. By blocking voltage gated sodium channels, and 
therefore action potentials, action potential-independent quantal events can be 
isolated, and these are termed miniature excitatory postsynaptic currents 
(mEPSCs). As action potentials may be influenced by NMDAr present on other 
neurones in the network, or on non-terminal regions of the recording cell, 
throughout our studies on preNMDAr we have exclusively examined mEPSCs.  
 
All spontaneous activity was analysed offline using Minianalysis software 
(Synaptosoft, Decatur). Events are detected automatically using a threshold 
algorithm and a checked visually. For each condition the last five minutes was 
analysed and the number of events and their amplitudes, rise (10-90%) and decay 
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(0.37 fraction) times were calculated. The number of events was used as a measure 
of frequency and was generally converted to frequency in Hertz.   
 
2.6 Evoked postNMDAr potentials. 
 
To assess postNMDAr, large postsynaptic responses were evoked by electrical 
stimulation of the slice using a bipolar tungsten electrode, placed laterally to the 
recording site. Biploar stimulations of 10-30 mA and 100 ms were applied every 
20 seconds. These stimulations were generated by a Digitimer DS3 Isolated 
Current Stimulator and triggered using an A.M.P.I Master-8 Pulse Stimulator. 
Intracellular MK801 was not used and TTX was not circulated. Neurones were 
held at +40 mV to relieve voltage dependent blockade by Mg2+ and the 
postNMDAr component was isolated by blocking GABA receptors with 
Bicuculline (20 µM) and picrotoxin (50 µM) and blocking AMPA receptors with 
NBQX (10µM). Under these conditions evoked potentials were mediated by 
postNMDAr and are referred to as evoked NMDAr post synaptic currents 
(eNEPSC). For analysis of eNEPSC, the last five events in each treatment 
condition were analysed using Minianalysis and the amplitude, rise and decay 
times were determined. Bi-exponential fitting was carried out on the averaged 
event of these five, again using Minianalysis.  
 
2.7 Extracellular Recordings 
 
For extracellular field recordings slices were transferred to an interface-type 
recording chamber. Slices are unsubmergerd and the upper face of the slice is open 
to warm, humidified carbogen. Slices are perfused by heated (31 ± 1 ºC), 
oxygenated aCSF from a reservoir at a rate of 1.5 ml/min. Patch pipettes were 
filled with aCSF and were arranged with microelectrode holders and grounding as 
previously described for patch clamp. The EC was visualised using a Leica Wild 
MZ8 microscope and pipettes were lightly pushed into the upper brain slice 
surface.  Field potentials were recorded using an EXT-02 extracellular amplifier 
(NPI Electronic). Signals were low-pass filtered at 0.5 kHz and digitised with a 
sample frequency of 10 kHz using a Minidigi 1B digitizer (Molecular Devices). 
Chapter Two  Materials and Methods 
46 
Co-agonist Regulation of Pre and Postsynaptic NMDA Receptors in the Entorhinal Cortex 
Data was recorded continuously to hard drive using Axoscope software. Drugs 
were applied by addition to perfusion aCSF reservoirs and treatment epochs were 
30 minutes. 
 
Epileptiform activity was induced by addition of strychnine (1µM), bicuculline 
(20µM) and picrotoxin (50µM) to the perfusion aCSF. Epileptiform activity 
generally began within 30 minutes of this treatment and was left to stabilise for at 
least 30 minutes after initiation before recording began. Novel methodology was 
adopted for the analysis of the epileptiform activity and this is given later. 
 
2.8 Drugs  
 
Drugs were generally made up as stock solutions (indicated below) and stored in 
aliquots at -20 ºC. Drugs were then defrosted on the day of use and added to aCSF 
reservoirs at such a quantity to produce the desired final concentration. For 
Picrotoxin (Sigma), a stock solution was made up in DMSO (Dimethyl sulfoxide) 
each day. MK801 (abcam) was dissolved directly into patch solution using 
sonication. Salts contained in aCSF were purchased from Fisher Scientific or 
Merck/BDH. Indomethacin, n-acetyl-L-cysteine, aminoguanidine, uric acid, 
Coomassie Brilliant Blue, and all items used for preparation of intracellular patch 
solution, aside from QX-314 (Tocris), were supplied by Sigma. Ketamine was 
purchased from Fort Dodge Animal Health Ltd.  
 
Recombinant Rhodotorula gracilis D-amino acid oxidase and Bacillus subtilis 
glycine oxidase were provided by Professor Loredano Pollegioni, University of 
Insubria. These enzymes are expressed in Escherichia coli and purified as 
described in Fantinato et al., 2001 and Job et al., 2002. Use of these enzymes 
differed to that of pharmacological drugs and were applied to slices by inclusion 
in the perfusion aCSF for 45 minutes prior to and then throughout recordings. The 
drugs used were: 
 
 2-AP5 (D-2-Amino-5-phosphonopentanoic acid), Tocris. H2O stock 
solution. 
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 ACBC (1-Aminocyclobutane-1-carboxylic acid) (Tocris). H2O stock 
solution. 
 Bicuculline methiodide, Tocris.  H2O stock solution. 
 CGS15943 (9-Chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-
amine) (Tocris). DMSO stock solution.  
 CPPG ((RS)-α-Cyclopropyl-4-phosphonophenylglycine) (Tocris). DMSO 
stock solution. 
 DCKA (5,7-Dichloro-4-hydroxyquinoline-2-carboxylic acid) sodium salt 
(Tocris). DMSO stock solution. 
 D-cycloserine (Sigma). H2O Stock solution.  
 D-serine (Tocris). H2O stock solution.  
 Fluoroacetate sodium salt (Sigma). DMSO stock solution. 
 Glycine (Tocris). H2O stock solution.  
 MCPG ((RS)-α-Methyl-4-carboxyphenylglycine) sodium salt (Tocris). 
DMSO stock solution. 
 NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-
dione), Tocris. DMSO stock solution 
 NMDA (N-Methyl-D-aspartic acid) (Tocris). H2O stock solution.  
 Suramin hexamethodium salt (Tocris). DMSO stock solution. Strychnine 
hydrochloride (Tocris). H2O stock solution. 
 Tetrodotoxin citrate, Alomone Labs. H2O stock solution. 
 UBP 141 ((2R*,3S*)-1-(Phenanthrenyl-3-carbonyl)piperazine-2,3-
dicarboxylic acid) (a gift from Professor David Jane, University of 
Bristol). DMSO stock solution. 
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3.1 Introduction 
 
As discussed in section 1.6, preNMDAr are now known to have a widespread 
expression in the CNS and are an important mechanism for controlling synaptic 
transmission and tuning neuronal networks. Several studies have indicated a role 
of preNMDAr in mediating synaptic plasticity changes whilst additionally work 
in this laboratory has shown that preNMDAr appear to have an enhanced activity 
in epilepsy and may contribute to seizure activity. Unlike postNMDAr, 
preNMDAr appear to have a diminished importance in the adult brain and so 
targeting the elevated activity of these receptors in epilepsy is a therapeutically 
practical approach for anticonvulsant development. However, clearly the greatest 
problem for both the wider study and therapeutic relevance of preNMDAr is that 
currently there is no basis for selectively targeting these receptors. 
 
We are particularly interested in the EC due to its role in both cognitive 
information processing and seizure pathology in TLE. Also many previous studies 
have examined preNMDAr in this area and these receptors are arguably most well 
defined at excitatory synapses in the EC. Although sporadic reports have made 
more direct observations of preNMDAr function, the methodology developed by 
Berreta and Jones (1996) remains the most practical for the study of these 
receptors. As with many other regions, preNMDAr in the EC exert a tonic 
facilitation of glutamate release and we use the facilitation of spontaneous 
glutamate release as an indirect reporter for preNMDAr function. By blocking 
postNMDAr in the recording cell with a high concentration of MK801 added to 
patch clamp solutions we can isolate AMPA receptor mediated mEPSCs. We 
monitor the frequency of these glutamatergic events in the recording cell and can 
add NMDAr ligands to the brain slice to selectively monitor the effect on 
glutamate release at synapses onto the recorded cell. 
 
The tonic activation of preNMDAr at excitatory synapses in the medial EC was 
demonstrated by a decrease in the frequency of AMPA receptor mediated events, 
without any change in event amplitude, upon addition of the glutamate site 
antagonist AP5 (Berretta and Jones, 1996). This indicated that the glutamate site 
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of the preNMDAr is tonically bound by ambient glutamate, in contrast to 
postNMDAr. Later, work by Woodhall et al (2001) demonstrated that the 
preNMDAr glutamate binding site was not fully bound and large increases in 
frequency were produced by the NMDAr agonist homoquinolic acid (HQA). This 
study also demonstrated that the preNMDAr in the medial EC were likely to have 
a GluN2B/GluN1 diheteromeric composition and that calcium entry mediated the 
facilitatory effects of preNMDAr in this region.  
 
Novel tools have contributed greatly to an increase in understanding of co-agonist 
regulation of NMDAr (see section 1.8). In particular, the co-agonist scavenging 
enzymes glycine oxidase (GO) and D-amino acid oxidase (DAAO). Purified 
DAAO from the yeast Rhodotorula gracilis (RgDAAO) and GO from the 
bacterium Bacillus subtilis (BsGO) can be produced by recombinant expression in 
Escherichia coli cells (Fantinato et al, 2001; Job et al, 2002) and then used to 
selectively metabolise the substrate co-agonist in brain slices during a period of 
incubation (Fossat et al, 2011; le Bail et al, 2014). Secondly is the astrocyte poison 
fluoroacetate which is selectively uptaken into glial cells by an unknown transport 
mechanism (Waniewski and Martin, 1998). Within cells, fluoroacetate is 
incorporated into the mitochondrial Krebs cycle (aka citric acid cycle or 
tricarboxylic acid cycle) which is central to the production of the cellular currency 
of energy, adenosine triphosphate. In the Krebs cycle fluoroacetate is converted to 
fluorocitrate which inhibits the enzyme aconitase arresting the cycle and causing 
metabolic inhibition and toxicity (Hassel et al, 1997; Paulsen et al, 1987). In this 
chapter we have utilised these novel tools to further examine the preNMDAr in the 
EC. The aim of this work was to establish the nature of co-agonist regulation of 
the preNMDAr to ascertain whether this may be utilised for the selective targeting 




All experiments in this chapter were performed using brain slices from juvenile 
rats as outlined in the methods section. mEPSCs were recorded in layer V neurones 
of the medial EC. In all experiments MK801 was added to intracellular patch 
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solutions at a concentration of 5 mM to block postNMDAr in the recorded cell and 
mEPSCs were isolated by application of TTX at a concentration of 1 µM. All cells 
had pyramidal morphology. In these cells EPSCs occur as spontaneously occurring 
inward currents when held at a potential of -60 mV. Although the frequency of 
events in layers II and V are low, clear preNMDAr mediated changes in frequency 
can be observed here (Jones and Woodhall, 2005). Data analysis and significance 
testing was carried out as outlined previously. 
 
RgDAAO and BsGO were supplied by Professor Loredano Pollegioni of the 
University of Insubria, Italy. These enzymes were overexpressed in Escherichia 
coli cells and purified with final activities of 100 ± 15 U/mg (RgDAAO) and 0.9 
± 0.2 U/mg protein (BsGO) and high specificity for the respective co-agonist. In 
these experiments slices were incubated with enzymes (at 0.2 U/ml) at room 
temperature for at least 45 minutes before recording started and incubation 
continued during recording (recordings are made at 32 oC). Matched slices from 
the same animal were used for control and were treated in the same manner but 
using the appropriate buffer without enzyme. Experiments using fluoroacetate 




3.3.1 Effects of exogenously applied co-agonists on mEPSCs 
 
To investigate the binding of the preNMDAr we first examined the effects of the 
endogenous NMDAr co-agonists glycine and D-serine on spontaneous AMPA 
receptor mediated events as a reporter for presynaptic glutamate release. mEPSCs 
were chosen over sEPSCs to avoid any potential complications of network derived 
effects from postNMDAr at other neurones. mEPSCs were recorded in three cells 
and glycine was applied at a concentration of 100 µM. Results are summarised in 
Fig. 3.1.A. No significant effects were detected in this data set. Mean frequency 
was 0.75 ± 0.13 Hz under control conditions and 0.73 ± 0.12 Hz in the presence of 
exogenous glycine. Mean event amplitude was 6.36 ± 0.13 pA in control and 6.00 
± 0.18 pA in the glycine treated condition. Mean mEPSC rise times were 4.7 ± 
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0.67 ms in control and 5.34 ± 0.30 ms after treatment. Mean decay time were 6.3 












































































Fig. 3.1. The effects of glycine (A) and D-serine (B) on mEPSCs in EC 
neurones. A. Upper traces show sample voltage clamp recordings of sEPSCs in 
layer V neurones in the medial EC in control and treatment conditions. Lower 
traces depict overlaid averaged events from control (black) and treatment 
conditions (grey). Bar graphs represent average frequency and amplitude data from 
3 neurones in the case of glycine and 4 in the D-serine experiment. The addition of 
glycine had little effect on the frequency or amplitude of mEPSCs. Exogenous D-
serine was similarly seen to have no observable effects.  
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The effects of exogenous D-serine (100 µM) on mEPSCs were tested in four 
neurones. These results are summarised in Fig. 3.1.B. Again no significant effects 
were observed here. Mean frequency was 0.51 ± 0.03 Hz in the control condition 
and 0.56 ± 0.15 Hz during perfusion of D-serine. Mean event amplitude was 6.7 ± 
0.1 pA in control and 6.52 ± 0.3 pA following treatment. Mean rise times were 4.3 
± 0.3 ms v 4.5 ± 0.3 ms and mean decay times were 5.5 ± 3.3 ms v 6.5 ± 0.3 ms in 
the control and D-serine treatment conditions respectively. 
 
The lack of any significant effect for either of glycine or D-serine on mEPSC 
frequency indicated that these co-agonists were not affecting preNMDAr function. 
The most likely explanation for this was that the co-agonist site of the preNMDAr 
was already highly bound by an endogenous co-agonist and this situation has 
already been demonstrated in the visual cortex (Li et al, 2007).  
 
3.3.2 Effects of the co-agonist site antagonist DCKA on mEPSCs 
 
To test whether tonic binding of preNMDAr by an endogenous co-agonist 
contributes to the tonic activation of these receptors the effects of the NMDAr co-
agonist site antagonist DCKA (10µM) on AMPA receptor dependent mEPSCs was 
tested in four neurones. These results are summarised in Fig. 3.2. DCKA was seen 
to produce a significant decrease in the frequency of events (p<0.01), no other 
significant effects were observed. mEPSC frequency was 0.80 ± 0.05 Hz under 
control conditions and 0.59 ± 0.01 Hz in the presence of DCKA, a decrease of 
~27%. Mean amplitude was 8.37 ± 0.5 pA under control conditions and 7.8 ± 0.4 
pA in the presence of DCKA. Mean event rise time was 4.8 ± 0.3 ms in control 
and 4.8 ± 0.4 ms following treatment. Mean event decay times were 5.8 ± 0.5 ms 
and 6.0 ± 0.7 ms respectively. The significant reduction of spontaneous excitatory 
events following application of DCKA, without any change in event amplitude, is 
a typical of a presynaptic inhibition of quantal vesicular transmitter release. This 
result is indicative of an antagonist effect at the preNMDAr which act to tonically 
facilitate glutamate release at excitatory synapses in this region (Berretta and 
Jones, 1996) and implied that the co-agonist binding site of the preNMDAr is 
indeed endogenously bound here.  
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Fig. 3.2. The co-agonist site antagonist DCKA elicits a reduction in 
spontaneous glutamate release. Upper traces show sample voltage clamp 
recordings of sEPSCs in layer V neurones in the medial EC in control and treatment 
conditions. Averaged traces are presented from control (black) and DCKA (red) 
conditions, overlaid. Amplitude histogram depicts the frequency distribution of 
event amplitudes in control (black) and DCKA (red) conditions for four cells. In 
both cases a single peak, normal type distribution with a slight skew towards larger 
events is observed, typical of such data. The distribution of event amplitudes is 
qualitatively the same between conditions, indicating that changes in frequency 
were not due to a shift in amplitude distribution. Bar charts depict the average 
frequency and amplitude data. mEPSC frequency was significantly lower in the 
DCKA condition indicating a presynaptic inhibition of spontaneous glutamate 
release. * denotes p<0.05 significance level. 
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To ascertain whether this effect was truly mediated by preNMDAr we examined 
whether the response to DCKA was affected by treatment with the prototypic 
NMDAr antagonist AP5.  In five cells the competitive glutamate site antagonist 
AP5 was applied followed by DCKA, without washing out AP5. The frequency of 
mEPSCs was significantly decreased in the presence of AP5 (p<0.01) and was 
subsequently unchanged by addition of DCKA (p<0.01). No other significant 








































Fig. 3.3. The glutamate site antagonist 2-AP5 reduces mEPSC frequency and 
precludes the effects of DCKA. Sample traces are shown of recorded mEPSCs in 
layer V EC neurones in each condition. Bar charts depict average values from five 
neurones. 2-AP5 significantly and selectively reduced mEPSC frequency but 
further addition of DCKA elicited no further change. * denotes p<0.05, ‘ns’ 
denotes not significant. 
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± 0.1 Hz under control conditions, 0.40 ± 0.1 Hz in the presence of AP5 alone, and 
0.38 ± 0.1 Hz in the presence of AP5 and DCKA.  
 
Thus AP5 precluded the inhibitory effect of DCKA confirming that this response 
was mediated by preNMDAr. Collectively these results indicate the following: 
preNMDAr at excitatory synapses in the EC are tonically bound by an endogenous 
co-agonist. The lack of effect by application of glycine or D-serine indicates that 
the endogenous binding is likely to be close to saturation. The response of mEPSCs 
to DCKA treatment is a suitable basis for the study of the tonic binding of 
preNMDAr by endogenous co-agonists. Rise times were 4.6 2.3 ms 4.7 ± 2.4 and 
4.8 ± 2.4 in the control, AP5 and AP5 and DCKA treatment conditions 
respectively. Accordingly, mean decay times were 6.6 ± 3.5 ms 6.3 ± 3.6 ms and 
6.3 ± 3.3 ms. 
 
3.3.3 Effects of enzymatic degradation of glycine on mEPSCs 
 
To attempt to identify the endogenous co-agonist at preNMDAr in the medial EC 
we now utilised co-agonist scavenging enzymes to selectively breakdown 
candidate ligands, an approach which has been useful for the investigation of co-
agonists of postNMDAr (Fossat et al., 2011; Papouin et al., 2012).  
 
We first investigated the possibility that the endogenous co-agonist was glycine 
and incubated six brain slices with BsGO. For comparison, six slices from the same 
preparation were subject to a sham incubation with empty buffer. In cells from 
each set of slices, AMPA receptor dependent mEPSCs were recorded and DCKA 
(10 µM) was applied. These results are displayed in shown in Fig. 3.4. In both 
BsGO and matched slices, mEPSC frequently was significantly lower than control 
in the presence of DCKA (p<0.05 and p<0.01 respectively). There were no other 
significant differences. The frequency of mEPSCs in untreated slices was 0.33 ± 
0.04 Hz in the control period and 0.24 ± 0.026 Hz with DCKA (p<0.01) whilst in 
BsGO treated slices these values were 0.41 ± 0.1 Hz and 0.32 ± 0.1 Hz (p<0.05) 
respectively. Mean amplitudes were 8.4 ± 1.4 pA for control v 8.4 ± 1.6 pA for 
DCKA in untreated slices and 7.7 ± 4.1 pA for control v 7.95 ± 0.9 pA for DCKA  
Chapter Three  Co-agonist Regulation of PreNMDAr 
57 
Co-agonist Regulation of Pre and Postsynaptic NMDA Receptors in the Entorhinal Cortex 
 





































naïve - DCKA (10µM)
BsGO control






Fig. 3.4. Enzymatic removal of endogenous glycine does not affect 
spontaneous release of glutamate in the EC. Above, sample traces from mEPSC 
recordings, middle, bar chart of average frequency data from six neurones each, 
below, amplitude distribution histograms. Slices incubated with BsGO to remove 
endogenous glycine exhibited no difference to untreated, matched slices. Control 
mEPSC frequency was similar between groups and the previously observed 
frequency lowering effect of DCKA was present in both groups.  * denotes p<0.05 
significance level. 
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in BsGO treated slices. Control v DCKA rise times were 4.7 ± 0.9 ms v 4.7 ± 0.9 
ms in untreated slices and 4.4 ± 0.4 ms v 4.3 ± 0.4 ms in BsGO treated slices. 
According decay time values were 7.3 ± 1.2 ms v 7.5 ± 1.3 ms in untreated slices 
and 7.1 ± 0.8 ms v 7.2 ± 0.75 ms in BsGO treated brain slices. Overall there was 
little difference between untreated and BsGO treated brain slices and the frequency 
of events was lowered in the presence of a co-agonist site antagonist in each. This 
indicated that the presence of glycine was unimportant to the function of 
preNMDAr suggesting that glycine was not regulating these receptors. 
 
3.3.4 Effects of enzymatic degradation of D-serine on mEPSCs 
 
Next we conducted the same format of experimentation but replacing BsGO with 
the enzyme RgDAAO which degrades the co-agonist D-serine. Again the effects 
of DCKA (10 µM) on AMPA receptor dependent mEPSCs were examined in six 
enzyme treated slices and six matched, untreated slices. These results are shown 
in Fig. 3.5. The frequency of mEPSCs was significantly reduced in the presence 
of DCKA in the untreated brain slices and no other significant differences were 
seen. The frequency of mEPSCs in untreated slices was 0.65 ± 0.13 Hz in the 
control period and 0.42 ± 0.10 Hz (p<0.05) in the presence of DCKA. Whereas the 
frequency of mEPSCs in RgDAAO treated slices was 0.38 ± 0.03 Hz in the control 
period and 0.36 ± 0.05 Hz in the presence of DCKA. Event amplitudes in control 
v DCKA conditions were 8.2 ± 0.5 pA v 8.1 ± 0.5 pA in untreated slices and 7.3 ± 
0.3 pA v 7.5 ± 0.3 pA in RgDAAO treated slices. Rise times in control v DCKA 
were 4.8 ± 0.9 ms v 4.7 ± 0.9 ms in untreated slices and 4.8 ± 0.9 ms v 5.1 ± 1.0 
ms in RgDAAO treated slices. Finally, decay times were 6.4 ± 1.2 ms v 6.7 ± 1.3 
ms in untreated slices and 6.5 ± 1.5 ms v 7.1 ± 2.0 ms in RgDAAO treated slices. 
The frequency lowering effect of DCKA was thus not present in slices treated in 
RgDAAO to remove endogenous D-serine and these slices also had a noticeably 
lower control frequency. These results thereby indicated that the presence of D-
serine was necessary for the facilitatory effects of preNMDAr in the EC and was 
likely to be the endogenous co-agonist at these receptors.  
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Fig. 3.5. Enzymatic removal of endogenous D-serine precludes the effects of 
DCKA on AMPA receptor mediated mEPSCs in the EC. Above, sample traces 
from mEPSC recordings, middle, bar chart of average frequency data from six 
neurones each, below, amplitude distribution histograms. Slices incubated with 
RgDAAO to remove endogenous D-serine exhibited a lower control frequency 
than untreated, matched slices. Again DCKA was seen to lower mEPSC frequency 
in naïve slices, though this was not present in slices treated with RgDAAO. 
Importantly, there were no substantive changes in the amplitude of events between 
the groups, indicating that the changes in frequency were due to changes in the 
probability of release. * denotes p<0.05 significance level. 
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3.3.5 Effects of glial cell inhibition by fluoroacetate on mEPSCs 
 
As previous studies have indicated that astrocytes are a source of D-serine at 
NMDAr we now investigated the possibility that these cells may provide D-serine 
for the tonic facilitation of glutamate release by preNMDAr in the EC. We used 
the metabolic inhibitor fluoroacetate which is selectively uptaken by glial cells, to 
investigate this possibility.  
 
Six EC-hippocampal slices were treated with fluoroacetate as outlined in 3.2 and 
six untreated, matched slices were used for comparison. Again AMPA receptor 
mediated mEPSCs were recorded in treated and untreated slices during control 
conditions and following perfusion of the co-agonist site antagonist DCKA (10 
µM). In untreated slices the frequency of mEPSCs was significantly lowered from 
control during perfusion of DCKA and no other significant differences were seen. 
In untreated slices mEPSC frequency was 0.66 ± 0.13 Hz under control conditions 
and 0.45 ± 0.09 Hz (p<0.05) in the presence of DCKA whilst in fluoroacetate 
treated slices mEPSC frequency was 0.35 ± 0.03 Hz in the control period and 0.34 
± 0.04 Hz in the presence of DCKA. Mean amplitudes for control v DCKA were 
7.6 ± 1.5 pA v 7.9 ± 1.9 pA in matched untreated slices and 7.0 ± 0.7 pA v 7.1 ± 
0.5 pA in fluoroacetate treated slices. Mean mEPSC rise times for control v DCKA 
were 5.0 ± 0.9 ms v 5.1 ± 1.0 ms in untreated and 5.0 ± 0.5 ms v 5.25 ± 0.5 ms in 
fluoroacetate treated slices. Respective decay times were 8.9 ± 2.4 ms v 8.4 ± 2.2 
ms in untreated and 7.5 ± 0.96 ms v 8.9 ± 1.3 ms in slices treated with 
fluoroacetate. Again the decrease in frequency independent of a change in 
amplitude with the co-agonist site antagonist DCKA indicated that the preNMDAr 
co-agonist site was tonically bound in untreated brain slices but not in slices which 
were treated with fluoroacetate to inhibit glial cell metabolism. Also the control 
frequency was noticeably lower in matched, untreated slices compared to 
fluoroacetate slices, mirroring the effects of RgDAAO. These findings suggested 
that glial cell function is necessary for the action of preNMDAr and that these cells 
may be important for the regulation of the preNMDAr co-agonist site by D-serine. 
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Fig. 3.6.  Compromising glial cell function reduces the frequency of mEPSCs 
in the EC. Above, sample traces from mEPSC recordings, middle, bar chart of 
average frequency data from six neurones each, below, amplitude distribution 
histograms. Incubation with the glial cell metabolic inhibitor sodium fluoroacetate 
was seen to produce a lower mEPSC control frequency and an abolished DCKA 
response, compared to matched slices. Again there were no changes in the 
distribution of event amplitudes between the groups. * denotes p<0.05 significance 
level. 
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3.3.6 Effects of D-serine on mEPSCs in fluoroacetate treated slices 
 
However, as glial cells have many roles and in particular are also involved in the 
recycling of glutamate further experimentation was needed to link this result to the 
co-agonist site of the preNMDAr. To achieve this we recorded mEPSCs in five 
brain slices treated with fluoroacetate and applied exogenous D-serine (100 µM). 
Results from this experiment are shown in Fig. 3.7. Here D-serine was seen to 
elicit a significant increase in mEPSC frequency, with no changes in any other 
event parameter. Under control conditions the frequency of mEPSCs was 0.23 ± 
0.04 Hz and this increased to 0.3 ± 0.04 Hz in the presence of exogenous D-serine 
(p<0.05). Mean amplitude was 6.3 ± 0.13 pA in control and 6.2 ± 0.07 pA 














































Fig. 3.7.  D-serine increases mEPSC frequency in slices with compromised 
glial function. Above, sample traces from mEPSC recordings, lower left, bar chart 
of average frequency data from six neurones, lower right, amplitude distribution 
histograms. In slices treated with the glial cell metabolic inhibitor sodium 
fluoroacetate mEPSC frequency was significantly increased in the presence of 
exogenous D-serine, compared to control. There were no changes in the 
distribution of event amplitudes between the two conditions. * denotes p<0.05 
significance level. 
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ms v 5.1 ± 0.16 ms and decay times were 8.1 ± 0.37 ms v 6.9 ± 0.48 ms. Thus in 
contrast to naïve slices, in fluoroacetate treated slices D-serine selectively 
increased the frequency of AMPA receptor dependent mEPSCs, indicative of a 
facilitatory action at preNMDAr. This indicated that a decreased supply of co-
agonist was a mechanism for the decrease in preNMDAr activity produced by 
disrupting glial cells with fluoroacetate. Therefore it is likely that astrocytes are 
acting as a source of D-serine at the preNMDAr observed here. 
 
Although the frequency of mEPSCs was significantly increased by D-serine in 
fluoroacetate treated slices, it remained noticeably low. As we have previously 
mentioned, astroglial cells are also involved in the production of glutamate and so 
we now investigated whether this role is important in the anti-preNMDAr effect 
produced by fluoroacetate treatment. To this end the effects of the glutamate site 
agonist NMDA (100µM) on mEPSCs were examined in five untreated brain slices 
and five slices treated with fluoroacetate. In both untreated and fluoroacetate 
treated slices, NMDA produced significant increases in mEPSC frequency, no 
other significant changes were observed. mEPSC frequency in untreated cells was 
0.56 ± 0.17 Hz in control and 1.03 ± 0.25 Hz (p<0.05) in the presence of NMDA 
whilst in fluoroacetate treated slices, mEPSC frequency changed  from 0.32 ± 
0.075 Hz in control to 0.49 ± 0.13 Hz (p<0.05) in the presence of NMDA. Mean 
mEPSC amplitudes for control v NMDA perfusion were 7.4 ± 0.48 pA v 7.4 ± 
0.30 pA in untreated slices and 7.5 ± 1.3 pA v 7.2 ± 0.59 pA in fluoroacetate treated 
slices. Likewise, rise times were 5.0 ± 0.71 ms v 6.2 ± 0.37 ms and 5.2 ± 0.66 ms 
v 6.4 ± 0.51 ms and decay times were 7.6 ± 0.93 ms v 7.2 ± 1.01 ms and 7.4 ± 0.93 
ms v 7.6 ± 1.03 ms for untreated and fluoroacetate treated slices respectively.  
 
Thus in both naïve slices and slices in which glial cell function has been 
compromised by fluoroacetate, NMDA is able to elicit increases in mEPSC event 
frequency indicating that the glutamate binding site of preNMDAr is not fully 
bound in both conditions. It is interesting that in naïve slices the increase in 
frequency with NMDA was ~131% whist in fluoroacetate treated slices this was 
noticeable less (58%). This suggests that compromising glial cells does was not 
compromising glutamate production, as this would logically be expected to 
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produce an increase in response to a glutamate site agonist. Instead it is possible 
that a decreased D-serine at preNMDAr is limiting the activation of these receptors 
in response to activation of the glutamate site. 
 
It is possible that glial cells regulate both the glutamate and co-agonist sites of the 
preNMDAr. This then may explain why the facilitatory effect of the glutamate site 
agonist NMDA was reduced in slices with compromised glial cell function, as 
NMDAr are thought to require the presence of both agonist and co-agonist to open 
and the activation of these receptors may then be limited by reduced binding of the 
co-agonist site. Likewise the only partial rescue of mEPSC frequency by D-serine 
in fluoroacetate treated slices may be due to a reciprocal effect.  
 
On the basis of these results then, we can conclude that astroglia are crucial to the 
tonic facilitatory action of preNMDAr at excitatory synapses in the EC. This 
regulation is mediated by D-serine and astrocytes are likely to be the source of this 
co-agonist at preNMDAr. However, it is noted that the reduction in control 
mEPSC frequency by fluoroacetate was somewhat less than that produced by 
RgDAAO and therefore we have not ruled out non-astrocytic sources of D-serine 
at preNMDAr. Though it is interesting to speculate on possible explanations for 
the complicated observations we have made here a more in depth study of these 
issues is limited by a lack of tools for direct investigation into preNMDAr 
pharmacology. However we have made some potentially useful observations 
regarding the regulation of these receptors (see 3.4.3). 
 
3.3.7 Effects of other gliotransmitter receptor ligands on mEPSCs 
 
The rescue of mEPSC frequency with D-serine in fluoroacetate treated slices 
strongly implies that glial production of this co-agonist at preNMDAr was 
impaired in this situation. However, it is noted that D-serine did not restore mEPSC 
frequency to a full extent compared to the reduction produced by fluoroacetate 
incubation suggesting that other mechanisms may also be important. Indeed as 
discussed in section 1.7, glial cells regulate synaptic transmission through multiple 
mechanisms. In particular, purinergic transmission is a well-known mechanism for 
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astrocyte-neuron signaling and we were interested in the possibility that release of 
adenosine or ATP may be important in the response observed here. To investigate 
what other mechanisms could mediate the reduced mEPSC frequency in 
fluoroacetate treated slices we examined the effects of several gliotransmitter 
receptor ligands on mEPSCs in untreated slices. Results from these experiments 
are shown in table. 3.1.  
 
Table 3.1. The effects of the purinergic antagonists Suramin and CGS15943, and the 
GluN2C/D specific antagonist UBP141 on the frequency, amplitude and kinetics of 
mEPSCs. * denotes significantly different compared to control (p<0.05). n=3 for each 
experiment. 
 
The broad spectrum P2X purinergic receptor antagonist suramin (100 µM) was 
added followed by DCKA (without washout; 10 µM) to three slices. The frequency 
of mEPSCs was significantly lowered following addition of DCKA, no other 
significant effects were seen. Then CGS15943 (1 µM), which is an antagonist of 
A1, A2A, A2B and A3 adenosine receptor, was added to three slices followed by 
DCKA (without washout; 10 µM). Again the only significant effect observed was 





















0.49 ± 0.07 
0.45 ± 0.04 
0.27 ± 0.01* 
 
0.46 ± 0.12 
0.48 ± 0.12 
0.34 ± 0.11* 
 
0.43 ± 0.09 
0.45 ± 0.08 
9.6 ± 1.1 
9.3 ± 1.0 
8.2 ± 0.7 
 
8.4 ± 1.1 
8.8 ± 1.4 
8.9 ± 1.1 
 
9.5 ± 2.1 
9.7 ± 1.5 
5.3 ± 0.9 
5.3 ± 0.9 
6.2 ± 0.6 
 
4.8 ± 0.6 
5.2 ± 0.5 
5.0 ± 0.6 
 
4.5 ± 1.2 
5.2 ± 1.4 
9.0 ± 1.5 
9.7 ± 0.7 
9.3 ± 1.9 
 
6.5 ± 1.0 
7.5 ± 1.0 
8.0 ± 0.9 
 
6.6 ± 1.0 
6.0 ± 2.6 
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indicated that purinergic signaling is does not contribute to spontaneous glutamate 
release in the EC, at least not in a tonic manner, and is therefore unlikely to be 
involved in the effects of fluoroacetate. 
 
Whilst an effect at preNMDAr is the most parsimonious explanation for the 
changes in mEPSC frequency observed here it is also interesting to consider the 
possibility that NMDAr on astrocytes themselves could also be involved. Recently 
functional NMDAr have been observed on astrocytes and have been shown to 
contain GluN2C/D subunits (Palygin et al, 2011). Previous work has indicated that 
NMDAr dependent tonic facilitation of mEPSCs in the EC is mediated by GluN2B 
heterodimeric receptors. Given this discrepancy in subunit dependence, it is 
unlikely that astrocyte NMDAr could be responsible for changes in mEPSC 
frequency though we decided to further examine this possibility using the NMDAr 
antagonist UBP141 which has a relative specificity for the GluN2C/D subunit 
(Morley et al., 2005). In three untreated slices we examined the effects of UBP141 
(2.5 µM) on AMPA receptor mediated mEPSCs (table 3.1). However, no changes 
were observed from control during perfusion of UBP141. This indicated that 
GluN2C/D receptors were not involved in NMDAr-dependent tonic facilitation of 
glutamate release. Therefore it is unlikely that astrocyte NMDAr were involved in 
the effects on mEPSC frequency previously observed.  
 
An additional consideration are presynaptic mGluRs which also regulate 
glutamate release in the EC and presynaptic mGluRs have prevsiouly been 
observed to be an astrocyte target (e.g. see Fiacco and McCarthy, 2004; Clasadonte 
and Haydon, 2012). However, it has previously been shown that such receptors 
here are also not tonically active (Evans et al, 2000) and are therefore not a 
candidate for a reduction in control frequency in treated slices. 
 
In summary then, it appears as though purinergic signaling is not involved in tonic 
glial-dependent facilitation of mEPSCs. Additionally it is unlikely that NMDAr 
present on astrocytes themselves are involved in mediating the changes in mEPSC 
frequency we have observed with the co-agonist site antagonist DCKA.  
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3.4 Discussion 
 
3.4.1 Overview  
 
In this chapter I have utilized AMPA receptor mediated mEPSC frequency as a 
reporter of preNMDAr activity and have presented experimental data which sheds 
further light on the properties of preNMDAr in the EC (see Fig. 3.8). Exogenously 
applying the co-agonists glycine and D-serine did not affect mEPSCs, though 
application of the co-agonist site antagonist DCKA selectively reduced the 
frequency of these events. This implied that the preNMDAr co-agonist site was 
endogenously bound in our slices and this contributed to the tonic facilitation of 
glutamate release by these receptors.  Enzymatic degradation of glycine and D-
serine was then employed and it was seen that whilst removal of glycine produced 










Fig. 3.8. Sites of action for compounds used to investigate co-agonist 
regulation of preNMDAr. DCKA, DAAO and fluroacetate were all seen to 
compromise the activity of these receptors. DCKA acts as an antagonist of the co-
agonist site on the receptors themselves whilst DAAO breaks down the 
endogenous ligand D-serine, and fluroacetate inhibits its production by glial cells. 
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and completely precluded the effects of DCKA. This strongly implied that D-
serine is the endogenous co-agonist at these receptors. Both of the effects of D-
serine removal were mimicked by inhibition of glial cell metabolism by 
fluoroacetate and exogenous D-serine was able to partially rescue the mEPSC 
frequency which indicated that glial cells were likely to be a source of this 
endogenous D-serine at the preNMDAr. We were unable to detect any 
involvement of purinergic transmission or astrocyte NMDAr in the tonic 
regulation of mEPSC frequency.  
 
3.4.2 Sources of D-serine 
 
In this work we have provided some evidence that glial cells are a source of D-
serine at preNMDAr. However, the production of D-serine by glial cells is highly 
controversial and so a fair overview of the conflicting evidence to date is 
necessary.  
 
In 1999, Wolosker et al first cloned serine racemase and performed 
immunohistochemical experiments to detect the expression of this enzyme and D-
serine itself in the hippocampus and unspecified regions of the cortex of juvenile 
rats. Here it was observed that both of these elements were selectively enriched in 
glial cells including astrocytes. In 2005, Mothet et al investigated D-serine release 
from astrocytes cultures, using a novel bioassay for D-serine detection. Here it was 
observed that kainate, AMPA and metabotropic glutamate receptor agonists 
prompt D-serine release and this occurs through an exocytotic mechanism which 
is dependent on both intracellular and extracellular calcium. 
 
From here several subsequent studies have made similar observations. In 2006, 
Panatier et al examined the rat hypothalamic supraoptic nucleus which only 
contains oxytocinergic and vasopressinergic neurons. Immunohistochemistry here 
indicated that serine racemase was located exclusively in astrocytes. D-serine was 
shown to be the co-agonist at postNMDAr due to partial reduction of postNMDAr 
mediated current amplitudes upon D-serine breakdown by RgDAAO. Also in 
2006, Williams et al utilized immunogold labelling, observing that D-serine was 
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largely localised to astrocytes throughout many regions of the adult rat brain, 
though is present in glutamatergic neurons in some areas such as the inferior 
colliculus, superior olivary complex and motor trigeminal nucleus. Later, 
Bergensen et al (2012) again using immunogold labelling, examined the rat 
hippocampus and observed that D-serine accumulated in vesicles in astrocytes and 
that glutamate and D-serine appeared to be localised to different vesicle pools. D-
serine labelling in nerve terminals was largely ignored and was described as ‘rather 
weak’ though D-serine density in neuron terminals was 9.2 ± 1.8 particles/μm2 
(supplementary result 4), which is of the same order as for the astrocytic processes 
(~22 particles/μm2, from figure 2). Then, in 2013, Martineau et al (Mothet group) 
used both immunohistochemical and immunogold labelling in non-specified 
regions of the rat cortex and observed that D-serine was “mainly” located in 
astrocytes but that there was a “moderate” presence in neurons, although 
quantification was not provided. This study then focused on mechanistic aspects 
of vesicular D-serine release from cultured astrocytes. 
 
However, conflicting results have been found. Kartvelishvily, working with 
Wolosker and others (2006) observed that that neurons in primary culture do 
contain D-serine and serine racemase and suggested that previous, differing 
observations were due to experimental shortcomings in the 
immunohistochemistry. Interestingly, production of D-serine was seen to be 
dependent on exogenous L-serine and it was also observed that cultured neurons 
can release D-serine in response to NMDA and AMPA receptor activation. Miya 
et al (2008) examined serine racemase expression in the mouse cortex and 
hippocampus, utilising a serine racemase knockout mouse as a control for the first 
time, observing that serine racemase was present in neurons. Also, powerful 
evidence was provided by Benneyworth et al (2012) who utilised the Cre-loxP 
method to create neuronal and astrocytic conditional serine racemase knockout 
mice, thereby overcoming the limitations of immunohistochemistry and cell 
cultures. Here it was observed that knocking out serine racemase in neurons 
reduced overall serine racemase expression by ~60% in cortical regions compared 
to 15% in the astrocytic knock out, indicating a proportionally larger contribution 
of neuronal serine racemase. D-serine itself was only reduced in the neuronal 
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knockout although interesting this was to a lesser extent than serine racemase 
(33%) indicating a non-linear relationship, perhaps due to regulation of DAAO or 
the involvement of peripheral D-serine/D-serine breakdown.  
 
The Wolosker group have now suggested the existence of a ‘serine shuttle’ 
whereby L-serine is exclusively synthesised in astrocytes and is then exported for 
uptake into neurons where it is converted to D-serine (Wolosker and 
Radzishevsky, 2013). Whilst useful for reconciling some differences in findings, 
there are many unclear elements in such a schematic. Therefore ultimately it is 
unclear what the true nature of co-agonist regulation of the NMDAr is and it would 
seem wise to be sceptical in the face of any simplistic scheme. 
 
3.4.3 Implications for targeting preNMDAr 
 
The observations here implying that preNMDAr in the EC are regulated by glial 
D-serine is highly interesting given the evidence for the involvement of glial cells 
and gliosis in epileptic pathology. It now appears that glial cells and preNMDAr 
are interconnected, providing a plausible basis for the mechanism by which 
preNMDAr activity is enhanced in epilepsy. However, the findings here may also 
provide an extended basis for targeting preNMDAr to allow the pathological role 
of these receptors to be further investigation and for potential therapeutic benefit. 
 
In this work we have observed that endogenous co-agonist binding contributes to 
the tonic increase in excitatory transmission produced by preNMDAr. Given the 
involvement of preNMDAr in epilepsy, this then gives added support to the 
negative targeting of the NMDAr co-agonist site for treatment of this condition 
(Chiamulera et al., 1990; Singh et al, 1990; Peeters and Vanderheyden, 1992; Wu 
et al., 2002). In particular NMDAr are one target of the anticonvulsant felbamate 
and whilst this interaction is complex and currently unclear it appears to involve a 
negative modulation of the co-agonist site (White et al, 1995; Chang and Kuo, 
2007).  Interestingly work from this laboratory has indicated that felbamate 
inhibits preNMDAr in the EC (Yang et al, 2007), lending support to the notion that 
targeting the NMDAr co-agonist site in epilepsy would involve a beneficial, 
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presynaptic component. An interesting candidate for such an anticonvulsant on 
this basis is the pro-drug 4-chlorokynurenine, which is converted to the co-agonist 
site antagonist, 7-chlorokynuerenic acid (highly similar to DCKA) within 
astrocytes (Zhang et al, 2005). 
 
Secondly, it is interesting to consider the findings of Le Bail et al (2014) where it 
was observed that postNMDAr in the hippocampus are bound both by D-serine 
and glycine. Also in prior studies by Fossat et al (2011) and Papouin et al (2013), 
D-serine degradation was only seen to produce partial decreases in postNMDAr 
currents. Although degradation of glycine did not produce any decrease in these 
studies, in contrast to Le Bail et al (2014), this could due to the less potent enzyme 
used here. We have also used a less potent form of BsGO than Le Bail et al (2014) 
however, importantly, we found that treatment with RgDAAO precluded the 
effects of the co-agonist site antagonist DCKA at preNMDAr entirely, which 
indicates that D-serine is the sole co-agonist at these receptors. Therefore it appears 
that preNMDAr may be unique in that the endogenous co-agonist at these 
receptors is solely D-serine. In light of our results implying that this D-serine is 
produced by glial cells it is possible that the sole co-agonist of preNMDAr binding 
by D-serine may be due to the intimate interaction astrocytes and these receptors 
as illustrated by Jourdain et al (2007). It is possible then that targeting D-serine 
production or removal may have a biased effect at preNMDAr and may be useful 
for manipulating these receptors, and it may be that postNMDAr function could 
be preserved by augmenting glycine. Such relevant strategies include the 
inhibition of serince racemase or enzymatic metabolism of D-serine both of which 
have previously been proposed as potentially useful approaches for the 
development of anticonvulsant treatments (Panizzutti et al, 2001; Sacchi et al, 
2012). 
 
Further to this it is interesting that from the extensive studies of Fossat et al (2011), 
Papouin et al (2013) and Le Bail et al (2014), it follows that the postNMDAr bound 
by D-serine are likely to be a GluN2A/GluN2B triheteromer. Previous work on 
preNMDAr in the EC from this laboratory has indicated that these receptors are 
likely to be GluN2B diheteromers. Therefore it is possible that preNMDAr 
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represent a pharmacologically distinct population of NMDAr which are sensitive 
to the removal of D-serine but only sensitive to GluN2B subtype selective 
antagonism.  
 
Finally, in this work we observed that the activity of preNMDAr could not be 
augmented by exogenously applied co-agonists indicating that the preNMDAr co-
agonist binding site was highly bound likely to the point of saturation. This again 
is in contrast to the postNMDAr which are commonly observed to be unsaturated 
(Fossat et al, 2011; Papouin et al, 2013) and this also could be utilized as a basis 
for selective targeting. A difference in the degree of co-agonist binding site 
activation would mean that theoretically, preNMDAr and postNMDAr could be 
distinguished between using partial agonists of the co-agonist site. This idea is 
particularly interesting as the co-agonist site partial agonist D-cycloserine (DCS) 
has been purported to have anticonvulsant properties (see 1.9.1). An NMDAr 
mediated anticonvulsant effect would be presumed to be an inhibitory/negative 
action, as NMDAr mediate excitation and anticonvulsant activity is highly typical 
of NMDAr antagonists (see Ghasemi and Schacter 2011). Interestingly, the 
efficacy of DCS varies with GluN2 subunit identity although in each case it is high 
(see 1.9.2). Therefore it follows that an anticonvulsant effect by DCS would be 
expected to occur at NMDAr which have a very high degree of endogenous co-
agonist activation, which we now know applies to the preNMDAr. For both of 
these reasons we were highly interested to explore the action of co-agonist site 
partial agonists, DCS in particular, and I chose this line of enquiry for further 
investigation. 
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4.1 Introduction 
 
For two reasons we were now interested to investigate the action of NMDAr co-
agonist site partial agonists at NMDAr in the EC. The first reason follows from 
the previous chapter where we observed that the preNMDAr co-agonist site is 
likely to be saturated which is in contrast to previous observations of the 
postNMDAr co-agonist site (Fossatt et al, 2011; Papouin et al, 2013). If there is 
such a difference in binding then examining the effects of different efficacy partial 
agonists should confirm this and may allow for selectivity to be achieved. The 
second reason is that the co-agonist site partial agonist D-cycloserine (DCS) has 
been demonstrated to be able to act as both a cognitive enhancer and an 
anticonvulsant drug (see 1.9), and so we were highly interested to examine the 
action of DCS and other partial agonists at NMDAr, particularly preNMDAr, in 
the EC to increase our understanding of the molecular basis of these therapeutic 
effects. 
 
In brain slices, postNMDAr are commonly studied by electrically evoking 
NMDAr mediated synaptic responses, referred to as evoked NMDAr excitatory 
postsynaptic currents (eNEPSCs). As discussed in the section 1.5, it is established 
that the amplitude of such events represents the number of receptors which 
transition from glutamate bound/closed to glutamate bound/open states whilst the 
decay is mediated by the gating of receptors between glutamate bound/open and 
glutamate bound/closed states and from glutamate bound/closed to 
unbound/closed states. The effects of partial agonists of the co-agonist site on 
eNEPSCs in neuronal cultures were well studied by Priestly and Kemp (1994). 
Here it was observed that the efficacy of the partial agonists activating the receptor 
not only determined the peak amplitude of the eNEPSC but also its decay. Recent 
kinetic schemes of NMDAr gating have indicated why this may be the case. 
Compared to a NMDAr bound by a full agonist, an NMDAr bound by a partial 
agonist has a broadly reduced gating efficiency which results in receptors spending 
more time in bound/closed states (Kussius and Popescu et al, 2009).  Therefore the 
reason why both eNEPSC peak amplitude and decay time are both determined by 
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agonist efficacy is likely to simply be that both are subject to the efficiency of 
gating transitions.  
 
As discussed in section 1.9, there has been a large amount of research conducted 
into the neuropharmacological and psychopharmacological properties of DCS and 
the pharmacology of DCS at NMDAr in expression systems and neuronal cultures 
is also well elucidated. However, there has been little mechanistic study of how 
one links to the other. The varying efficacy of DCS means that it is unclear what 
effect it has in the endogenous situation and clearly the effect of a partial agonist 
is also dependent on the level of endogenous activation of its target. In this chapter 
I present novel findings exploring the action of DCS at NMDAr in the EC, an area 
central to both memory and epileptic pathology, using acute brain slices as a 
physiologically relevant preparation. We have also examined the effects of another 
co-agonist site partial agonist Aminocyclobutane carboxylic acid (ACBC). ACBC 
has not been well studied in vivo as with DCS and was chosen largely on the basis 




In one experiment in this chapter brain slices were from adult rats (50-60 days) 
and all other experiments aside one were performed using brain slices from 
juvenile rats. Slices were prepared as described in section 2.2 and whole cell patch 
voltage clamp recordings were made from neurones in layer II of the EC with 
pyramidal morphology. preNMDAr were again monitored using AMPA receptor 
mediated mEPSCs and postNMDAr function was assessed using eNEPSCs as 
outlined in section 2.6 (also see Fig. 4.1). Data analysis and significance testing 
was also carried out as outlined previously.  
 
Many of our findings in this chapter pertain to the decay phase of eNEPSCs which 
is often found to have two exponential components. We observed that eNEPSCs 
in layer II principal neurones were also somewhat better described by 
biexponential over monoexponential kinetics although the difference between fits 
was very small (see Fig. 4.2.A). In addition to this small difference, the parameters 
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produced by biexponential fitting were seen to be highly variable and this 
precluded meaningful analysis. Owing to this and the lack of any inference that 
such analysis provides I have described decay phases with a monoexponential time 
constant in keeping with the data of Priestley and Kemp (1994). This time constant 
(referred to as ‘decay time’) was simply calculated by the time taken to reach the 
0.37 fraction of peak amplitude, eliminating any variability introduced by fitting 
procedures. The correct basis of eNEPSCs was confirmed by blockade with 2-AP5 
(50µM) in three neurones (Fig.4.2.B). In eNEPSC experiments baseline holding 
current was also monitored as changes in this parameter can be indicative of effects 
at extraNMDAr. However, no changes in holding current were observed 









Fig. 4.1. Experimental paradigms used for the study of pre and post synaptic 
NMDAr. Left, to study preNMDAr, the frequency of AMPA receptor mediated 
mEPSCs were used as a reporter for the activity of these receptors whilst postNMDAr 
were blocked by intracellular MK801 (see also Fig. 1.9). Right, to study postNMDAr, 
all other synaptic receptors were blocked and postNMDAr mediated currents 
(eNEPSCs) were evoked via bipolar electrical stimulation. 
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Fig. 4.2 The eNEPSC response. A – Monoexponential and biexponential fitting of 
the eNEPSC decay phase. eNEPSCs are sometimes described as having two 
exponential components, a fast (τ1, A1) and a slow (τ2, A2) exponential. Τ is the 
exponential time constant and A is the factor of multiplication.  Here, we observed 
that eNEPSCs were well described by biexponential kinetics, with a high coefficient 
of determination (R2) but were also very well described by a monoexponential decay. 
B – An example trace showing removal of the eNEPSC response by the prototypic 
NMDAr antagonist 2-AP5. This confirmed that the responses here were mediated by 
NMDAr. C – An example trace showing abolishment of the eNEPSC by the coagonist 
site antagonist, DCS. This indicated that activation of the NMDAr coagonist site, as 
well as the agonist site, mediated this response.    
Chapter Four   Partial Co-agonists at Pre- and PostNMDAr 
78 
Co-agonist Regulation of Pre and Postsynaptic NMDA Receptors in the Entorhinal Cortex 
4.3 Results 
 
4.3.1 Effects of DCS and ACBC at preNMDAr 
 
To begin our study of the effects of co-agonist site partial agonists at NMDAr in 
the EC I examined the effects of the high efficacy co-agonist site partial agonist, 
DCS at preNMDAr. The activity of these receptors was again monitored using 
AMPA receptor mediated mEPSCs as a reporter for the release of glutamate. In 
six layer II neurones these events were recorded and the effects of DCS at a 
concentration of 300 µM was tested followed by the addition of 2-AP5 (50 µM) 
without washout of DCS. The results from this experiment are summarised in Fig. 
4.3. The frequency of mEPSCs was significantly lowered following addition of 2-
AP5 (50 µM), compared to control, and no other significant changes were seen. 
The mean frequency of mEPSCs was 0.65 ± 0.29 Hz in control, 0.62 ± 0.32 Hz in 
the presence of DCS and 0.47 ± 0.23 Hz (p<0.05) following addition of 2-AP5. 
Mean amplitudes were 7.0 ± 0.4 pA, 6.9 ± 0.4 pA and 6.9 ± 0.36 pA in the control, 
DCS and DCS + 2-AP5 conditions respectively. Mean rise times were 2.2 ± 0.4 
ms, 2.4 ± 0.4 ms and 2.1 ± 0.3 ms and mean decay times were 2.2 ± 0.3 ms, 2.0 ± 
0.3 ms and 2.0 ± 0.3 ms for these three conditions. Therefore in this experiment 
we did not observe any effect of DCS at preNMDAr dependent glutamate release. 
However, further addition of the antagonist 2-AP5 again, selectively decreased 
mEPSC frequency confirming that preNMDAr were active here.  
 
The effect of DCS on mEPSCs was again tested in a further 6 neurones, at a lower 
concentration of 100 µM but no significant changes were observed. Mean mEPSC 
frequencies for control and DCS treatment conditions were 0.55 ± 0.1 Hz and 0.53 
± 0.2 Hz respectively and likewise mean amplitudes were 8.5 ± 1.0 pA and 8.6 ± 
1.1 pA. Respective mean rise times for control v DCS were 2.6 ± 0.4 ms v 2.5 ± 
0.4 ms and decay times were 3.8 ± 1.2 ms v 4.1 ± 1.2 ms. The lack of any effect 
of DCS repeated here confirmed that DCS was not eliciting any effect on 
spontaneous glutamatergic release. From these experiments then it appeared that 
DCS did not affect the function of preNMDAr on tonic glutamate release in the 
EC. On this basis it seemed unlikely that preNMDAr would be relevant to the 
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neuro- and psychopharmacological properties of DCS and that other receptor 
populations were more likely to give an insight into the molecular basis of DCS 
action.  These results also indicated that DCS may be a useful tool to study the 
possible differences in co-agonist binding between NMDAr populations.   
 
We next tested the effects of the low efficacy co-agonist site partial agonist, ACBC 
(1mM) on mEPSCs in 5 layer II neurones. These experiments were carried out by 
Emma Robson. Data from these experiments is summarised in Fig. 4.4. The 
frequency of mEPSCs was significantly reduced following perfusion of ACBC and 
no other significant changes were observed. Mean mEPSC frequencies for control 
v ACBC were 1.7 ± 0.3 Hz v 1.2 ± 0.2 Hz (p<0.05) and mean amplitudes were 6.9 
± 0.3 pA v 6.5 ± 0.3 pA) or in frequency distribution of event amplitudes. 
Likewise, average mEPSC rise times were 2.18 ± 0.14 ms v 2.38 ± 0.06 ms and 
decay times were 2.85 ± 0.26 ms v 3.27 ± 0.23 ms. This selective decrease in 
AMPA receptor mediated mEPSCs indicated that ACBC was reducing the tonic 
activity of preNMDAr.  
 
Therefore, whilst a high efficacy partial agonist of the co-agonist site did not affect 
preNMDAr, a lower efficacy co-agonist produced an inhibitory effect. In the 
previous chapter it was established that the co-agonist site of preNMDAr has a 
high level of tonic activity due to endogenous binding by D-serine. Therefore the 
most parsimonious explanation for the observations at hand is that DCS had no 
effect because its efficacy is closely matched to the endogenous activation of the 
preNMDAr co-agonist site and so there will be no change in the overall activity of 
this receptor population when it is added. However, when ACBC is added and 
displaces the full agonist D-serine, although it may bind the entire preNMDAr 
population, as its efficacy is less that the overall endogenous activation of these 
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Fig. 4.3. The effects of DCS on mEPSCs in layer II neurones of the medial EC. 
The high efficacy co-agonist site partial agonist, DCS was added at 300 µM followed 
by the glutamate site antagonist 2-AP5 (50 µM), without washout of DCS. Upper 
traces show sample voltage clamp recordings in control, DCS and 2-AP5 treatment 
conditions. Lower traces are averaged events from control (black) and DCS (red) and 
2-AP5 (Blue). An overlaid trace on the right clearly shows no differences in kinetics 
or amplitude. Bottom left, a bar graph representing average frequency data. mEPSC 
frequency unchanged in the presence of DCS but is significantly lowered following 
treatment with 2-AP5. Bottom right, a histogram representing the amplitude 
distributions of events in the three conditions. There was no effects on amplitude in 
this data set, indicating that the change in frequency by 2-AP5 reflected a decreased 
glutamate release probability. * denotes p<0.05 significance level, n=6. 
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Although this schematic largely fits with our observations in the previous chapter 
we previously observed a lack of effect of exogenous D-serine on preNMDAr 





















































Fig. 4.4. The effects of ACBC on mEPSCs in layer II EC neurones. The low 
efficacy partial coagonist ACBC was tested at 1 mM in five neurones. Upper traces 
illustrate mEPSC frequency in the control condition and in the presence of ACBC, 
averaged traces for control (black) and ACBC (red) are shown below. In the bottom 
left, a bar graph of average frequency for the data set. In the bottom right, a histogram 
of mEPSC amplitudes in the two conditions. ACBC produced a significant decrease 
in mEPSC frequency without affecting the amplitude of these events, characteristic of 
a inhibitory presynaptic action. * denotes p<0.05 significance level. 
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To this then there are two possible explanations. The preNMDAr co-agonist site 
is saturated by endogenous D-serine and DCS does reduce the activity of this site 
but it is below the threshold of detection. Alternatively the preNMDAr co-agonist 
may be matched to the high efficacy of DCS and the effects of D-serine are limited 
by the activation of the preNMDAr agonist (glutamate) site, or are themselves too 
small to detect. However, a third explanation is offered in section 4.4.3. 
 
4.3.2 Effects of DCS at postNMDAr 
 
To examine the effects of DCS at principal cell postNMDAr in the EC, eNEPSCs 
were recorded in six neurones and DCS was applied at 1-30 µM. Results from this 
experiment are shown in Fig. 4.5. Interestingly there were no significant effects on 
the amplitude of these events, but the decay time was significantly reduced at all 
concentrations of DCS. Average eNEPSC amplitude at control was 190.9 ± 53.8 
pA and 160.6 ± 35.3 pA in the presence of 30 µM DCS. Average rise times were 
44.7 ± 9.3ms in the control period and 52.3 ± 15.1ms at 30 µM DCS. Average 
decay times were 593.8 ± 94.6 in control and 417.4 ± 78.7ms (P<0.01) in the 
presence of 30µM DCS. The reduction of decay time was concentration dependent 
and from normalised data the maximum effect was 68.1 ± 5.9% at 30 µM and the 
IC50 was 2.1 µM. Fascinatingly then, DCS was exerting a kinetic effect at 
eNEPSCs but not effecting the peak amplitude of these events and further 
experiments were conducted to determine the basis of this effect. 
 
To confirm that DCS was acting at the postNMDAr co-agonist site we conducted 
a reversal experiment using the co-agonist site antagonist DCKA. eNEPSCs were 
recorded in eight neurones and 100 µM DCKA was applied followed by DCS first 
at 2 mM and then increased to 10 mM, without washout of DCKA. Results from 
this experiment are shown in Fig. 4.6. DCKA abolished the eNEPSC response. 
eNEPSC amplitude was significantly lower than control during perfusion of 2mM 
but not 10mM eNEPSC and decay time was significantly reduced at both 
concentrations of DCS. There were no significant effects on eNEPSC rise time. 
Average normalised eNEPSC amplitude was recovered to 42.4 ± 7.3% of control 
at 2 mM and 73.9 ± 13.6% at 10mM DCS. Average normalised eNEPSC decay  
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time was recovered to 26.1 ± 2.3% at 2 mM DCS and 34.4 ± 1.8% at 10 mM DCS. 
The removal of eNEPSC response by DCKA indicated that the postNMDAr was 
indeed active, contributing to this response. Although not completely, the 
abolished amplitude of eNEPSCs by the competitive co-agonist site antagonist 
DCKA was largely reversed by high concentrations of DCS indicating that DCS 
















































Fig. 4.5. The effects of DCS on eNEPSCs in layer II of the medial EC. DCS was 
added during recording of eNEPSCs over the 1-30 µM range in six neurones. Example 
eNEPSCs from control (black) and at 30 µM DCS (red) are above, traces are overlaid 
on the right. Averaged, normalised data is shown beneath for amplitude (left) and 
decay time (right), inhibition curves are fitted over the concentration range. DCS 
produced a clear, concentration dependent decrease in eNEPSC decay time, which was 
seen to plateau at 30 µM. DCS had no similar effect on the amplitude of the eNEPSCs. 
* denotes p<0.05 significance level, ** denotes p<0.01 significance level. 
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To further confirm that the kinetic effect of DCS that we had observed was due to 
a partial agonist action, we examined whether it was reversed by a full agonist. 
eNEPSCs were recorded in seven neurones and DCS was applied at a submaximal 
concentration (10 µM) followed by a high concentration of D-serine (1 mM), 
without washout. Results from these experiments are shown in Fig. 4.7. eNEPSC 
decay time was again significantly decreased in the presence of DCS and 
significantly higher than control following addition of D-serine. eNEPSC 
amplitude was also significantly above control after addition of D-serine and no 
other significant effects were detected. Normalised decay time was 84.7 ± 2.9% of 
control in the 10 µM DCS condition and 109.8 ± 2.1% with subsequent addition 
of D-serine. Normalised eNEPSC amplitude was 126 ± 4.0% following addition 























































Fig. 4.6. DCS rescues the eNEPSC from abolition by DCKA. In eight neurones, the 
co-agonist site antagonist DCKA was added at 100 µM followed by DCS at 2 mM and 
then at 10 mM, without washout of DCKA. Example average eNEPSCs from each 
condition are shown above and averaged amplitude and decay time data from all 
experiments are shown below in bar chart form. eNEPSCs were completely blocked 
by DCKA, though high concentrations of the partial agonist DCS were able to reverse 
this blockade, indicating a competitive, opposing effect. Recovered eNEPSCs had 
significantly lower decay time than control. * denotes p<0.05 significance level, ** 
denotes p<0.01 significance level. 
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of D-serine. Mean decay times for control, DCS and DCS+D-serine conditions 
were 391.0 ± 26.6 ms, 333.0 ± 28.7 ms (p<0.01) and 430.1 ± 31.5 ms (p<0.01), 
respectively and mean amplitudes were 123.5 ± 23.9 pA, 124.8 ± 26.2 pA and 
160.1 ± 34.3 pA (p<0.05) respectively. Likewise, mean rise times were 42.3 ± 16 
ms, 49.6 ± 23.8 ms and 68.0 ± 46.9 ms respectively. The decrease in eNEPSC 
decay time produced by DCS was therefore effectively counteracted by a full 
agonist. Therefore it was concluded that the selective kinetic effect of DCS at 
eNEPSC were indeed due to a partial agonist effect at the NMDAr co-agonist 
binding site. The increase in eNEPSC amplitude produced by D-serine indicated 
that the postNMDAr co-agonist binding site is not saturated and this limits the 
eNEPSC response. The increase in eNEPSC decay time beyond control produced 
by D-serine was highly interesting and is discussed later.  
 
 



















































Fig. 4.7. D-serine opposes the effects of DCS on eNEPSCs. eNEPSCs were recorded 
in seven neurones and a submaximal concentration of DCS (10 µM) was added 
followed by the coagonist site full agonsit D-serine (1 mM) without washout. Sample 
averaged eNEPSCs from control and DCS (red) and D-serine (blue) treatment 
conditions are shown above. Overall average amplitude and decay time bar charts are 
below. Again DCS selectively decreased the decay of eNEPSCs, this effect was 
reversed beyond control by D-serine. D-serine also significantly increased the 
amplitude of eNEPSCs. * denotes p<0.05 significance level. 
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Therefore we have shown that DCS is indeed acting as a partial co-agonist at 
postNMDAr in the EC but that it produces a selective effect on the decay phase of 
macroscopic synaptic responses. The most parsimonious explanation for this is 
that the postNMDAr are activated by a full efficacy co-agonist but the overall 
concentration is matched to the efficacy of DCS. Then, when DCS is added, the 
maximal number of receptors opening is substantially unchanged but the 
macroscopic decay is reduced. 
 
4.3.3 Effects of ACBC at postNMDAr 
 
We now examined the effects of the low efficacy co-agonist site partial agonist 
ACBC at principal cell postNMDAr in the EC. eNEPSCs were recorded in seven 
layer II neurones and ACBC was added cumulatively at 30 µM, 100 µM, 300 µM 
and 1 mM. Results from this experiment are presented in Fig. 4.8. ACBC produced 
concentration dependent decreases in both eNEPSC amplitude and decay, which 
were significant at 300 µM and 1 mM for amplitude and at every concentration for 
decay time. There were no effects on rise time. Average eNEPSC measurements 
for the control and 1 mM ACBC periods were 239.4 ± 47.3 pA and 141.5 ± 21.2 
pA (p<0.05), respectively, for amplitude, 524.8 ± 102.96 ms and 249.0 ± 26.5 ms 
(p<0.05), respectively, for decay time and 31.3 ± 4.2 ms and 30.3 ± 5.3 ms for rise 
time. The effects of ACBC appeared to be approaching maximum at 1mM, where 
the normalised eNEPSC decay was 57.5 ± 12.4% and the normalised amplitude 
was 62.0 ± 5.9%. In contrast to DCS then, ACBC decreased both the decay time 
and amplitude of eNEPSCs, which is consistent with an NMDAr partial agonist 
with an efficacy which is lower than the tonic level of activation. Therefore it 
appears that due to high levels of endogenous co-agonist binding, ACBC has 
negative effects on the activity of both preNMDAr and postNMDAr on principal 
neurones in the EC. 
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Fig. 4.8. The effects of ACBC on eNEPSCs in the EC. ACBC was added to 
eNEPSCs in over the 0.03-1 mM range in seven neurones. Example eNEPSCs for the 
control (black) and 1 mM ACBC (red) periods are shown above, left. Overlaid traces, 
and overlaid traces with matched amplitudes are shown on the right. Average, 
normalised amplitude and decay time data is shown beneath with fitted concentration 
response curves. ACBC was seen to elicit large concentration dependent decreases in 
decay time but also significantly reduced the amplitude of eNEPESCs, reflecting its 
lower efficacy. * denotes p<0.05 significance level. 
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4.3.4 Effects of D-serine at postNMDAr 
 
To elucidate the tonic activation of the postNMDAr we wanted to examine the 
action of a full agonist at these receptors. Although we had previously applied D-
serine to eNEPSCs to test the nature of DCS, we now tested the effects of D-serine 
(100 µM) singly at eNEPSCs in six cells. These results are summarised in Fig. 4.9. 
eNEPSC amplitude and decay time were significantly increased in the presence of 
exogenous D-serine, with no effect on rise time. Mean peak amplitude was 205.5 
± 40.7 pA in control and 240.3 ± 50.1pA (p<0.05) during perfusion of D-serine 
and mean decay times changed from 381.3 ± 105 ms to 450.5 ± 112 ms (p<0.01). 
Mean rise times were 36.2 ± 8.0 ms in the control period and 33.4 ± 6.3 ms with 
D-serine. The average normalised amplitude in the presence of exogenous D-
serine was 115.9 ± 4.0% and the average normalised decay time was 121 ± 4.4%. 
This result again indicated that the postNMDAr co-agonist site is highly, but not 
fully activated.  
 
4.3.5 Effects of DCS at postNMDAr in the adult EC 
 
In the previous chapter we observed that preNMDAr are regulated by D-serine, 
likely with a glial source.  Whilst the potential importance of glial dysregulation 
in epilepsy, of preNMDAr in epilepsy and the age dependence of preNMDAr 
function are discussed in the general introduction. Further to this, D-serine has also 
been implicated in ageing and changes in the developing brain (Hashimoto et al, 
1993; Turpin et al, 2011). Given these ideas we were highly interested in the 
prospect of a unifying schematic of enhanced glial co-agonist signalling in the 
juvenile brain and in epilepsy. To this end we prepared slices using adult rats (50-
60 days) and examined co-agonist binding at postNMDAr, as the most directly 
observable NMDAr population. As DCS appeared to be matched to the 
endogenous co-agonist activation of postNMDAr in juvenile brain slices it was 
now an excellent tool to test whether binding of this site was different in adult 
slices. In adult brain slices eNEPSCs were recorded in 5 neurones and DCS was 
added at 1 mM. However, the only significant effect of DCS was on decay time, 
which had a mean value of 372.9 ± 69.2 ms in control and 226.4 ± 34.0 ms (p<0.05)  
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Fig. 4.9. The effects of D-serine on eNEPSCs in the mEC. eNEPSCs were recorded 
in six layer II neurones and the effects of D-serine (100 µM) were tested. Above, 
example eNEPSCs from control (black) and D-serine (red) treatment periods. Middle, 
traces are overlaid and overlaid with matched amplitudes for decay time comparison. 
Below, dataset amplitude and decay time bar charts. Interestingly the endogenous full 
coagonist D-serine produced small but significant increases in both the amplitude and 
decay time of eNEPSCs here. * denotes p<0.05 significance level. 
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following DCS perfusion. This corresponded to a normalised value of 63.7 ± 6.7% 
of control following DCS treatment. Mean amplitudes were 112.8 ± 34.6 pA in 
control and 113.3 ± 33.1 pA with DCS. Mean rise times were 37.7 ± 12.5 ms in 
control and 27.9 ± 6.4 ms with DCS. So in adult slices DCS again only affected 
the decay of eNEPSCs. Again the amplitude of these events was not affected and 
so it appears that the level of endogenous postNMDAr co-agonist binding is 






In this chapter I have used mEPSCs and eNEPSCs to study the effects of co-
agonist site partial agonists at pre and post synaptic NMDAr, respectively, in the 
EC. The high efficacy partial agonist DCS had no effect on mEPSCs and had no 
effect on the amplitude of eNEPSCs but reduced the decay time. This effect was 
confirmed to be due to a partial agonist action at NMDAr co-agonist sites. The low 
efficacy partial agonist selectively reduced the frequency of mEPSCs and also 
reduced the amplitude, as well as the decay time, of eNEPSCs. The full agonist D-
serine increased the amplitude of eNEPSCs by 15-26% and also increased the 
decay time of eNEPSCs. The effects of DCS on eNEPSC were unchanged in brain 
slices from adult rats. 
 
4.4.2 Endogenous activation and pharmacology of postNMDAr 
 
A parsimonious explanation for the lack of effect of DCS on eNEPSC amplitude 
was that the postNMDAr co-agonist sites are endogenously activated at a level 
which is matched to the efficacy of DCS. However, if this endogenous activation 
was provided by a higher/full efficacy agonist then DCS would still be expected 
to alter the macroscopic decay. As previously discussed, endogenous activation of 
these sites is thought to be provided by a full agonist, probably D-serine (Papouin 
et al, 2012). High exogenous concentrations of the full agonist D-serine increased 
the amplitude of eNEPSC responses by 15-26% indicating that the postNMDAr 
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co-agonist sites were originally 79-87% tonically active. This is indeed in 
agreement with the efficacy of DCS on eNEPSCs which was calculated to be 86 ± 
5% by Priestley and Kemp (1994) in neuronal cultures. Also consistent with this 
simple explanation is that the lower efficacy partial agonist ACBC did decrease 
eNEPSC amplitude, in addition to decay time.    
 
Interestingly, in their investigation of the subtype dependence of DCS efficacy, 
Dravid et al (2010) calculated that at GluN2A and GluN2B heterodimers, DCS 
had 90% and 65% efficacy, respectively. Previous work from this laboratory as 
indicated that the postNMDAr at hand are likely to be a triheteromer (Chamberlain 
et al, 2008). Although the efficacy of DCS at these receptors has not been 
established, as the pharmacological properties of triheteromers have generally 
been observed as lying between the two respective diheteromers, an efficacy of 86 
± 5% is consistent with such a triheteromeric structure.  
 
The observed increase in NMDAr decay time following application of exogenous 
D-serine is also highly interesting, particularly as currently endogenous binding of 
the NMDAr co-agonist site is thought to be by full agonists only. One possible 
explanation is that in the control condition there are partially liganded NMDAr 
openings, which contribute to a submaximal macroscopic decay, but these are not 
present when the co-agonist site is saturated with an exogenous agonist. On this 
note it is interesting that DCS recovered eNEPSC amplitude from DCKA blockade 
but the decay times were disproportionately low, which may again implicate 
partially liganded openings. However, partially liganded openings are not thought 
to occur with the NMDAr (see Schorge and Colquhoun, 2003). 
 
Perhaps the most likely explanation however is that in the control condition 
postNMDAr co-agonist sites are bound by a mix of glycine and D-serine as 
observed by Le Bail et al (2014). These receptors may produce a submaximal 
decay compared to receptors bound by D-serine alone, which occurs when the high 
concentration of exogenous D-serine is added. However, to my knowledge there 
is no data comparing macroscopic decay kinetics with glycine bound and D-serine 
bound NMDAr. In their extensive kinetic study, Priestley and Kemp (1994) tested 
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glycine but not D-serine, although it is interesting to note that L-Alanine was 
almost a full agonist (96%) but had a greatly different effect on macroscopic decay 
compared to glycine (375ms for L-Alanine vs 502ms for glycine). Thus it is 
conceivable that D-serine could produce higher macroscopic decay times than a 
D-serine/glycine mix.    
 
4.4.3 Endogenous Activation of preNMDAr and selective targeting of 
postNMDAr 
 
In this chapter we observed that DCS had no observable effect at preNMDAr 
whilst the lower efficacy ACBC appeared to reduce the tonic activity of these 
receptors on glutamate release. In the previous chapter however, we observed that 
the preNMDAr co-agonist site may be saturated, as D-serine also had no effect on 
these receptors. Again as the only method available for studying the activity of 
preNMDAr was indirect it is difficult to establish exactly why DCS and D-serine 
did not affect preNMDAr activity.  Due to this we are unable to make clear 
deductions on the binding of the preNMDAr co-agonist site. It is highly plausible 
that the lack of effect on of DCS on glutamate release was a function of the 
preNMDAr tonic activity. A kinetic effect on postNMDAr is clearly impactful as 
glutamate binding to postNMDAr is rapidly removed following unbinding from 
these receptors concluding the synaptic signal via these receptors. However, at the 
preNMDAr, glutamate is readily available and so a faster rate of closing may not 
be of large significance to these receptors as activation of these receptors is 
continuous.  
 
Some inference may be achievable by observing the pattern of effects of D-serine, 
DCS and ACBC at preNMDAr and postNMDAr. D-serine enhanced postNMDAr 
but had no observable effect at preNMDAr, DCS did not affect eNEPSC amplitude 
(but did affect kinetics) and did not affect preNMDAr and ACBC reduced both 
preNMDAr and postNMDAr activity. Perhaps it is more likely then, that 
preNMDAr and postNMDAr have a similar level of co-agonist binding, which is 
arguably a sensible schematic, given the shared synaptic location of these two 
populations. It may be that the kinetic effects of DCS are not noticeably disruptive 
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to the role of preNMDAr in regulating transmitter release. The lack of effect of D-
serine at preNMDAr may then be due to activity of this receptor population being 
limited by the activity of glutamate sites (Woodhall et al, 2001)., which are not 
saturated in contrast to postNMDAr during synaptic firing.   
 
Although it may seem to be the most likely explanation for the results so far, as 
mentioned it was not possible to explicitly probe this idea. If true, it would indicate 
that, unfortunately, the co-agonist site may not be a suitable basis for 
distinguishing between preNMDAr and postNMDAr. However, functionally we 
have achieved selectivity for postNMDAr, as DCS produced a functional effect at 
postNMDAr but not preNMDAr and this may be useful in selectively examining 
postNMDAr over preNMDAr. 
 
4.4.4 Molecular basis of DCS action 
 
The kinetic role of co-agonist site partial agonists has been well studied previously 
(Priestley and Kemp, 1994). However, here we have presented the novel 
observation that in a physiologically relevant situation, DCS selectively reduces 
the decay of NMDAr synaptic currents in principal neurones, in the EC at least, 
and that this is due to the level and nature of the endogenous co-agonist site 
activation.  
 
On a simple level DCS has reduced the extent of NMDAr signalling in these cells 
and this effect is an anti-NMDAr effect. This is clearly highly interesting given the 
observations that DCS can act as an anticonvulsant and a cognitive enhancer. As 
previously mentioned anticonvulsant activity is highly typical of NMDAr 
antagonists (see Ghasemi and Schacter, 2011, Table 4) and as NMDAr are 
excitatory receptors it is highly plausible that this reduction in NMDAr signalling 
on principal cells represents an antiepileptic property. As discussed in section 1.9 
the cognitive enhancing properties of DCS are typically seen at lower doses and a 
currently popular theory of cognitive enhancement by DCS is that it is mediated 
by a biased effect at GluN2C containing NMDAr, which are present on other types 
of neurone and glial cell but not typically on principal cells. The findings in this 
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chapter do not conflict with this theory and indeed if the effect at principal cell 
postNMDAr did indeed underlie an anticonvulsant property at higher 
concentrations, it could also underlie the abolished cognitive effect at higher 
concentrations. However, it is interesting to consider that the NMDAr blocker 
memantine is an approved cognitive enhancer in the treatment of Alzheimer’s 
disease, where it may act to redress ‘noisy’ NMDAr signalling. Therefore it is 
possible that DCS act similarly and the anti-NMDAr effects observed here may 
underlie cognitive enhancement by DCS. 
 
Whilst such a simplistic discussion is interesting, both cognition and epileptic 
activity clearly involve highly complicated processes that extend beyond the level 
of single neurones. A selective kinetic effect at postNMDAr in principal cells is 
highly interesting in this regard given the role that such kinetics may play in 
activity on the network level. Whilst it is possible to speculate, the complex, 
emergent nature of network activity makes prediction problematic and necessitates 
empirical investigation. Thus we were now highly interested to study the effects 
of DCS on the level of the neuronal network to try to establish how the novel 
findings here might be linked to the neuropharmacological and 
psychopharmacological properties of DCS. We were also highly interested that 
our results here indicated that DCS now represented a unique tool for selectively 
investigating the role of kinetics of the NMDAr in emergent network activity. 
Furthermore by contrasting the effects of DCS with other ligands, we may gain an 
insight into the roles of the different receptor populations.  
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5.1 Introduction 
 
For two reasons it was of interest to now examine the effects of the co-agonist site 
partial agonists on epileptiform activity in the EC. Firstly, previous reports have 
indicated both an anticonvulsant and a pro-convulsant potential of DCS. 
Moreover, there has been a great deal of interest in DCS as a cognitive enhancer. 
By examining the effects of partial agonists on epileptiform activity we may shed 
light on these findings and the therapeutic possibilities offered by such 
compounds. Secondly, as we have now examined the actions of these compounds 
in brain slices we can use them as tools to produce insights into the mechanics of 
epileptiform bursts. Furthermore, we consider that epileptiform activity induced 
by GABAA is of interest more generally for the study of the neuronal 
synchronisation as, though artificial, it represents a simplified form of emergent 
network activity. 
 
Hypersynchronous epileptiform activity can be induced in brain slices through 
various means which act to shift the balance of activity in favour of excitation; 
here we have examined epileptiform activity induced by blockade of GABAA 
receptors by bicuculline. In the hippocampal-EC structure, such epileptiform 
activity has been shown to originate in the medial EC (Jones and Lambert, 1990). 
Extracellular epileptiform activity consists largely of bursts of high amplitude 
spikes and sometimes with single spikes between these bursts. Going beyond this 
highly general description is problematic as such activity is highly variable 
between and within slices. This variability and the complicated form of 
epileptiform activity make analysis highly problematic with most studies resorting 
to descriptions of visual interpretation without providing any quantification. 
Therefore to examine the effects of partial agonists on epileptiform activity 
meaningfully it was necessary to develop new methods of analysis to allow 
changes to be objectively quantified and significance testing to be performed.  
 
The GABAA receptor is the major source of inhibition in the CNS and epileptiform 
activity induced by GABAA blockade is necessarily majorly constituted by 
principal cell interactions. Therefore this form of network synchronisation is 
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relatable to the previous work examining principal cell NMDAr populations. In 
layer II of the EC glycine receptors and/or bicuculline insensitive GABAA 
receptors may also contribute to inhibition (Greenhill et al, 2014) and for this 
reason the non-competitive GABAA receptor inhibitor picrotoxin, and the glycine 
receptor antagonist strychnine were used alongside bicuculline here. Furthermore, 
in the previous chapter we observed that when this combination of drugs is applied 
(in addition to an AMPA receptor antagonist) only an NMDAr response remains 
when the synapses are stimulated. This indicates that in the presence of the current 
cocktail of drugs, only NMDA and AMPA receptors are likely to be active post-
synaptically. The aims of this chapter are then to examine the effects of the ligands 




In combined EC-hippocampal rat brain slices, extracellular recordings were made 
from layer II of the medial EC as described in the general methods section. 
Epileptiform activity was provoked by continuous perfusion of strychnine (1 µM), 
bicuculline (20 µM) and picrotoxin (50 µM) and left to stabilise for at least 40 
minutes after initiation before the addition of drugs. Drugs were perfused for 25 
minutes and washout periods were 45 minutes. 
 
Novel methodology for the gross analysis of epileptiform activity was devised with 
Dr. Peter Massey. Using the program DataView (Dr. W. J. Heitler, University of 
St Andrews), extracellular recordings are rectified and then smoothed by 
calculating a 50 ms moving average (mean) which is iterated ten times. In 
processed traces, events over the last five minutes of each treatment condition were 
then detected using a threshold crossing algorithm. The times between events 
(‘gaps’), and the durations, amplitudes and areas of the events were then 
automatically calculated. The number of events in this period were also counted 
and used to calculate the overall frequency of events. The processing of traces and 
the gross analysis is shown in Fig. 5.1. This methodology allowed large numbers 
of events to be analysed, countering the large variability of this data. 
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The form of epileptiform events was also examined. Typical epileptiform activity 
contains within event spikes and these were analysed using Minianalysis software 
(Synaptosoft, Decatur). Spikes were detected visually and the inter-event-intervals 
(IEI), rise (10-90%) and decay (0.37 fraction) times were calculated. analysis was 
carried out on the last five epileptiform events in each treatment condition and 
pooled together producing one set of data per condition, per cell. Amplitudes from 
this analysis were not considered as this was examined in the more powerful gross 
analysis. 
 
Fig. 5.1. Example trace of typical epileptiform activity in raw and processed 
forms and analysis parameters of processed traces. Raw traces of epileptiform 
recordings (above) were rectified and smoothed to produce easily quantifiable 
events (below). For the last five minutes in each treatment condition, these 
processed events were analysed and peak amplitudes (mV), durations (ms), gaps 
(ms) and areas (µVs) were calculated as indicated.  The frequency at which 
epileptiform bursts occurred was calculated through counting the number of events 
in the 5 minute analysis period. The inter-event intervals for the spikes within 
(unprocessed) events was also calculated for the last 5 events in each condition. 
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For every parameter of analysis in each cell and condition a mean and standard 
deviation is calculated. From these the coefficient of variation (standard deviation 
divided by the mean; CoV) was calculated as a measure of consistency. The 
differences between the mean and CoV in the drug conditions and the control 
condition were tested for significance using a paired, two tailed Student’s t-test. 
For each treatment condition the grand mean was then calculated as well as a mean 









Fig. 5.2. Variability of epileptiform burst activity. Four consecutive 
epileptiform bursts from one slice in the control condition are shown to illustrate 
the highly variable nature of this activity. As is the case here, epilepfiform bursts 
in layer II of the EC were often seen to occur at fairly regular intervals and also the 
amplitude of such activity is generally consistent in scale. However, the intraburst 
characteristics and duration of these bursts is highly variable making meaningful 
analysis problematic. Here we have introduced methodology which allows large 
numbers of bursts to be analysed easily, countering somewhat the large within slice 
variability. 
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Due to the highly variable nature of this activity (see Fig. 5.2), we have chosen to 
additionally point to results which were below the p<0.1 level i.e. results which 
would be significant with a one-tailed test. These results which tended towards 
significance are denoted by the letter ‘T’. However, it is important to note the 
increased possibility of false positive results due to the large amount of 
comparisons made here. Owing to the large number of parameters analysed, in 
figures we have focussed on results which were indicated to be relevant by 
changing during one of these experiments. CoV is referred to as ‘variability’ in 
figures. Example traces in results figures are selected as being representative of 




5.3.1 Effects of DCS on epileptiform activity in the EC 
 
We were now highly interested to investigate the effects of DCS on epileptiform 
bursts as a form of emergent network activity related to epilepsy and to contrast 
these with our previous findings. In combined EC-hippocampal brain slices from 
juvenile rats epileptiform activity was induced by continual perfusion of the 
GABAA receptor antagonists bicuculline and picrotoxin and the glycine receptor 
antagonist strychnine, which remove inhibitory synaptic activity onto principal 
cells in the EC. In seven slices treated this way, DCS was then perfused at three 
concentrations, 3, 30 and 300 µM, followed by a washout period. Results from 
these experiments are shown in Fig. 5.3a and Fig. 5.3b.  
 
Fig. 3a summarises the analysis of the effects of DCS on burst inter-event-interval 
(IEI), that is, the time between spikes within the epileptiform bursts. DCS across 
the concentrations tested, had no discernible effect on the IEI of epileptiform bursts 
which remained at an average of 74-76 ms, the reciprocal within frequency for this 
being 13.2 - 13.5 Hz. However, one significant effect was observed during the 
washout period. Here IEI was still unchanged but the variability of the IEI within 
slices was reduced. In other words, although the average IEI was unchanged, it had 
become more consistent during the washout period. Such a result during washout 
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of a drug indicates that DCS may have elicited an adaptive response resulting in a 
reflective change following its removal. 
 
Whilst having no detectable effect on the within burst IEI, the gross analysis of 
this data indicated that DCS produced substantial changes in the magnitude of 
epileptiform bursts (Fig. 5.3b). The mean duration of epileptiform bursts in these 
slices was 1.18 ± 0.12 s in the control condition and was then elevated to 1.26 ± 
0.13 s during perfusion of 3 µM DCS (p<0.1), 1.42 ± 0.14 s during perfusion of 
30 µM DCS (p<0.05) and 1.39 ± 0.13 s during perfusion of 300 µM DCS (p<0.05) 
and returned nominally to baseline (1.22 ± 0.11 s) following washout of DCS. 
Interestingly the peak amplitude of bursts followed a similar pattern with a mean 
value of 0.18 ± 0.05 mV for control and values of 0.21 ± 0.05 mV for 3 µM DCS, 
0.25 ± 0.05 mV for 30 µM DCS (p<0.05), 0.23 ± 0.05 mV for 300 µM DCS and 
0.16 ± 0.04 mV for the washout period. Also, the average area of epileptiform 
events, which is clearly related to the duration and peak amplitude, followed this 
pattern with a value of 190 ± 47 µVs in control and values of 232 ± 49 µVs for 3 
µM DCS (p<0.01), 302 ± 63 µVs for 30 µM DCS (p<0.01), 272 ± 54 µVs for 300 
µM (p<0.01) and 199 ± 50 µVs for the washout period. The frequency at which 
bursts occurred was 0.15 ± 0.03 Hz during control and was unchanged during this 
experiment. 
 
Clearly we were highly interested to observe that DCS increased the magnitude of 
these epileptiform bursts in terms of duration, peak amplitude and area. 
Furthermore we were highly interested to observe that these effects were maximal 
at the intermediate concentration, 30µM, which corresponds to the Emax of DCS 
at postNMDAr calculated in the previous chapter (4.3.2). Also, as each of these 
parameters was seen to return to control levels following washout of DCS, these 
effects were unlikely to be merely due to progressive changes in the epileptiform 
activity with time. 
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Control 3µM 30µM 300µM Washout
Fig. 5.3a. The effects of DCS on epileptiform activity in the medial EC, within 
burst analysis. During disinhibition-induced epileptiform activity, DCS was 
added at 3, 30 and then 300 µM, followed by a washout period. Above are example 
traces showing a characteristic epileptiform burst from each condition. Below are 
bar charts of the grand mean inter-event interval (IEI) across samples (left) and the 
mean IEI CoV (right), termed ‘variability’. Whilst there were no changes in these 
parameters with DCS, interestingly during the washout period, IEI variability was 
significantly lower than control. * denotes p<0.5, n=7. 
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Control 3µM 30µM 300µM Washout
Control 3µM 30µM 300µM Washout Control 3µM 30µM 300µM Washout
Control 3µM 30µM 300µM Washout
0.0
Control 3µM 30µM 300µM Washout
Fig. 5.3b. The effects of DCS on epileptiform activity in the medial EC, gross 
analysis. For the same data set as Fig .5.3a, a large scale gross analysis of 
epileptiform events is presented. Bar charts are shown for the grand mean of the 
frequencies at which bursts occurred during the 5 minute analysis period 
(‘frequency’), mean CoV of times between the events (‘gap variability’), grand mean 
of event durations (‘duration’), mean CoV of durations (‘duration variability’), grand 
mean of event amplitudes (‘peak amplitude’) and grand mean of event areas (‘area’). 
This powerful analysis indicated several significant changes in epileptiform bursts 
with DCS from control. Interestingly, the durations, peak amplitudes and areas of 
events were significantly increased by DCS and followed a U-shaped dose response, 
with maximal changes at 30µM. T denotes p<0.1, * denotes p<0.5, ** denotes 
p<0.01, n=7. 
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5.3.2 Effects of ACBC on epileptiform activity in the EC 
 
Having established the effects of DCS on epileptiform activity, we were now 
interested to examine the effects of the other NMDAr co-agonist site partial 
agonist which we have characterised, ACBC. To achieve this, in five brain slices 
with induced epilptiform activity, ACBC was added cumulatively at 100 µM, 300 
µM and 1 mM, followed by D-serine at 100 µM (with washout of ACBC). The 
within burst analysis of these experiments is shown in Fig. 5.4a. The IEI within 
the epileptiform bursts was seen to be significantly elevated by perfusion of 
ACBC, progressing with the concentration applied, and was then further increased 
by D-serine. The average value in control was 92.2 ± 12.4 ms and values were then 
101.6 ± 13.9 ms for 100 µM ACBC (p<0.05), 141.5 ± 29.6 ms for 300 µM ACBC, 
148.5 ± 25.1 ms for 1 mM ACBC (p<0.05) and 182.6 ± 26.5 ms for D-serine 
(p<0.01). No changes in within slice IEI variability were observed. 
 
Results from the gross analysis of this data is shown in Fig.5.4b. The frequency at 
which epileptiform bursts occurred over the analysis period was lowered at the 
higher concentrations of ACBC, although it was only approaching significance at 
the higher concentration it did appear to be reversed during perfusion of D-serine. 
Average values for this parameter were 0.15 ± 0.02 Hz for control, then 0.17 ± 
0.03 Hz for 100 µM ACBC, 0.13 ± 0.01 Hz for 300 µM ACBC, 0.10 ± 0.01 Hz 
for 1 mM ACBC (p<0.1) and 0.15 ± 0.02 Hz for D-serine. The average peak 
amplitude of bursts followed a similar pattern with a control value of 0.17 ± 0.06 
mV and values of 0.17 ± 0.06 mV for 100 µM ACBC, 0.14 ± 0.05 mV for 300 µM 
ACBC, 0.12 ± 0.04 mV for 1 mM ACBC (p<0.1) and 0.15 ± 0.04 mV for D-serine. 
The duration and area of bursts and was essentially unchanged during the 
experiments, with average control values of 1.11 ± 0.18 s and 152 ± 48 µVs, 
respectively. Finally the within slice variability (average CoV) of the gaps between 
bursts was unaltered by application of ACBC but was significantly reduced during 
the perfusion of D-serine. In other words, the time between events became more 
consistent following the application of D-serine.  
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Fig. 5.4a. The effects of ACBC on epileptiform activity in the medial EC, 
within burst analysis. During field recording of epileptiform burst activity, ACBC 
was added at 100 µM, 300 µM and then 1 mM, followed by D-serine at 100 µM 
with washout of ACBC. Above are example recording traces of epileptiform bursts 
during each condition in one experiment. Below are bar charts of the mean inter-
event interval (IEI) and IEI variability. Interestingly, ACBC progressively and 
significantly increased the interval between events within epileptiform bursts (i.e. 
a decrease in their frequency). However, this was further increased during 
perfusion of D-serine. * denotes p<0.5, ** denotes p<0.01, n=5. 
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Control 100µM 300µM 1mM D-serine
Control 100µM 300µM 1mM D-serine Control 100µM 300µM 1mM D-serine
Control 100µM 300µM 1mM D-serine Control 100µM 300µM 1mM D-serine
Fig. 5.4b. The effects of ACBC on epileptiform activity in layer II of the EC, gross 
analysis. In the same experiment as Fig. 5.4a, a gross analysis of epileptiform events was 
conducted. Bar charts are presented showing mean data across samples for the 
parameters of interest. Both the frequency at which epileptiform bursts occurred, and 
their peak amplitudes appeared to undergo a concentration dependent decrease with 
ACBC, which was tending towards significance at 1 mM. Also, the variability of the 
time between events (gap variability) was significantly decreased following perfusion of 
D-serine. T denotes p<0.1, * denotes p<0.5, n=5. 
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In summary then, the low efficacy partial agonist ACBC was here seen to increase 
the time between spikes (IEI) within the epileptiform bursts. However, this 
parameter was further increased by the full agonist D-serine. ACBC also appeared 
to produce a concentration dependent decrease in the peak amplitude of 
epileptiform bursts as well as the frequency at which they occur, and these effects 
reversed when ACBC was replaced with exogenous D-serine. Interestingly, the 
variability in gaps between events was unaffected by ACBC but was decreased in 
the D-serine condition. 
 
5.3.3 Effects of D-serine followed by DCS on epileptiform bursts 
 
Finally we were interested in whether the effects of DCS on epileptiform activity 
were likely to be due to the anti-NMDAr effect, such as that which we had 
observed at postNMDAr. To this end we tested the effects of the full agonist D-
serine (100 µM) and then DCS (300 µM), applied separately, on epileptiform 
activity in seven slices. The within burst analysis of this data is shown in Fig. 5.5a, 
IEI was 70.6 ± 9.5 ms in control and was unaffected by either treatment. Fig. 5.5b 
shows results from the gross analysis, though interestingly again here there were 
no notable effects throughout. The frequency at which bursts occurred was 0.11 ± 
0.03 Hz in the control period, 0.10 ± 0.02 Hz in the presence of D-serine and 0.11 
± 0.01 Hz in the presence of DCS.  Average burst duration was 1.34 ± 0.34 s in 
control, 1.48 ± 0.35 s with D-serine and 1.53 ± 0.31 s with DCS. Average peak 
amplitude was 0.24 ± 0.06 mV in control, 0.24 ± 0.06 mV in D-serine and 0.23 ± 
0.05 Hz with DCS. 
 
Fascinatingly, then D-serine appeared to have no discernible effect on epileptiform 
activity, despite having a positive effect at postNMDAr when examined with 
eNEPSCs (4.3.4). However, here we also did not see that any of the effects of DCS 
observed in 5.3.1 were replicated when DCS was applied following D-serine. 
These results may suggest that adaptive changes have taken place with D-serine 
treatment which then alter the network’s response to DCS. Our previous 
experimentation in 5.3.1 indicated that the washout conditions used were effective 
Chapter Five  Partial Co-agonists and Epileptiform Activity 
108 
Co-agonist Regulation of Pre and Postsynaptic NMDA Receptors in the Entorhinal Cortex 
at removing drug, although here the previously established effects of DCS were 


















































Fig. 5.5a. The effects of D-serine and DCS on epileptiform activity, within 
burst analysis. In 7 slices, epileptiform activity was induced and the effects of 100 
µM D-serine followed by 300 µM DCS (with washout of D-serine), were 
examined. Above are representative traces from one slice for each treatment 
condition, below are bar charts of data across slices of average IEI and the IEI 
variability of events within bursts. In this experiment neither D-serine or DCS 
elicited any significant change in the characteristics of the within burst spikes. 
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Fig. 5.5b. The effects of D-serine and DCS on epileptiform activity in the EC, 
gross analysis. Bar charts are given for the parameters of interest resulting from 
large scale gross analysis of recordings from the experiments of Fig. 5.5a. Again 
no consistent effects were observed in this data set with the gross analysis. n=7. 
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5.4 Discussion 
 
Without inhibition, spontaneous action potentials in principal cells can spread 
rapidly through the excitatory network and when these action potentials reach a 
frequency threshold, the entire network is activated producing a population 
response. This threshold is thought to represent the average requirement of 
excitation for a neurone to fire, summed across the network (De la Prida et al, 
2006, Cohen et al, 2006). The population response consists of every neurone firing 
in synchronisation. Principal cell firing drives this response, but the recurrent 
excitation also drives principal cell firing. This is emergence, the self-organisation 
of a complex system giving rise to a distinct form of activity. 
 
During the population response, on the single cell level a prolonged depolarisation 
with superimposed bursts of spikes is seen. (It is important to note the potential for 
confusion here, as generally the word ‘burst’ has been used here to describe the 
episodes of spiking on the extracellular level). These spikes are action potentials 
and the burst form in which they occur is due to the intrinsic bursting 
characteristics of pyramidal neurones. These bursting characteristics are thought 
to result due to the coupling between dendrites and soma portions of the neurones, 
either electrically and/or via intracellular calcium dynamics. This initial 
depolarisation with superimposed bursts of spikes corresponds to the initial 
singular spike seen at on the extracellular field level, which represents this activity 
coordinated across neurones and is commonly termed the paroxysmal depolarising 
shift. After this several similar but smaller groups of events termed ‘after 
discharges’ can occur in the intracellular recording, corresponding to the 
secondary spikes in the field recording burst (Traub et al, 1993).  
 
The AMPA receptor is the most crucial receptor in disinhibition induced 
epileptiform activity as blockade of this receptor is commonly seen to virtually 
abolish all population events, whilst blockade of NMDA receptors can reduce the 
amplitude and duration of epileptiform activity (Lee and Hablitz, 1991; Thompson 
and West, 1986; Dingledine et al, 1986; Jones and Lambert, 1990). As mentioned 
previously, the form of the population response is thought to be determined by the 
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intrinsic bursting characteristics of the principal cells. This neuronal bursting is 
highly dynamic and in computational models of epileptiform activity a fast AMPA 
receptor synaptic conductance provides the timely recurrent excitation required to 
produce a synchronised population response (Traub et al, 1993).  
 
5.4.1 DCS action on epileptiform activity 
 
In the experiments here, the effects of DCS were pro-synchronous. DCS increased 
both the peak amplitude and the duration of the epileptiform bursts. As the effects 
of duration closely mirrored those on amplitude this indicates that the two effects 
may share a common basis. It is possible that the effects of DCS at NMDAr during 
epileptiform bursting differs to those seen in quiescent slices. Or it may be possible 
that the effects seen here arise from areas within the brain slice where the NMDAr 
regulation is different. However, if DCS was now increasing amplitude/decay time 
we would expect similar effects with D-serine. Likewise if it was now decreasing 
amplitude we would expect the effects to be similar to ACBC, both of which were 
not the case. So it is likely that the effects of DCS here were unchanged from those 
observed at the NMDAr in the previous chapter (see section 4.3, 4.4). 
 
We were somewhat surprised then that DCS, which decreases the decay time of 
postNMDAr conductance, had pro-synchronous effects. One possible way to 
reconcile these findings may be to consider the AMPA receptor. As mentioned 
previously, the AMPA receptor is the most crucial receptor to epileptiform activity 
but the AMPA receptor also has very fast kinetics. So in terms of kinetic behaviour 
at least, by selectively reducing the decay of the postNMDAr with DCS we have 
effectively made them more AMPA receptor–like, without sacrificing the extent 
of the conductance which they provide. In other words the fact that AMPA 
receptors are the principal receptor in the production of epileptiform activity 
supports the notion that faster kinetics are pro-synchronous. As mentioned 
previously, computational models require a fast excitatory synaptic conductance 
to convey the quickly dynamic form of neuronal activity for synchronisation across 
the network.  In the presence of DCS, the average postNMDAr is now closing 
faster and are therefore able to re-open sooner and respond to glutamate release 
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more frequently. Given insights from the AMPA receptors, this is a highly 
plausible basis for a pro-synchronous effect.   
 
A different way to think about this may be to consider the reduced Traub 
computational model of disinhibition induced epileptiform activity produced by 
Pinksky and Rinzel (1993). This model indicates that during AMPA receptor 
blockade, the postNMDAr is sufficient for neurones to excite each other and fire, 
in line with intracellular observations (Traub et al, 1993), although the firing is 
muted in length as activity in the network does not persist for as long. However, 
in the extracellular field the signal is abolished, as the firing is no longer 
synchronised between neurones. The modelling indicates that this occurs due to 
the properties of the postNMDAr conductance, which introduce an element of 
unpredictability or ‘chaos’ into the network, causing rapid desynchronisation when 
AMPA receptors are not active. Perhaps then, by reducing the atypical kinetics of 
the postNMDAr conductance we have reduced this element of desynchronising 
chaos. The amplitude of the extracellular signal was then enhanced by DCS 
because the firing of neurones was more coordinated, and the length of the events 
was extended because the network was less prone to desynchronise. 
 
An alternative explanation could be based on the idea that in the presence of 
exogenous DCS, all postNMDAr would now be decaying at the same rate. Prior 
to the addition of DCS, postNMDAr responses could be decaying at varying rates, 
possibly due to the difference in glycine and D-serine bound. This change to a 
unified postNMDAr decay time would then be a highly plausible basis for 
increasing the synchrony of the neuronal network. However, if this was the case a 
similar response would be expected when exogenous D-serine was applied as this 
would also act to unify the decay of postNMDAr, but D-serine lacked any such 
effect (5.3.3). 
 
Clearly in light of the well-established biphasic dose relationship of DCS in 
cognitive enhancement (see section 5.1) we were extremely interested to observe 
that the prosynchronous effects of DCS followed a biphasic pattern. Furthermore 
the maximal effect was seen at 30 µM which was chosen as the central 
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concentration as it was observed to be the Emax at postNMDAr in principal cells. 
This, alongside the fact that these slices were disinhibited, indicates that the 
prosynchronous effects were indeed mediated by postNMDAr on principal cells. 
Unfortunately it is not currently known what CNS concentration is produced by a 
pro-cognitive dose of DCS as this would now be useful in ascertaining the possible 
relationship between these effects and cognitive enhancement by DCS. 
 
But why should a higher concentration produce a non-maximal effect here? One 
possible explanation is that interneurons were still able to have an inhibitory action 
via non-postsynaptic GABAB receptors. If this were the case then at 300 µM DCS, 
a pro-postNMDAr effect at interneurons may be enlarged relative to the effect at 
principal cells in comparison to when at 30 µM. There is evidence that inhibition 
of GABAB does have a small influence on picrotoxin induced epileptiform activity 
(De la Prida et al, 2006; Cohen et al, 2006). The prosynchronous effects observed 
here are clearly unlikely to underlie an anticonvulsant effect. However, if the 
schematic suggested here is correct it is possible then that an effect at interneurons 
may predominate at higher doses, producing an anticonvulsant effect. As 
previously mentioned (section 4.1) Wlaz et al (1994) found that an anticonvulsant 
dose of DCS represented a concentration of 860 µM in brain tissue, which would 
fit with this schematic.  
 
DCS was not seen to have any effect on the IEI within bursts although after 
washout, IEI variability was seen to decrease. As discussed earlier, these spikes 
represent coordinated periods of action potential bursts in the contributing 
neurones. It is unclear why washout of DCS should provoke a change in the 
variability of IEI but a change from control with the washout of a drug suggests 
that an adaptive response has taken place. Although it is only a single result, the 
possibility of adaptive plasticity changes taking place following DCS treatment is 
again clearly of interest when considering the pro-cognitive properties of DCS. 
However these properties are typically highly acute suggesting that immediate 
effects of DCS are responsible. 
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5.4.2 ACBC action on epileptiform activity 
 
 The mechanism of the effects of ACBC on epileptiform activity is more difficult 
to dissect as we have observed that ACBC has less specific effects at NMDAr. 
Indeed, unlike DCS, we observed that ACBC not only reduces the decay time of 
postNMDAr responses but also reduces the amplitude of these responses. 
Furthermore we have observed that ACBC can reduce glutamate release and as 
epileptiform activity entirely dependent on effective glutamatergic transmission, a 
presynaptic inhibition of glutamate release would very much be expected to 
generally antagonise this form of activity. It is interesting to contrast the effects of 
ACBC with those of DCS although ACBC still had two actions at principal cell 
NMDAr that DCS did not and so it problematic to comment on whether such 
differences are due to the reduction in the amplitude of postNMDAr responses or 
in glutamate release, by ACBC. 
 
In contrast to DCS the effects of ACBC were generally anti-synchronous. 
Although not strictly significant, ACBC appeared to both reduce the peak 
amplitude of epileptiform bursts and reduced the frequency at which bursts 
occurred. Neither of these effects occurred with DCS, indicating that they would 
not be directly due to a decrease in decay time of postNMDAr responses. As 
previously discussed, the peak amplitude of the epileptiform burst likely indicates 
the degree of coordination of cell firing which could foreseeably occur due to 
reduction in excitation via a postNMDAr inhibition or a preNMDAr inhibition. 
However, the latency between bursts is likely to represent the threshold of 
excitation required for neurones to fire, summed across the network (De la Prida 
et al, 2006). As postNMDAr are thought to be only weakly active in non-
depolarised cells due to the voltage dependent Mg2+ blockade, this may be more 
likely to be due to a presynaptic inhibition of glutamate release. An inhibition of 
glutamate release may reduce the effectiveness of excitation via AMPA receptors 
prolonging the time taken to reach the threshold of excitation whereby mutual 
depolarisation occurs. 
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The most pronounced effect of ACBC on epileptiform activity however, was on 
the intraburst IEI, where ACBC reduced the number of spikes within epileptiform 
events. This again was not seen with DCS. Such an effect indicates that less 
synchronised groups of action potential bursts are occurring and could again 
foreseeably be due to a direct reduction in postNMDAr conductance or an indirect 
reduction of AMPA receptor activity through preNMDAr. However, this result is 
confused by the even more pronounced increase following replacement of ACBC 
with D-serine. As D-serine has opposing effects at NMDAr it is puzzling that it 
would extend the response of ACBC. When D-serine was applied as the initial 
drug in section 5.3.3, no effect on intraburst IEI was seen at all. Again then there 
appears to be complex adaptive changes taking place during this activity and thus 
all inferences reliant on theory which is influenced by purely mechanical 
computational models should be made with caution. 
 
It is interesting that ACBC did not replicate any of the responses to DCS. Whilst 
the effects of DCS were all positive, ‘pro-synchronous’ effects, the effects of 
ACBC were all negative ‘anti-synchronous effects’. It is interesting then that 
whilst, as discussed, the (selective) reduction in postNMDAr decay time by DCS 
resulted in pro-synchronous changes, the multitude of effects of ACBC which 
included a reduction in postNMDAr decay time were anti-synchronous. It is 
therefore likely that the extent of excitatory transmission provided by the 
amplitude of postNMDAr responses and the effective release of glutamate are 
more important to epileptiform synchrony than the kinetics of the postNMDAr 
response. As previously discussed, this activity represents a severe over-excitation 
of a neuronal network and is thereby a model for epileptic seizures. Therefore these 
results can be taken to indicate that ACBC is a potential candidate for 
anticonvulsant drug therapy. 
 
5.4.3 Treatment of epileptiform activity with D-serine followed by DCS 
 
When D-serine was applied as the initial drug it was not seen to have any effects 
on epileptiform activity. Furthermore, when D-serine was subsequently replaced 
by DCS again no effects were observed. It is unclear why the full agonist D-serine 
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should have no effect on this activity. In the previous chapter it was observed that 
D-serine increased the amplitude and decay time of eNEPSCs, though only to a 
small extent. It is possible that then that this small change is simply not 
mechanically important to the epileptiform activity, though it is not possible to 
speculate further on why this would be the case.  
 
It is again unclear why none of the previously observed effects of DCS should be 
replicated when it was applied following treatment by D-serine. It is highly 
plausible that this may have been influenced by the post-maximal concentration of 
300 µM used here. Therefore these results are somewhat inconclusive. However, 
again this may indicate the importance of adaptive effects in epileptiform activity 
in the EC-hippocampal slices. The activity we have examined here likely involves 
the entire EC-hippocampal circuit and given the large capacity of this system for 
synaptic plasticity there is a clear basis for such adaptive changes to take place. 
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6.1 Co-agonist Regulation of PreNMDAr 
 
6.1.1 Glial D-serine as an endogenous ligand at preNMDAr 
 
Initial work utilised mEPSC frequency as an indirect measure of preNMDAr 
activity to extend the characterisation of this receptor in the medial EC. 
Experiments with co-agonists and co-agonist site antagonists indicated that 
endogenous binding of the preNMDAr co-agonist site contributes to the tonic 
facilitatory action of these receptors. Experiments with scavenging enzymes 
indicated that the endogenous co-agonist was D-serine and further experiments 
with fluoroacetate suggested that this D-serine came from glial cells. Glial cells 
are increasingly being recognised as being important for computation in the brain 
and may exhibit a direct association with preNMDAr. This finding extends such 
ideas and adds an additional layer of complexity to the interactions at tripartite 
synapses. As preNMDAr are a target for the treatment of epilepsy, these results 
support existing initiatives to target the NMDAr co-agonist site for anticonvulsant 
therapy.  
 
6.1.2 Selective targeting of NMDAr 
 
A principle aim of this line of experimentation was to examine whether the co-
agonist site could be useful as a basis for establishing a selective pharmacological 
profile of preNMDAr. From these results and others it appears that preNMDAr 
may be unique in that D-serine appears to be the sole endogenous co-agonist at 
these receptors. It is possible then that targeting D-serine production would affect 
preNMDAr activity more greatly than other NMDAr populations, which could 
also then possibly be compensated for by increasing glycine. The complete 
inhibition of preNMDAr by GluN2B antagonists may further aid discrimination of 
these receptors. However, most simply we observed that unlike postNMDAr, the 
preNMDAr co-agonist site appears to be saturated. This difference in degree of 
activation indicated the possibility of selectively targeting one receptor population 
over the other using a co-agonist site partial agonist.  
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6.2 The Actions of Co-agonist Site Partial Agonists at NMDAr in the EC 
 
6.2.1 Co-agonist regulation and pharmacology of the postNMDAr 
 
We examined the effects of the full co-agonist D-serine, the high efficacy partial 
co-agonist DCS and the low efficacy partial co-agonist ACBC on eNEPSC 
responses in principle cells of the medial EC. By examining the effects of these 
co-agonists of varying efficacy on the macroscopic response we were able to 
establish that the postNMDAr here exhibits an endogenous co-agonist activation 
of 79-87%. This matched with the efficacy of DCS as reported by Priestley and 
Kemp (1994), around 85%. Interestingly more recent studies have examined DCS 
efficacy at recombinant NMDAr, and this value lies between those for GluN2A 
and GluN2B diheteromers, supporting previous evidence that the postNMDAr has 
a GluN1(x2)/GluN2A/GluN2B triheteromic structure. Examining the effects of 
exogenous D-serine on the decay of the eNEPSC indicated that the endogenous 
binding of the postNMDAr sites was by a full or very high efficacy co-agonist but 
probrably not by pure D-serine, possibly by a mixture of D-serine and glycine as 
recently demonstrated for the hippocampus. This would then be in contrast to the 
endogenous co-agonist regulation of preNMDAr in the EC which we have shown 
to be mediated exclusively by D-serine. 
 
6.2.2 DCS is a tool for investigating the role of postNMDAr kinetics 
 
Examining the effects eNEPSCs at principal cells, we observed that DCS effected 
only the kinetics of these events, acting to decrease the decay time.  This appeared 
to occur due to the level of endogenous postNMDAr co-agonist site activation and 
the identity of the endogenous co-agonist. The level of activation appeared to be 
matched to the efficacy of DCS meaning DCS did not change the amplitude of the 
events. However, the endogenous co-agonist had a higher efficacy, producing the 
larger control decay time. Moreover, DCS did not appear to have any effect at 
preNMDAr in the EC, though the exact reason for this is less clear (see section 
4.4.3). So with DCS, at principal cells in the EC at least, we see a selective effect 
at postNMDAr over preNMDAr. Furthermore, this is a selective effect to reduce 
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the decay of the postNMDAr response. Therefore we have shown that DCS is a 
highly intriguing tool for investigating the role of the uniquely long kinetics of the 
postNMDAr, at principal cells in brain slices. In contrast the lower efficacy ACBC 
decreased the amplitude, as well as the decay, of eNEPSCs and also had an 
inhibitory action at preNMDAr. 
 
6.3 The Actions of Co-agonist Site Agonists on Epileptiform Synchrony in the 
EC 
 
6.3.1 The long decay of PostNMDAr on principal cells is anti-synchronous 
 
With disinhibition induced epileptiform activity in the EC, DCS was tested at three 
concentrations, with a middle concentration corresponding to the Emax for the 
reduction of eNEPSC decay time (30 µM) at principal cells. The results were 
highly interesting. We observed that DCS across these concentrations, increased 
the amplitude and duration of population extracellular activity indicating a greater 
and more sustained synchrony of the network (sections 5.3.1 and 5.4.1). 
Fascinatingly the concentration dependence of this effect was biphasic, peaking at 
30 µM. Owing to the nature of disinhibition induced epileptiform activity, which 
is an emergent form of activity arising from the recurrent excitatory network, and 
that this response peaked at the eNEPSC Emax, we believe that this was mediated 
by an effect at postNMDAr on principal cells. Also, as this effect was not 
replicated at all with a lower efficacy co-agonist or a full co-agonist, we believe 
that it was indeed produced by the action at postNMDAr which we had observed 
with eNEPSCs, that is, a selective reduction in decay time. 
 
This leads to what may be the most fascinating implication of this work: that the 
long decay of postNMDAr on principal cells is anti-synchronous and this finding 
has potentially profound implications for the study of diseases which are suggested 
to be disorders of network dynamics, such as epilepsy and psychosis. This result 
raises the question of why the long decay of the postNMDAr would be anti-
synchronous, and why the brain would work at sub-maximal level of synchrony. 
An interesting explanation for this would be that the brain has evolved based on a 
Chapter Six  General Discussion 
121 
Co-agonist Regulation of Pre and Postsynaptic NMDA Receptors in the Entorhinal Cortex 
compromise between the benefits of good neuronal synchrony and the risk of 
epilepsy resulting from excessive synchrony. This idea would imply an 
evolutionary balance between the synchronous properties of the varying neuronal 
receptors. 
  
6.3.2 Cognitive enhancement by DCS could be mediated by a negative kinetic 
effect at GluN2A/B containing NMDAr at principal cells 
 
Owing largely to the high efficacy of DCS, the cognitive enhancement produced 
by DCS has been commonly thought to occur through a pro-NMDA effect. This 
also fits with the simple view of NMDAr as being a broadly pro-cognitive receptor. 
More recently, the pharmacology of DCS has been well established and it has been 
observed that at GluN2C containing receptors, DCS has an efficacy 200% that of 
glycine, compared to sub-maximal efficacies at the other NMDAr subtypes (see 
section 4.11). This has led to the idea that the pro-cognitive effects of DCS are 
mediated by GluN2C containing receptors, which are commonly located on non-
principal cells such as interneurons (see Dravid et al, 2010; Goff et al, 2012; Ogden 
et al, 2014). Crucially this schematic accounts for the biphasic dose response curve 
of DCS in cognitive enhancement. 
 
Initially, our observations with DCS at eNEPSCs seemed to fit such a schematic 
as we had observed essentially an anti-NMDAr effect at principal cells. However, 
subsequently we observed a pro-synchronous response of DCS which was 
mediated by this action at principal cell postNMDAr, and these have been shown 
to be a GluN2A/B triheteromeric subtype. Moreover, this effect was biphasic itself 
and so can also account for the u-shaped dose response. Although this is an 
artificial form of synchrony in slices of rat brain, such an effect could plausibly 
underlie a cognitive enhancement in vivo. We therefore propose an alternative 
theory of DCS action: that the cognitive enhancement occurs by a negative kinetic 
effect at GluN2A/GluN2B containing postNMDAr on principal cells which 
counterintuitively causes an enhanced neuronal network synchrony. On this idea 
it is interesting to note that the clinically utilised cognitive enhancer memantine 
has been shown to enhance gamma and theta oscillations in cortical brain regions 
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Fig. 6.1. The effects of DCS on gamma frequency oscillations. These 
experiments were carried out by Nadine Aboutara and Emma Robson. Above; 
sample traces, mid; a sample power spectrum produced by analysis of a one minute 
period of the continuous oscillation using a fast fourier transform, below; average 
data for 9 brain slices. Continuous gamma oscillations were induced in brain slices 
using kainic acid, and measured in the hippocampus as this activity was too weak 
in the EC for reliable study. At 3µM DCS significantly (p<0.05) increased the peak 
spectral amplitude of these oscillations, but this effect progressively diminished at 
30µM and 300µM.  Again then there appears to be a U-shaped pro-synchronous 
response, but peaking at a lower concentration than as was observed for the effects 
on epileptiform activity. Within our theory this could be explained by the fact that 
these slices are not disinhibited, meaning a larger anti-synchronous effect from 
interneurons and thus a lower concentration at which the pro-synchronous effect 
by pyramidal cells is overcome 
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of conscious rats (Ahnaou et al., 2014). Memantine is an NMDAr channel blocker 




Recently, further experiments from this laboratory have extended this study to the 
effects of DCS and ACBC on gamma oscillations, a more physiologically relevant 
form of synchronised behaviour which is thought to be highly important in 
cognition (see Wang, 2010). Interestingly this work has largely been seen to match 
well with the observations made in the study of epileptiform activity (Fig. 6.1 & 
6.2), adding support to the observations on the synchronous properties of NMDAr 
and novel theory of cognitive enhancement by DCS presented here. 
 
6.3.3 Other implications  
 
The effects of the lower efficacy co-agonist ACBC on epileptiform activity were 
unrelated to those of DCS and were anti-synchronous. This is interesting as, like 
DCS, we observed that ACBC also reduced eNEPSC decay but unlike DCS, 
ACBC also decreased eNEPSC amplitude. Additionally, we also observed that 
unlike DCS, ACBC can reduce the tonic facilitation of glutamate release by 








Fig. 6.2. The effects of ACBC on gamma frequency oscillations. This 
experiment was carried out by Nadine Aboutara and Emma Robson. ACBC 
abolished gamma synchrony and the response then recovered following washout. 
This is in agreement with the antisynchronous effects of ACBC observed on 
epileptiform activity in section 5.3.2. 
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from pro-synchrony to anti-synchrony. However, as a reduction of efficiency of 
glutamate release would alter transmission by the crucially important AMPA 
receptor, the inhibitory effect at preNMDAr is a highly plausible candidate for this 
stalk change in effect between the two co-agonists. Whatever the mechanism, these 
results indicate the possibility that ACBC or a similar compound may be a 
potential lead for anticonvulsant therapy. Interestingly D-serine was not seen to 
have any effect on epileptiform activity, when applied as the principal drug, and 
the reason for this is unclear. Other results with each drug indicated the capacity 
of this activity to undergo adaptive changes in response to treatment and indicating 
that more complex inferences, which are beyond the scope of the current work, 
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Abstract
The entorhinal cortex (EC) controls hippocampal input and output, playing major roles in memory and spatial navigation.
Different layers of the EC subserve different functions and a number of studies have compared properties of neurones
across layers. We have studied synaptic inhibition and excitation in EC neurones, and we have previously compared
spontaneous synaptic release of glutamate and GABA using patch clamp recordings of synaptic currents in principal
neurones of layers II (L2) and V (L5). Here, we add comparative studies in layer III (L3). Such studies essentially look at
neuronal activity from a presynaptic viewpoint. To correlate this with the postsynaptic consequences of spontaneous
transmitter release, we have determined global postsynaptic conductances mediated by the two transmitters, using a
method to estimate conductances from membrane potential fluctuations. We have previously presented some of this data
for L3 and now extend to L2 and L5. Inhibition dominates excitation in all layers but the ratio follows a clear rank order
(highest to lowest) of L2.L3.L5. The variance of the background conductances was markedly higher for excitation and
inhibition in L2 compared to L3 or L5. We also show that induction of synchronized network epileptiform activity by
blockade of GABA inhibition reveals a relative reluctance of L2 to participate in such activity. This was associated with
maintenance of a dominant background inhibition in L2, whereas in L3 and L5 the absolute level of inhibition fell below that
of excitation, coincident with the appearance of synchronized discharges. Further experiments identified potential roles for
competition for bicuculline by ambient GABA at the GABAA receptor, and strychnine-sensitive glycine receptors in residual
inhibition in L2. We discuss our results in terms of control of excitability in neuronal subpopulations of EC neurones and
what these may suggest for their functional roles.
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Introduction
The entorhinal cortex (EC) acts as a dynamic processor of
information entering and leaving the hippocampus. The lamina
and columnar structure of the EC provides a means of internal
integration of information processing, and organization of its
inputs and outputs determines its associative interactions with the
rest of the neuraxis. The perforant path provides the major source
of hippocampal input, projecting from layer II (L2; principally to
the dentate gyrus and CA3) and layer III neurones (L3; principally
to CA1 and the subiculum). These neurones receive convergent
input from higher order cortices directly, and via adjacent cortices
(presubiculum, perirhinal, parahippocampal). Hippocampal out-
put is directed back to the neocortex via projections from CA1 and
subiculum to neurones in layer V (L5) of the EC. In addition, the
deeper neurones have associative connections with neurones in the
superficial layers, and these provide a substrate for reverberant
activity, which may be involved in reinforcement of stored
information. The intimate association of the EC and the
hippocampus probably indicates a complementary role of these
areas in memory processes [1–2].
Increasing attention is being paid to the crucial role of the EC in
spatial memory, in particular, in spatial representation and
navigation [3]. To navigate, most animals derive spatial cues
from external landmarks, combining this with computation of
position from motional self-location cues. Principal neurones in the
hippocampus may function as place cells to fulfill the former
function, whilst grid cells, head-direction cells, and conjunctive
cells (both grid and head-direction properties) in other areas,
including the EC, may contribute to the latter [3]. Within the EC
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there appears to be a lamina-based gradation of function, with L2
cells biased towards grid function, those in L3 towards head-
direction, and L5 towards conjunctive function.
Other studies point to a lamina-specific delineation of functional
responsiveness within the EC. For example, slow-wave oscillations
(akin to cortical up-down states) in the EC are prominent in L3,
but similar activity is weaker in L2, and L5 is reluctant or unable
to participate in such activity [4]. Pharmacologically-induced
gamma-frequency oscillation are also more pronounced in L3
compared to deeper and more superficial layers [5], whereas theta
oscillatory activity is more prominent in L2, than in L3 or L5 [6].
EC dysfunction has often been implicated in neurological
disorders particularly temporal lobe epilepsy (TLE) [7–15]. In vitro
experiments in rat brain slices have demonstrated a pronounced
susceptibility of the EC to acutely provoked epileptogenesis [16–
23]. Pharmacologically induced seizures arise predominantly in
the EC and propagate to adjacent cortical and hippocampal areas
[16,20,24–27], but within the EC, acute epileptiform activity
appears to be initiated in deep layers of the EC [16,20,21,27,28]
leading to the suggesting that deep layers may be more susceptible
to pathological synchronization [20,21,29].
The functional roles played by subpopulations of neurones in
integrative processing and pathological activity will be dependent
on many factors, including their intrinsic properties and connec-
tivity within internal and external networks. Increasing attention
has been paid to the role of background synaptic activity in
modulating the properties of cortical neurones and determining
input and output responsiveness. Individual cortical neurones are
synaptically targeted by thousands of inputs derived from both
excitatory (glutamate) and inhibitory (GABA) neurones in a dense
and complex network. Both transmitters are continuously released
by action potentials within network interconnections and by
activity-independent release (miniature events). This background
synaptic activity is a reflection of the moment-to-moment state of
the network and is suggested to be instrumental in determining the
excitability of any given neurone. It provides a source of stochastic
resonance enhancing gain and signal detection [30–34]. Such
activity may play a major role in shaping the processing of entrant,
reentrant and afferent information in the EC.
One way of studying background synaptic activity is to monitor
spontaneous excitatory and inhibitory currents using whole cell
patch clamp recording, and we have adopted this approach in the
EC to make qualitative comparisons of background inhibition and
excitation in L5 and L2 neurones [35–38]. In the present
investigation we have extended these observations to include L3
pyramidal neurones. However, there are a number of technical
limitations with this approach (see methods), and, more recently,
we have employed an analytical method to estimate global
background synaptic conductances from measurement of fluctu-
ations in membrane potential (termed VmD) derived from sharp
electrode, intracellular recordings [39–44]. In the current inves-
tigation we have used both whole cell patch clamp recording, and
VmD estimations to compare fast background inhibition mediated
via GABAA-receptors (GABAAr) and excitation mediated by
AMPA-receptors (AMPAr) in L2, L3 and L5 neurones in the
EC. We have investigated how these background synaptic




All experiments were performed in accordance with the U.K.
Animals (Scientific Procedures) Act 1986, European Communities
Council Directive 1986 (86/609/EEC) and the University of Bath
ethical review document, which requires that the number of
animals used is kept to a minimum and every precaution was taken
to reduce suffering and stress. At this institution, all research work
involving use of animal tissue requires submission of a consider-
ation of ethical implications form by the principal investigator.
This is reviewed by a second investigator, external to the research
group, and by the Head of Department, and requires signatory
approval from both before being submitted to and reviewed by the
Departmental Research Ethics Officer (DREO). The DREO will
discuss any issues raised with the investigator. The DREO submits
report to the University Ethics Committee detailing the ethical
implications of all research within the Department on an annual
basis. This ensures that the ethical implications of the research
have been considered and that there is be a process in place for
managing any ethical issues. All these processes have been adhered
to in the current experimental work.
Slice preparation
EC slices were prepared [45] from male Wistar rats (60–100 g;
P28–40) anaesthetised with ketamine (120 mg/kg) plus xylazine
(8 mg/kg). Rats were decapitated and the brain removed and
immersed in artificial cerebrospinal fluid (aCSF; see below for
composition) at 4uC. Slices (400 mM) were cut using a Campden
Vibroslice and stored in aCSF bubbled with carbogen (95% O2/
5% CO2) at room temperature. Because of the orientation of the
cutting [45], ours slices were largely restricted to more ventral
locations, so dorso-ventral variation in intrinsic properties of
neurones was minimized. To increase neuronal survival and
viability, ketamine (4 mM) and indomethacin (45 mM) were
included in the cutting solution and the antioxidants, n-acetyl-l-
cysteine (6 mM) and uric acid (100 mM), added to both cutting and
storage solutions. We have established (Woodhall, G.L. and Jones,
R.S.G., unpublished observations) that the use of additives during
cutting and storage produces robust and long-lasting slices, but
does not have any apparent effect on the pharmacology of
glutamate or GABA transmission. Nevertheless, in both recording
situations slices were allowed to equilibrate in the recording
chambers for at least 1 hour prior to recording to allow for
washout of these agents. For patch clamp recordings slices were
transferred to a recording chamber perfused (2 ml/min) with
oxygenated aCSF at 31–32uC on an Olympus BX50WI micro-
scope. Neurones were visualized using DIC optics and an infrared
video camera. In VmD experiments slices were transferred to a
recording chamber where they were held at the interface between
a continuous perfusion of oxygenated aCSF (1.5 ml/min) main-
tained at 3260.5uC and warm, moist carbogen gas. Intracellular
recordings were made ‘‘blind’’ from slices visualised with a
binocular microscope (Wild M8). The perfusion and storage aCSF
contained (in mM): NaCl (126), KCl (3.25), NaH2PO4 (1.4),
NaHCO3 (19), MgSO4 (2), CaCl2 (2), and D-glucose (10). For
cutting the slices at 3–4uC, NaHCO3 was increased to 25 mM to
maintain pH at acceptable levels (7.3).
Experimental approaches
As noted, we have used two experimental approaches to
examine background synaptic activity in these studies. The more
traditional approach involves whole cell voltage clamp recording
of spontaneous synaptic currents. This is essentially looking at
background activity from a presynaptic viewpoint, comparing the
probabilistic release of glutamate and GABA, and making the
assumption that a higher rate of release will result in greater
postsynaptic excitation or inhibition, respectively, and vice versa.
There are several technical issues with this approach. Experimen-
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tal conditions are tailored towards recording of either excitatory or
inhibitory currents in isolation, and therefore do not take into
account how alterations in network activity and the postsynaptic
responses to either transmitter may be altered by changes in the
other. Recordings are conducted at somatic sites and these will not
adequately detect events at distal dendritic sites. This means that
frequencies of IPSCs and EPSCs will not reflect a true
contribution of inhibition or excitation to overall cellular activity.
The differential location of excitatory and inhibitory synapses also
means that synaptic excitation (distal location) may be underes-
timated compared to inhibition (more proximal) by this approach.
Patch solutions for recording of synaptic currents generally include
Na+ and K+-channel blockers to improve postsynaptic space-
clamp and partially obviate some of the issues with recording
resolution. However, this means that a realistic estimation of
cellular excitability is impossible.
We have developed a complementary approach based on what
is referred to as the VmD method. This was developed by Alain
Destexhe and colleagues [42–44], using the presumptive synaptic
activity of model neurones to attempt to recreate the biological
activity of real neurones under conditions of intense synaptic
activity (referred to as a ‘‘high-conductance state’’ [42–44]). We
have adapted this mathematical approach as a means of
quantifying the background synaptic activity based on the ongoing
biological fluctuations in real neurones. The approach essentially
looks at background synaptic activity from a postsynaptic
perspective. The VmD method relies on the premise that
momentary fluctuation in somatic membrane potential largely
reflects the combined effects of on-going global inhibitory and
excitatory postsynaptic conductances, which result from the
presynaptic transmitter release occurring in response to network
activity. Although this method was developed and tested using
theoretical and experimental approaches applicable to high
conductance in vivo network states, we have experimentally and
pharmacologically validated its use to estimate background
conductances in the relatively quiescent conditions extant in EC
slices, and, subsequently, employed it to determine the effects of
diverse anticonvulsants on these conductances [39–41]. There are
potential errors and limitations that have to be considered in terms
of establishing absolute levels of background conductances,
particularly membrane potential fluctuations arising from intrinsic
membrane ion channels [42]. However, since we are looking
principally at relative differences within and between neurones,
these are not prohibitive issues, and it provides an excellent way to
complement studies of presynaptic release with overall postsynap-
tic activity.
Whole-cell patch clamp recordings of transmitter release
Patch pipettes pulled from borosilicate glass were used for
recording spontaneous or miniature excitatory postsynaptic
currents (sEPSCs and mEPSCs, respectively). They were filled
with a Cs-gluconate based solution containing (in mM) D-
gluconate (100), HEPES (40), QX-314 (1), EGTA (0.6), MgCl2
(5), TEA-Cl (10), phosphocreatinine (5); ATP-Na (4) and GTP-Na
(0.3). To record spontaneous or miniature inhibitory PSCs (sIPSCs
and mIPSCs), the patch solution contained CsCl (100), HEPES
(40), QX-314 (1), EGTA (0.6), TEA-Cl (10), MgCl2 (5), ATP-Na
(4) and GTP-Na (0.3). Solutions were adjusted to 275 mOsmol
and pH 7.3 with CsOH. Whole-cell voltage clamp recordings
(holding potential 260 mV) were made from pyramidal neurones
in L3 of the medial division of the EC, using an Axopatch 200B
amplifier. Signals were filtered at 2 kHz and digitized at 20 kHz.
Series resistance compensation was not employed, but access
resistance (10–30 MV) was monitored at regular intervals and cells
were discarded if it changed by more than 610%. Liquid junction
potentials (EPSC +12.0 mV; IPSC +10.2 mV) were estimated
using pClamp-8 software, and compensated for in the holding
potentials. When recording IPSCs, AMPA-receptors and NMDA-
receptors were blocked with bath applied NBQX and 2-AP5,
respectively.
Data were recorded using Axoscope software, and Minianalysis
(Synaptosoft, Decatur) was used for analysis of PSCs off-line.
Spontaneous events were detected using a threshold-crossing
algorithm. Cumulative probability distributions of interevent
interval (IEI) were compared using the Kolmogorov-Smirnoff test
(KS). When data were pooled for this analysis, a minimum of 200
events was sampled during a continuous recording period for each
neurone under each condition. Mean amplitudes, rise times (10–
90%) and total decay times were compared using a t-test.
VmD estimations of postsynaptic background
conductances
Sharp electrodes pulled from borosilicate glass and filled with
potassium acetate (3M, pH adjusted to 7.3); tip resistances of 80–
120 MV) were used to make intracellular voltage recordings using
an Axoprobe 1A amplifier (Molecular Devices). When membrane
potential had stabilised after impalement, estimates of global
background excitation (Ebg) and inhibition (Ibg) were derived from
membrane potential fluctuations at regular intervals throughout
the recordings using the VmD method. This approach was derived
by Rudolph et al., [42] and we have adapted it for recording in EC
slices [39–41]. Precise technical details of the approach are
available in these papers [39,42], and are not repeated here.
Briefly, neurones were depolarised (for 15–20 s) by injection of two
levels of known positive current via the recording electrode. The
values of the currents differed from neurone to neurone, but were
maintained the same throughout any individual experiment. One
level was chosen to elicit a depolarization to within 1–2 mV of
action potential threshold, and the second was adjusted to
depolarize the neurone to about half way between this and resting
membrane potential. Membrane potential fluctuations at these
two levels were fitted to Gaussian distributions (Prism 4 software,
GraphPad, San Diego, USA) and the mean and variance of the
membrane potential determined. Leak conductance in each
neurone was calculated from the ohmic response produced by a
small (0.1 nA 100 ms) hyperpolarizing current, injected at resting
membrane potential. These parameters, together with mean
reversal potentials for AMPA-receptors and GABAAr mediated
synaptic responses ([39] plus unpublished data), allowed us to use
the VmD relationship to quantitatively estimate background
inhibitory and excitatory conductances resulting from global
network input onto individual neurones. Statistical analysis (paired
t-tests or one-way ANOVA) was performed with Prism 4 software.
All error values in the text refer to standard error of the mean.
Cellular excitability was determined by injecting depolarizing
current pulses at resting potential. Action potential (AP) thresholds
with respect to resting membrane potential were determined using
brief incremental peri-threshold injections of depolarising current
(0.1–1.0 nA, 50 ms) via the recording electrode. Trains of action
potentials were also elicited by longer, supra-threshold current
pulses (0.2–1.0 nA, 200 ms), and the number of spikes per pulse
determined.
In some experiments, designed to compare the effects of
blocking GABA inhibition in L2, we employed extracellular
recording of spontaneous epileptiform activity. In these studies we
used patch pipettes (filled with normal ACSF, and broken back to
give tip resistances of around 1–5 MV) and an NPI EX-10C
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differential amplifier for recording local field potential activity. In
some cases simultaneous recordings were made in different layers.
Materials
Salts used in preparation of aCSF and electrode solutions were
purchased from Merck/BDH or Fisher Scientific (UK). Indo-
methacin, n-acetyl-l-cysteine and uric acid were purchased from
Sigma (UK). Ketamine was supplied by Fort Dodge Animal
Health Ltd (Southampton, UK) and xylazine by Bayer AG
(Leverkusen, Germany). Drugs were applied by bath perfusion.
The following drugs were supplied by Tocris UK or Ascent
Scientific UK: 2-AP5 (D-2-amino-5-phosphonopentanoic acid),
NBQX (6-nitro-7-sulphamoylbenzo[f]quinoxalone-2,3-dione diso-
dium), bicuculline methiodide, QX-314 (N-(2,6-Dimethylphenyl-
carbamoylmethyl) triethylammonium chloride). Picrotoxin and
strychnine HCl were purchased from Sigma UK.
Results
Lamina comparison of spontaneous GABA and
glutamate release
Previous work from this laboratory has detailed characteristics
of s/mEPSCs and s/mIPSCs in L2 and L5 of the EC [35–38]. To
complete the laminar comparison of spontaneous release of
glutamate and GABA across the EC, we have made similar
studies in L3 and we present representative data (from 19 neurones
each for sEPSCs and sIPSCs) here. We stress that some of the data
are from previously published studies [35,38] but a summary
(supplemented by some additional recordings) is presented here for
direct comparative purposes.
EPSCs. The properties of EPSCs in the 3 layers are
summarized in Figure 1. As in L2 and L5 [35], the vast majority
of sEPSCs were mediated via AMPAr (Figure 1A). Thus,
spontaneous currents were essentially undetectable in the presence
of AMPAr antagonists (NBQX, SYM 2206, or GYKI 53655) at a
holding potential of 260 mV. However, at more positive holding
potentials, occasional small slow events could be detected; these
reversed at around 0 mV and were blocked by 2-AP5, indicating
that in this layer, as in L2 and L5 [35], sEPSCs mediated by
NMDA receptors were evident at a very low frequency.
The mean IEI of sEPSCs in L3 was 198628 ms, corresponding
to a mean frequency of 5.161.1 Hz, which is considerably higher
than that of sEPSCs in either L5 (714639 ms) or L2 (756628 ms)
(Figure 1B; cf. [38]). In contrast, the mean amplitude (Figure 1C)
in L3 (14.160.7 pA) did not differ greatly from the other layers,
although it was slightly greater than that in L2 (13.260.3 pA) and
less than that in L5 (15.760.5 pA). Rise and decay kinetics
(Figure 1D) in L3 (1.860.2 ms and 5.960.5 ms, respectively) were
similar to those recorded for sEPSCs in L5 (1.960.1 ms and
5.760.3 ms; [35]), but both parameters were slower in L2
(2.560.1 ms and 8.060.4 ms; [35]). Previously, we have also
shown that neurones in all layers are not particularly electronically
compact, with estimated electrotonic lengths of 2.5 and 1.6 in L5
and L2, respectively [35]. The value estimated for L3 (1.6; [46])
was the same as that in L5, so it is possible that the faster kinetics of
sEPSCs in L3 and L5 may be associated with the shorter electronic
lengths of the neurones in these layers compared to L2.
There was a clear difference between L3 and L2 or L5 in the
contribution of activity-dependent release to overall spontaneous
release (Figure 1E). Thus, in L3 neurones, application of TTX
(1 mM; n= 8) caused a 6-fold increase in IEI from 220628 ms to
12846243 ms, reflecting a decrease in frequency from 6.461 Hz
to 1.060.3 Hz. The mean amplitude of events (Figure 1E) was
slightly less in the presence of TTX, but not significantly so.
However when we examined the cumulative probability distribu-
tions in pooled data, it was apparent that there was a loss of some
of the larger amplitude events, which produced a significant
(P,0.01; KS) shift to the left, evident at the top end of the
distribution. In contrast, in both L2 and L5, TTX only caused a
15–20% reduction in sEPSC frequency [35]. Thus, L3 neurones
show a much great preponderance of action potential driven
release compared to the other layers where activity-independent,
monoquantal release predominates.
IPSCs. IPSCs in L3 neurones were recorded at a holding
potential of 260 mV, with symmetrical [Cl2], where they were
evident as fast inward currents. In agreement with our studies in
L2 and L5 [37] these were largely eliminated (n= 7) by the
GABAA-receptor blocker, gabazine (20 mM; Figure 2A). However,
the glycine receptor antagonist, strychnine, applied before
gabazine (1 mM), also had a weak effect on sIPSCs reducing the
frequency by around 10–20% (n= 6) without affecting amplitude
(mean IEI 1686117 ms v 1986134 ms Figure 2A). KS analysis of
the cumulative probability distribution of IEIs (not shown) from
pooled data indicated an effect that just reached significance
(P,0.01). We found a similar small reduction with strychnine in
L2 neurones previously [37]. We have now added further studies
to those in this previous sample and the summary data shown in
Figure 2A confirm a small, but significant, decrease in frequency of
sIPSCs in L2 with no effect in L5.
Overall, sIPSCs in L3 (n= 19) occurred at a high frequency (10–
15 Hz; Figure 2B) reflected by a mean IEI of 112621 ms, which is
similar to that seen in L2 (IEI 8762 ms; Woodhall et al, 2005) and
much shorter than that in L5 (IEI 404610 ms; Woodhall et al,
2005). Mean amplitude in L3 (30.962.0 pA; Figure 2C) was larger
than that in either L2 or L5 (24.061.8 and 25.763.9 pA
respectively; [37]). Mean decay time of sIPSCs in L3 was
15.861.5 ms, which is longer than those seen in the other layers
(L2 10.5 ms; 10.6 in L5), but rise time (2.260.2 ms) was similar to
those reported for L2 and L5 (2.060.03 ms and 1.960.03 ms,
respectively; Figure 2D; [37])
The relative contribution of action potential driven and action
potential-independent release was determined (Figure 2E). IEI of
sIPSCs in the presence of TTX (1 mM) approximately doubled
from 112621 ms to 238644 ms (n = 10) in L3. This represents a
decrease in frequency from 15.562.8 Hz to 6.061.1 Hz, indicat-
ing that approximately half of the IPSCs are action potential-
dependant. This effect is similar to that seen in L5 where the IEI
more than doubled (from 368.2613.1 ms to 979.9631.5 ms;
[37]), but contrasts markedly to L2 where TTX had little or no
effect [37]. In terms of absolute numbers of sIPSCs, L3 neurones
actually showed a much greater decrease than L5 in the presence
of TTX, as a result of their higher baseline frequency of sIPSCs.
EPSC to IPSC comparison
Looking at baseline levels of spontaneous synaptic activity across
the three layers, there are some general and obvious differences.
The most prominent difference in sEPSCs is the higher frequency
noted in L3. Amplitudes are similar, with slightly larger events in
L5, and in terms of kinetics the slower decay time in L2 is
prominent. In the case of inhibition, the high frequency of sIPSCs
in L2 and L3 compared to L5 is the most notable difference. To
gain a better comparative picture of overall spontaneous synaptic
activity across the three layers, we derived arbitrary charge
transfer (CT) values for spontaneous synaptic activity. These
values are the product of mean frequency, amplitude and decay
times.
For sEPSCs, CT was highest in L3 (340.3) and approximately
the same in L2 (147.8) and L5 (125.3) (Figure 3 top). In the case of
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sIPSCs (Figure 3 middle), again L3 gave the highest CT value at
4345.2. This was followed by L2 at 2898.0 with L5 markedly lower
at 653.8. Cortical neurones are under a simultaneous and
continuous bombardment from both glutamate and GABA
synapses. Although we have not recorded excitatory and inhibitory
currents simultaneously in individual neurones, we determined the
ratio of CT values as an approximate measure of the relative
influence of spontaneous excitation to inhibition across the
different populations of neurones. This gave inhibition:excitation
(I:E) ratios of 19.6. in L2 followed by 12.8 in L3 and 5.2 in L5
(Figure 3 bottom). These values represent, at best, a rough
comparison, as sEPSCs and sIPSCs were recorded isolated from
each other, and the former were recorded with inhibition intact
but the latter with excitation blocked. Nevertheless, they do
indicate that overall, background inhibition predominates in all
three populations, but that its relative strength is more marked in a
progression from deep to superficial in the EC.
Laminar comparison of global background synaptic
activity
Recordings of sEPSCs and sIPSCs give an indication give us
some idea of the relative level of inhibition and excitation exerted
via the network, from a presynaptic view point and on a moment-
to-moment basis. However, a more integrated assessment of the
on-going inhibition and excitation seen by the postsynaptic cell
and its effects on excitability requires a different approach. We
have adopted the VmD method [39,42] to assess global synaptic
conductances, estimating background GABAergic inhibition and
glutamatergic excitation concurrently in the same neurone. We
have used this approach to complement and extend the results of
our whole cell patch clamp studies, and to examine whether
background network activity may be instrumental in determining
the susceptibility of different populations of EC neurones to
participation in synchronous activity.
The comparative lamina data obtained using the VmD
approach are illustrated in Figure 4. Ibg, estimated in L5 neurones
(n = 10; Figure 4A), was 6.161.7 nS. Concurrently, Ebg was about
half this at 3.160.7 nS, with a mean I:E ratio in these neurones of
2.360.6. Similar estimations in L3 neurones (n = 17) gave a much
higher Ibg of 11.262.1 nS and a slightly greater Ebg of
4.160.7 nS, but the I:E ratio based on these estimates was similar
to that in L5 at 2.760.5. Ibg, estimated in L2 neurones (14.362.7;
n = 11), exceeded that in L3 and was substantially greater than
that in L5. In contrast, Ebg was similar (2.960.3 nS) to L5 but
again lower than L3. Consequently the I:E ratio in L2 (4.660.4)
was considerably higher than that recorded in the other layers.
Comparing the data from whole cell patch clamp recordings
(Figure 3), and VmD measurements (Figure 4) shows a good
correlation between the levels of inhibition and excitation derived
from the intracellular and whole-cell patch clamp recordings, with
the standout difference between the layers being the greater
preponderance of inhibition in L2.
As noted above, strychnine caused a small but significant
reduction in sIPSC frequency in L2 in patch clamp recordings, so
we determined its effect on Ibg and Ebg (n = 4). There was no
significant change in Ebg with the glycine receptor antagonist
(3.161.1 v 2.961.3), and although Ibg fell slightly (11.163.3 v
9.962.7) the change was not significant. The I:E ratio was
unaltered (3.760.7 v 3.360.7).
The VmD approach also allows us to estimate of the variance of
the global background conductances. Destexhe and his colleagues
[42–44] have suggested that conductances reflect the overall rate
of release from the afferent neurones, whereas the variance may be
related to the temporal correlation of the release in the presynaptic
inputs. Thus, a large variance could reflect large numbers of
synaptic terminals releasing transmitter synchronously or semi-
synchronously [42–44]. However, this association is based on large
numbers of synapses releasing at a high rate in an in vivo-like
situation [42–44] and there are obvious limitations in making
similar inferences from variance measures in our slices, where we
are studying reduced networks (and hence synapses numbers) with
a consequent reduction in release rates. Nevertheless, we did find
some marked differences in mean variances in the different layers
of the EC (Figure 4B). Under resting conditions, the mean
variance of Ibg in L2 neurones was 52156407 pS. This contrasts
markedly with L3 and L5 where the mean variances were
99649 pS and 105627 pS, respectively. Likewise, the variance of
Ebg was considerably greater in L2 neurones (21076333 pS)
compared to L3 (88621 pS). The variance in Ebg was lowest in L5
(27624 pS).
One possible confounding factor in comparing L2 to L3 and L5,
is the heterogeneity of neurones in the former. Previous studies,
including from this laboratory, have suggested that neurones in L2
with a pronounced time-dependent inward rectification (TDIR)
during hyperpolarization, due to a strong expression of Ih, are
likely to be stellate in nature, whereas those that do not exhibit
TDIR are more likely to present pyramidal-like morphology
[19,47]. Based on subsequent recordings in several hundred L2
neurones (R.S.G. Jones, unpublished), we have found that there is
much more of a continuum within the correlation of expression of
TDIR and morphological characteristics, and a demarcation of
stellate v pyramidal on this basis is less clear than originally
supposed. Nevertheless, we thought it worthwhile to compare
background conductances in neurones with prominent TDIR, to
those in which it is less evident. We used the population of
neurones from the analysis above, together with a further 10 in
which we just recorded baseline conductances. In these 21
neurones we classified 15 with clear TDIR and 6 where TDIR
was minimal (non-TDIR). Mean IBg was 15.163.6 nS (variance
38296851 pS) in the former and 13.464.0 nS (variance
46286711 pS) in the latter. In neurones with TDIR, EBg was
3.160.9 nS (variance 17076402 pS) and in non-TDIR neurones
it was 2.960.9 nS (variance 22236512 pS). None of these values
differed between the groups or from the values in the pooled
neurones. I:E ratios were also very similar (5.060.7 v 4.460.9).
Thus, it seems unlikely the differences in L2 compared to L3 and
L5 are explicable in terms of heterogeneity of morphology/
intrinsic properties in the L2 population.
Figure 1. Characteristics of EPSCs in L3. A. Voltage clamp recordings from one neurone show that the AMPAr antagonist NBQX essentially
abolished sEPSCs. At more positive holding potentials, occasional, slow sEPSCs were detected that were mediated by NMDAr, as they were blocked
by 2-AP5. B. A comparison of sEPSC properties Showed that the mean frequency of events in L3 was greater than that in either L2 or L5. Amplitudes
were similar across layers, but kinetics (C) were slower in L2 compared to the deeper layers. D. Action potential driven release accounts for a much
higher proportion of spontaneous excitation in L3. Cumulative probability analysis of data pooled from 10 neurones (graph on left) showed a large
increase in IEI (shift to the right) in L3 that was substantially greater than that seen in L2 or L5. This is very clearly illustrated by the bar graphs (right)
showing the accompanying change in frequencies (sEPSC frequency minus mEPSC frequency). E. Neither amplitude nor kinetics of EPSCs in the same
neurones were significantly different in the presence of TTX (mEPSCs shown in blue).
doi:10.1371/journal.pone.0085125.g001
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Figure 2. Characteristics of IPSCs in L3. A voltage clamp recordings from one neurone show that sIPSCs are largely mediated by GABAAr.
However, there was a reduction in frequency with the glycine receptor antagonist strychnine. Although this generally only amounted to around 10–
15% it was significant when assessed by a paired t-test. A similar effect was seen previously in L2 [37]. We have added a number of new recordings to
this data and the reduction again just reaches significance with a paired t-test. In contrast, no effect of strychnine was seen in L5. B. sIPSC frequency
was lower than in L2 but still considerably higher than in L5, whereas the both mean amplitude and decay time in L3 (C) were greater than either of
the other layers (D). Action potential driven GABA release, like glutamate release (see Figure 1) was more prominent in L3 compared to L2 or L5. Thus
application of TTX resulted in a marked change in frequency of events (sEPSC frequency minus mIPSC frequency). (E) In addition, the mean amplitude
of events was also lower in TTX, although time to decay was slower.
doi:10.1371/journal.pone.0085125.g002
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Another potential confounding factor in comparing background
synaptic conductances across layers could be the intrinsically
generated theta oscillations reported to occur in L2 stellate
neurones at depolarized potentials [48,49,50]. However, similar
intrinsic oscillations have also been reported in L5 neurones,
although not in L3 [51,52,53]. Whilst intrinsic theta oscillations do
appear to be a characteristic of L2 neurones, in over 25 years of
recording EC neurones, we have not seen such oscillations
consistently expressed to the same extent as reported by others
[48,49,50]. It does not appear to be present in all neurones that
would be tentatively identified as stellate on the basis of TDIR,
and, when detectable, can be weak and intermittent. Even if
present, it should not influence our VmD estimations since Vm
fluctuations are estimated on a considerably higher moment-to-
moment time scale (in 10 ms bins) than that pertaining to the low
frequency (7–8 Hz) intrinsic theta oscillations. Nevertheless, we
looked at this as a possible confounding factor in our VmD
estimations in L2. We subdivided the population of neurones with
TDIR into those in which we could see evidence of theta
oscillatory activity (n = 8) and those where we could not (n = 7). In
the former, IBg was 12.264.6 nS, and in the latter, non-
significantly different at 13.365.0 nS. Likewise, EBg was also very
similar in the two populations (2.960.7 nS v 3.561.2 nS).
The oscillatory activity in L2 is principally dependent on a low-
threshold, persistent Na- current and can be eliminated by Na-
channel blockade [48,49]. We recorded from L2 neurones with
electrodes containing QX-314 (50 mM), to block the Na-currents
(n = 5). We also substituted Cs-methanesulphonate (2 mM) for K-
acetate in the recording solution, which eliminates TDIR [19,47]
(although the underlying Ih-current does not play a prominent role
in oscillatory activity [48]). We estimated conductances 4–
5 minutes after impalement with these electrodes and the values
obtained were well within the range of those seen with K-acetate
electrodes (10.162.0 nS and 3.260.5 nS for IBg and EBg,
respectively). Fifteen minutes after impalement, Na-dependent
action potentials had disappeared, and there was no evidence of
TDIR, or of theta oscillatory activity at depolarized potentials.
Respective values for inhibition and excitation at this time were
12.262.7 nS and 3.660.3 nS. Neither conductance was signifi-
cantly altered when comparing the early and late time points and
ratios remained remarkably similar (3.2 v 3.5). Thus, we are
confident, that intrinsically generated oscillatory activity is unlikely
to influence the comparison of VmD estimations in L2.
Background activity during acute network synchronization-
Blocking GABAAr in cortical slices leads to progressive network
synchronization culminating in emergent paroxysmal events that
have often been used as a model of epileptiform activity. The EC is
no exception and we have previously shown that such events are
likely to originate in L5 and propagate from here to other layers of
the EC and to other areas [18,20,21]. We have also shown that
events in L2 are less frequent and not as pronounced as those in
the L5 and we have suggested that the intrinsic properties of the
superficial network may make them less susceptible to synchro-
nization [20,29]. We have used the VmD approach to chart the
time course of changes in background inhibition and excitation
that occur across L2, L3 and L5 in the period leading to overt
synchronization of the synaptic networks. The intracellular
recordings in the different layers were not conducted simulta-
neously but represent distinct data sets in different slices. As far as
possible, matched experiments in slices from the same animal were
conducted on the same day.
Examples of intracellularly recorded, network-driven, paroxys-
mal depolarizing shifts in the different layers during perfusion with
the GABAAr antagonist, bicuculline (10 mM), are shown in
Figure 5A. For illustrative purposes these were actually recorded
in the same slice (although not concurrently) after synchronous
network activity had developed, and the events are typical of those
arising during early network synchronization. They can vary
somewhat between slices and preparations, but are fairly
stereotypical in morphology. They are emergent network driven
events as they correspond to population events recorded extracel-
lularly at adjacent sites (not shown). Those in L3 and L5 were
similar, and different in several ways from those in L2. Due to the
complex nature of events it is difficult to quantify them
meaningfully, but nominal values give some indication of
differences. Peak amplitudes from resting potential (ignoring
spikes) were almost the same in L5 and L3 (4268 mV and
3769 mV, respectively) but considerably and significantly greater
(P.0.05) than those in L2 (1666 mV). Duration was greatest in
L5 (687688 ms) followed by L3 (4896101 ms) and L2
(242644 ms), and the number of spikes (full or truncated)
associated with events showed a similar pattern (26611 v 1466
v 662). We measured the mean latency to appearance of the first
Figure 3. Comparison of inhibition to excitation in whole cell
patch clamp studies. The total charge transfer (CT) associated with
sEPSCs, was greatest in L3 and approximately equal in L2 and L5.
Charge transfer of sIPSCs was also greatest in the middle layer, but
substantially markedly less in L5 than the more superficial layers. The
resultant ratio calculations suggested a substantial dominance of
inhibition in all layers, with L2 showing by far the greatest bias and L5
the least.
doi:10.1371/journal.pone.0085125.g003
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Figure 4. Simultaneous VmD estimations of excitatory and inhibitory background conductances. A. The raw traces show sample
intracellular recordings from three neurones recorded in the same slice, and showing a great peak-to-peak voltage activity in L2. Estimation of
background inhibition and excitation (see methods) required calculation of mean and variance of membrane potential at two levels of injected
current (not shown). The histograms show the frequency distributions of membrane fluctuations at the two levels of injected current (geen being
closer to resting potential and blue slightly more depolarized) in sample neurones from each layer. The solid lines on the graphs show the potential
fluctuations constrained to a Gaussian function and in each case the goodness of fit (R2) was close to unity. B. Comparison of average data for
background synaptic conductances estimated in the three layers of the EC. Background excitation (EBg) was highest in L3 and approximately 40%
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spontaneous event after the entry of the antagonist into the bath
(Figure 5B) and this showed that synchronized discharges
appeared at around 450 s from initial exposure to bicuculline in
both L3 and L5 but was significantly (P.0.05) delayed in L2
appearing around 700 s.
Thus, this comparison supports our previous studies [20]
showing a greater susceptibility to disinhibition-induced synchro-
nicity amongst L5 neurones compared to L2, and puts L3
intermediate between the two. We have now used the VmD
approach to document how this may be related to changes in I:E
balance and excitability during the process of disinhibition. We
have previously described some of this information for L3
neurones [40], and now present a fuller description with
comparison to L5 and L2.
Figure 6C illustrates the time course of changes in background
conductances during perfusion with bicuculline (10 mM) in L5
neurones (n = 6). As expected, there was a rapid decrease in Ibg
during the first 2 minutes of contact with the antagonist,
concurrent with a small, but non-significant, decrease in Ebg. At
this stage the absolute levels of the conductances were approxi-
mately equal. Thereafter, Ibg continued to decline whereas Ebg
returned to its original level, with the absolute magnitude of the
conductance levels reversing between 2 and 4 minutes. The net
effect of these changes was a substantial switch in I:E ratio to
favour excitation compared to the bias towards inhibition under
control conditions. Results for L3 neurones (Figure 6B) were
similar, but the decline in Ibg was less rapid and the reversal of
conductance levels occurred a little later (around 5 min). I:E ratio
in L3 neurones also reversed in favour of excitation, and, although
the change was slightly less rapid, it reached the same end point as
in L5 and the time of appearance of paroxysmal activity occurred
when the I:E ratio reached approximate equivalence (Figure 6D).
Results for L2 neurones (n = 6) are shown in Figure 6A. Again,
there was an initial rapid fall in Ibg. However, after 4 min, this had
plateaued at around 45% of control, and thereafter there was no
further substantial fall. Ebg showed little concurrent change, and
the absolute values of the conductances did not reverse at any
point. Consequently, although the I:E ratio fell by around 50%, it
always remained substantially in favour of inhibition (Figure 6C,D).
Thus, the delayed appearance of spontaneous synchronized events
and, perhaps, the extent of synchronization in L2 could be related
to the amount of residual inhibition. We have also monitored the
variance of the background conductances throughout application
of bicuculline (Figure 7). During bicuculline perfusion, the
variance of Ebg initially fell quite steeply and then essentially
plateaued. Perhaps not surprisingly, the variance of Ibg fell
precipitously, but then actually increased towards control levels.
In L3, the variance of IBg fell markedly but that of EBg was largely
unaltered. Likewise, in L5 the variance of Ibg fell progressively
throughout, whereas, after an initial fall, there was a delayed
increase in Ebg variance taking it beyond control levels.
Finally, we noted small changes in intrinsic neuronal excitability
in all three layers during perfusion with bicuculline. In L2, spike
threshold fell slightly from 18.860.4 mV (positive to rest) to
1760.7 mV, and in L3 from 20.6618.2 mV to 18.260.9 mV,
although neither change reached significance. In L5, threshold
higher than that in L2 or L5. Inhibition (IBg) was greatest in L2 followed by L3 and L5. The resultant ratios showed a predominance of inhibition in a ll
three layers, but in L2 this was this was almost double that seen in the other layers. C. The variance associated with the conductances (which is
suggested to reflect the level of temporal synchrony in presynaptic inputs) was dramatically higher for both inhibition and excitation in L2 than in
either of the deeper layers.
doi:10.1371/journal.pone.0085125.g004
Figure 5. Bicuculline induced paroxysmal depolarizing shifts in EC neurones. A. Intracellular recordings show large depolarizing events
associated with multiple spikes were recorded in both L5 and L3 during bicuculline (10 mM) perfusion. In L2 these were much smaller and often
associated with just one or two spikes. B. In addition their appearance (timed from the entry of bicuculline into the bath) was delayed in L2 compared
to the deeper layers.
doi:10.1371/journal.pone.0085125.g005
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was reduced from 24.260.5 mV to 20.760.8 mV, and this was
significant (P,0.05). However, it should be noted that the
normalized change was very similar in all three layers (around 9
to 10%). Concurrently, the number of spikes evoked by a long
depolarizing pulse was slightly increased in all layers (L2: 4.060.8
v 5.760.6; L3: 4.360.3 v 5.561.0; L5: 2.760.2 v 3.360.9) but
none of the changes reached significance. The normalized changes
were again similar in all layers (around +13%). Thus, there were
indications that the loss of background synaptic inhibition
increased intrinsic excitability per se (cf [39]), and this could
contribute to an overall increase in network excitability.
An important question concerns the origin of the residual
inhibition in L2. Our patch clamp studies showed that glycine
receptors were likely to make a minor contribution to spontaneous
Figure 6. Time course of changes in global background synaptic conductances during perfusion with bicuculline. Bicuculline (10 mM)
was appied at time 0. Arrows show the approximate time at which paroxysmal activity appeared. In all cases, once synchronized activity was
established it became difficult to conduct further meaningful VmD measurements as the events increased in frequency and complexity. A. In L2
inhibition declined rapidly for the first 5–6 minutes before stabilizing at around 30–40% of control. Background excitation was largely unaffected.
Despite this, the fall in estimated inhibition, the latter predominated throughout and the I:E ratio never fell below 1. B. In L3 inhibition also fell rapidly
over 5 minutes and continued to decline reaching a loss of around 85–90%. Simultaneously, excitation showed a gradual increase, although this did
not reach significance. The combine effect was a sustained decrease in I:E ration that reversed in favour of excitation around the time when
paroxysmal activity appeared. C. Changes in background activity in L5 were similar to those in L3 except that the fall in inhibition was even more
precipitous, and reached close to 100% in some cases. D. The time course of changes in I:E ratio show that this occurred more rapidly in L5 than L3
but reached a similar end-point whereas that in L2 never reached the same level as that in either of the deeper layers.
doi:10.1371/journal.pone.0085125.g006
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inhibition in L2, although the VmD analysis did not show a
significant fall in Ibg with strychnine. Nevertheless, we thought it
worthwhile to examine whether strychnine could enhance the
epileptogenic effects of bicuculline in L2. In 4 slices where
bicuculline failed to elicit synchronous discharges in L2, subse-
quent addition of strychnine (up to 4 mM) failed to provoke the
appearance of such activity. In a further 4 slices where brief
discharges were present, these were unaffected by strychnine (1–
2 mM). However, in 2 slices, brief synchronized discharges
appeared to be enhanced by strychnine (1 mM; not shown), a
weak effect that reversed on washing out the antagonist. To
attempt to further block the residual inhibition in L2 we combined
bicuculline and strychnine with the non-competitive blocker,
picrotoxin (n = 4). Fifteen minutes after perfusion with bicuculline
and strychnine Ebg was essentially unaltered compared to control
(4.161.1 nS v 4.561.2 nS). IBg was concurrently reduced from
13.963.9 nS to 6.362.7 nS, similar to or slightly greater than to
the fall seen with bicuculline alone (see above). Subsequent
addition of picrotoxin saw a further fall in IBg to 4.962.3 nS
(P,0.05). Overall, the changes reflect a fall in I:E ratio from
4.461.1 in control to 1.560.6 with all 3 antagonists present, and
show that the combined blockers resulted in a greater decline in
inhibition (by approximately 60%) than with bicuculline alone
(40–50%), although the decrease was still less than that seen with
bicuculline alone in either L3 or L5.
The combination of blockers did appear to be associated with
an increased severity of epileptiform discharges in L2 (n= 6). This
is illustrated Figure 8. In these slices bicuculline-induced
discharges were already present, and we applied the other blockers
sequentially and cumulatively, and compared the epileptiform
activity induced, using extracellular recording. We found that
addition of strychnine resulted in a weak enhancement of the
discharges in three slices and these were then further enhanced by
picrotoxin. In one slice strychnine had little detectable effect, but
the discharges were enhanced by picrotoxin. In two other slices
picrotoxin was applied first and enhanced the discharge;
subsequently, strychnine further enhanced the discharge in one
but had little effect in the other. When simultaneous recordings
were made in other layers, we saw little change in the local
discharges when picrotoxin and strychnine were added to
bicuculline.
Discussion
Patch clamp recordings of EPSCs in L3 revealed a greater
degree of spontaneous excitation compared to L2 and L5. This
was mainly reflected by a substantially higher frequency of
sEPSCs. Interestingly, the frequency of mEPSCs was very similar
in all 3 layers, indicating that activity dependent release driven by
action potentials was considerably higher in L3. Using paired
intracellular recordings we have previously shown a relatively high
incidence of single axon connections between principal cells in L3
[46]. It is possible that the greater frequency of sEPSCs seen in our
patch clamp recordings reflects a high level of spontaneous firing
in recurrent axon collaterals between L3 pyramids. What may also
be significant is that spontaneous firing rates of L3 neurones in vivo
is generally higher than those in L5 or L2, which could contribute
to greater recurrent excitation in the middle layer [6]. In addition,
we have provided evidence for a high degree of electrical coupling
between L3 neurones [46], which could reinforce a high level of
recurrent excitation. There was a similar incidence of recurrent
excitatory connections in L5 and L3, although the recurrent
EPSPs were considerably smaller in the deeper layer [46], but a
lower neuronal firing rate could be a factor in a lower recurrent
excitation and hence lower frequency of sEPSCs. Interestingly,
Quilichini et al., [6] found no correlation between the firing rate of
neurones and intrinsic excitability suggesting that the former was
dependent on the network connectivity rather than biophysical
characteristics.
In previous patch clamp recordings we demonstrated that
spontaneous GABA release in L2 was dramatically higher than in
L5 [37]. The current experiments show strong similarity between
L2 and L3 in this respect, with a high level of baseline release.
However, in L3, action potential driven IPSCs (around 50%)
accounted for a much higher proportion of baseline release than in
Figure 7. Changes in variance of background conductances
during bicuculline perfusion. There were substantial differences in
variances between and within layers, but scales have been adjusted to
allow for comparison of the time course of changes. A. In L2 the
variance (and thus synchronicity) of both inhibition and excitation fall
rapidly over 2–3 minutes and thereafter remained reasonably stable at
the lower level, although that of inhibition tended to increase again
after the first fall. B. In L3 variance of inhibition fell steadily and
remained stable whereas that of excitation showed little change. C.
Similar to L3, inhibition variance fell throughout in L5, but an initial fall
in variance of excitation was followed by a clear recovery to control
levels. Again, the arrows indicate the approximate time at which
paroxysmal activity appeared.
doi:10.1371/journal.pone.0085125.g007
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L2, where sIPSC and mIPSC frequencies were almost the same.
Thus, a patch-clamp comparison of spontaneous glutamate release
in the three layers shows that levels are highest in L3, with L5 next,
and L2 lower than L5, but not dramatically so. In contrast,
spontaneous GABA release is highest in L2, with L3 similar but L5
dramatically lower than either. Monitoring the frequency of
spontaneous currents can be misleading and probably tells us little
about the level of functional background inhibition or excitation.
Estimating arbitrary charge transfer levels associated with
spontaneous currents over time may give us a better picture of
this, and these estimations suggested a dominance of inhibition
over excitation in all three layers, with a rank order of I:E ratio
L2.L3.L5. However, this comparison gives an approximate
view of the situation at best because the somatic whole cell patch
clamp recordings assess inhibitory and excitatory currents in
isolation, and are also likely to exclude many events occurring at
distal dendritic sites. Nevertheless, it does give a relative picture of
what the neurones see from their presynaptic inputs in terms of
excitatory and inhibitory network activity.
To obviate some of the limitations associated with the patch
clamp recordings, and to align the presynaptic activity with what
the neurone undergoes postsynaptically, we made VmD measure-
ments [42] to estimate global background excitation and
inhibition. This has a number of advantages: it specifically
estimates conductances mediated via AMPAr activation and
GABAAr activation, which are, overwhelmingly, the source of
background postsynaptic excitation and inhibition, respectively;
inhibitory and excitatory conductances are estimated concurrently
in the same neurone, and essentially reflect network input to all
compartments (somatic, dendritic) integrated across the whole
Figure 8. Additional effects of strychnine and glycine on paroxysmal activity in L2. A. In the presence of bicuculline the spontaneous
activity recorded in L2 consisted of single brief negative-gong events. Following addition of strychnine this was joined by a series of brief
afterdischarges. A further, and more pronounced, exacerbation of the activity was seen when the non-competitive GABAAr antagonist, picrotoxin was
added to the cocktail. B. A similar study in L2 of another slice shows that the same result was obtained when the order of application of strychnine
and picrotoxin was reversed. C. In this slice we made simultaneous recordings at locations in L2, L3 and L5. Spontaneous events in bicuculline were
briefer and less complex than those seen in the deeper layers (cf. Fig. 5). Addition of strychnine and then picrotoxin, as in the other studies increased
the duration and complexity of events in L2, but left those in L3 and L5 largely unaltered.
doi:10.1371/journal.pone.0085125.g008
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neurone; within limitations, the variance of the conductances may
partly reflect the degree of correlation between presynaptic inputs,
and hence, the state of the network; sharp electrode recordings
permit simultaneous measures of neuronal excitability.
VmD estimations of postsynaptic conductances generally
aligned with the presynaptic activity monitored by the whole cell
patch clamp experiments, although relative differences were less
pronounced. Thus, Ebg was approximately equal in L2 and L5,
and, although higher in L3, not dramatically so. Ibg was highest in
L2, lower in L3, but considerably lower in L5 compared to the
more superficial neurones. In agreement with CT estimations
from the patch clamp recordings, I:E ratios from VmD estimations
again showed a dominance of inhibition over excitation in all three
layers, and the rank order was the same, albeit with a somewhat
reduced difference between L3 and L5. This suggests that the
dominant effect of on-going presynaptic network activity in all
layers in our slices is inhibition. Although the brain slice, with its
reduced synaptic network, reflects a generally quiescent situation,
there is qualitative agreement with the situation in vivo. For
example, VmD estimations from in vivo intracellular recordings in
parietal cortex (layer not specified) of un-anaesthetized cats [54],
show that an inhibition-dominant network situation is extant
during both the awake state, and during natural sleep, although
the I:E ratio in the latter was higher in the former (approx. 3.9)
compared to the latter (approx. 2.6). Interestingly, the I:E ratio
during wakefulness is similar to that seen in L3 and L5 neurones in
our experiments, whilst that in L2 approximated the sleep state in
vivo. It would be a huge leap of imagination to propose that the
networks in L5/L3 are in an ‘‘awake state’’ whereas that in L2 is
‘‘sleeping’’, but the data does suggest that network excitability in
L2 and, thus, afferent transfer to the hippocampus, is very tightly
controlled by synaptic inhibition.
It has been suggested that the variance of postsynaptic
background synaptic conductances may give an estimate of the
average correlation of inhibitory or excitatory activity in the
presynaptic inputs, with a high variance predicting some degree of
synchronization [42–44]. It should be noted that this prediction
relates to the in vivo situation where transmitter release rates are
likely to be much higher than in our slices. Examination of the
variances across layers in our slices reveals that the most obvious
difference was the high degree of variance in both Ebg and Ibg in
L2 compared to L3 and L5. If we make the assumption that
conductance variance provides a measure of synaptic correlation,
even under the relatively quiescent conditions in the slice, this
could be taken as evidence that there is some degree of
synchronization in the network of L2. This may be supported by
observations that the power of theta, gamma and high-frequency
oscillations, which could reflect synchronized network activity, is
high in superficial layers compared to the deeper layers
[5,6,55,56].
If we accept that that there may be some correlated activity in
L2 synaptic inputs, it is possible to speculate that such a property
could be related to the level and organization of synaptic
inhibition. It is clear that number, diversity, and synaptic
connectivity of inhibitory neurones is progressively greater as we
move from L5 through L3 to L2 of the EC [57–69], and this is
reflected by functional measures of inhibition (present study;
[37,38]). Network synchrony can be driven by interneurone-
interneurone interactions and/or interneurone/principal cell
interconnectivity [70–73]. Thus, it is possible that the high
variance of Ibg in L2 is at least partly due to correlated release from
GABA inputs resulting from interneuronal interactions with
principal neurones and other interneurones. Using paired cell
recordings we demonstrated a paucity of recurrent connectivity
between principal neurones in L2 [46]. This was confirmed by a
recent study [74], which also showed that the high level of
inhibition in L2 is congruent with extensive interconnectivity of
principal neurones via interneurones. We previously demonstrated
that basket-like interneurones in L2 have widespread axonal
arbors restricted to the layer and have a powerful NMDAr
mediated excitatory drive [75]. A reduction in the number of these
neurones or blockade of the NMDAr-mediated drive onto them
disrupts gamma oscillations, which may depend on synchrony
within the principal neurone-interneurone connectivity [76].
It has long been accepted that synaptic inhibition is able to
‘‘balance’’ and control neuronal excitation. Trevelyan et al., [77]
provided a very clear demonstration of how emergence of network
synchronization during epileptiform activity is restrained by on-
going synaptic inhibition. In our studies, reducing background
inhibition by blocking GABAAR resulted in a rapid synchroniza-
tion in L5 and the emergence of interictal-like epileptiform
activity. Despite a much higher level of background inhibition, the
result was almost identical in L3, and this could be associated with
the higher initial Ebg in this layer, suggesting that the inhibition-
excitation balance is crucial in restraining network synchroniza-
tion. Paradoxically, L2, which may already have a degree of
correlative activity in its synaptic networks, was relatively resistant
to emergent network synchronization when inhibition was
pharmacologically reduced with bicuculline. Emergent synchro-
nization was delayed, was less marked than in other layers, and
was not seen in some slices that did display such activity in other
layers.
Examination of the changes in Ibg and Ebg during bicuculline
perfusion revealed that the former fell rapidly and network
synchronization emerged around the time when its absolute value
was exceeded by the latter, in both L5 and L3. However, this did
not occur in L2 and normalized data showed that Ibg was reduced
by only 50–60% compared to 80–90% in the deeper layers.
Residual inhibition in L2 could have a source other than GABAAr
activation, and one possibility is that it could be mediated by
glycine. There is evidence for expression of glycine receptors in the
EC with the b-subunit, in particular, apparently localized to the
superficial layers [78] and glycine elicits strychnine-sensitive
inward currents in L2 neurones [79]. sIPSC frequency is weakly
reduced by strychnine in L2 but not L5 (present study; [37]). The
VmD approach will not readily distinguish between GABA and
glycine as the reversal potentials for the two are essentially the
same, but we did not find any overwhelming evidence that glycine
receptors make a major contribution to the residual inhibition in
L2. Ibg showed a very small, but non-significant fall during
blockade of receptors with strychnine. Although we occasionally
found that strychnine appeared to enhance the synchronizing
effects of GABAAr blockade in L2, in the majority of cases it had
no such effect. Interestingly, glycine receptors in L2 can be
desensitized by GABA but the reverse is not true [79]. Thus, it is
possible that glycine inhibition may actually become more effective
as GABA-inhibition is reduced by bicuculline, but this was not
really supported by the failure of strychnine to consistently
enhance the effects of bicuculline. Finally, strychnine also slightly
reduced sIPSCs in L3 as well as L2, but residual inhibition was not
evident in in VmD estimations in the former.
An alternative explanation for residual inhibition is that very
high levels of ambient GABA associated with spontaneous release
are able to compete with the bicucullne to maintain the level of
spontaneous inhibition. Addition of the non-competitive GABAAr
blocker, PTX did reduce IBg to a greater extent than bicuculline
alone, although there was still around 30–35% residual inhibition
in L2. Thus, the source of the residual inhibition in L2 is still a
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matter for debate, but what seems clear is that the overall
‘‘inhibitory veto’’ [70] is much stronger in this layer than in L3 and
L5.
The significance of our results for the overall functional roles of
the EC in physiological processes is a matter for speculation at
present. Nevertheless, it is clear that the network properties across
layers support very different processing roles and capabilities. For
example, as mentioned above, L2 neurones express prominent
grid cell properties that contribute to a vital role in spatial
navigation. Grid firing is suggested to be generated within the
recurrent inhibitory microcircuitry of this layer rather than
dependent on recurrent excitatory interactions [74]. Our current,
and previous, observations [38,46,75] support the suggestion of
predominance of recurrent inhibition in this layer and an inherent
rhythmicity in this network that could help define grid cell activity.
The powerful background synaptic inhibition may be crucial in
this regard. Destexhe [44] has argued that spike firing and
patterning in cortical networks is determined by fluctuations in
background inhibitory ‘‘noise’’. The high level of background
inhibition, coupled with a low level of background excitation could
support a crucial role in determining grid cell patterning. Varying
ratios could be deterministic in different firing patterns and
functionalities in other layers.
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Abstract
Partial agonists at the NMDA receptor co-agonist binding site may have potential therapeu-
tic efficacy in a number of cognitive and neurological conditions. The entorhinal cortex is a
key brain area in spatial memory and cognitive processing. At synapses in the entorhinal
cortex, NMDA receptors not only mediate postsynaptic excitation but are expressed in
presynaptic terminals where they tonically facilitate glutamate release. In a previous study
we showed that the co-agonist binding site of the presynaptic NMDA receptor is endoge-
nously and tonically activated by D-serine released from astrocytes. In this study we
determined the effects of two co-agonist site partial agonists on both presynaptic and post-
synaptic NMDA receptors in layer II of the entorhinal cortex. The high efficacy partial ago-
nist, D-cycloserine, decreased the decay time of postsynaptic NMDA receptor mediated
currents evoked by electrical stimulation, but had no effect on amplitude or other kinetic
parameters. In contrast, a lower efficacy partial agonist, 1-aminocyclobutane-1-carboxylic
acid, decreased decay time to a greater extent than D-cycloserine, and also reduced the
peak amplitude of the evoked NMDA receptor mediated postsynaptic responses. Presynap-
tic NMDA receptors, (monitored indirectly by effects on the frequency of AMPA receptor
mediated spontaneous excitatory currents) were unaffected by D-cycloserine, but were
reduced in effectiveness by 1-aminocyclobutane-1-carboxylic acid. We discuss these
results in the context of the effect of endogenous regulation of the NMDA receptor co-ago-
nist site on receptor gating and the potential therapeutic implications for cognitive disorders.
Introduction
The entorhinal cortex (EC) acts as a crucial dynamic processer of information entering and
leaving the hippocampus, controlling its interaction with the rest of the neuraxis. This intimate
association means that the EC plays a pivotal role in declarative and spatial memory, particu-
larly spatial cognition, representation and navigation, and in other cognitive processes such as
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attention, and conditioning [1–5]. Dysfunction of the EC and of EC-hippocampal interactions
has been implicated in many pathological conditions, particularly initiation and propagation of
temporal lobe seizures and the cognitive abnormalities/decline associated with a variety of psy-
chiatric/neurological disorders (including schizophrenia, bipolar and depressive disorders, Alz-
heimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis etc.;
see refs in [6]). This laboratory has a longstanding interest in control of neuronal activity and
excitability in entorhinal networks. One focus of this research has been the role and regulation
of NMDA receptors (NMDArs) in both normal synaptic function and epileptic activity [6–8].
The NMDAr consists of two obligatory GluN1 subunits and two GluN2 subunits. A gluta-
mate binding site is present on the GluN2 subunit whilst a co-agonist site that can be activated
endogenously by both glycine and D-serine is located on the GluN1 subunit. There has been an
interest in targeting the NMDAr co-agonist binding site for therapeutic treatment of CNS dis-
orders (see [9]). Cognitive decline is a pronounced characteristic of Alzheimer’s disease and
other dementias, but is also a feature of Parkinson’s disease, Huntington’s disease, stroke,
amyotrophic lateral sclerosis, epilepsy, and psychosis [10–15]. D-cycloserine (DCS), which is
used therapeutically as an antimicrobial agent, is a partial agonist at the NMDAr co-agonist
binding site, and has been demonstrated to induce cognitive enhancement at low doses in
behavioural and psychological studies [16–25]. Thus, it could be useful in treatment of neuro-
degenerative disorders involving cognitive decline, in therapy of mood and thought disorders
such as schizophrenia and depression, and for augmenting psychotherapies for the treatment
of drug addiction and anxiety disorders. On the other hand, DCS has also been suggested to
have direct antiepileptic actions or be a useful adjunct in the treatment of epilepsy [26–28]. In
this context it is interesting that epilepsy is often associated with cognitive impairment, and
this may be related to a loss of D-serine and reduced co-agonist regulation of the NMDAr [29].
Thus, DCS could have a dual effect to reduce seizures and restore cognitive activity in people
with epilepsy.
We have previously shown that presynaptic NMDArs (preNMDArs) on excitatory termi-
nals can tonically facilitate the release of glutamate at EC synapses [30–32]. These receptors
are predominantly diheteromeric GluN1-N2B receptors [8,31,32] whereas those located post-
synaptically at the same sites may be largely triheteromeric GluN1-N2A-N2B receptors [8].
Recently, we have investigated the co-agonist regulation of the preNMDAr and shown that
endogenous D-serine, released from astrocytes, is the preferred ligand for the co-agonist-bind-
ing site, which appears to be fully saturated by the ligand under baseline conditions [33]. Given
the potential therapeutic relevance of the co-agonist binding site, we have now examined the
effects of partial agonists at this site. We compared effects on the presynaptic NMDAr-medi-
ated regulation of glutamate release in the EC to actions on NMDAr-mediated responses at
postsynaptic sites (postNMDAr). Our data indicate a differential modulation of the receptors
by the two partial agonists, which was apparently dependent on efficacy. These effects could be
relevant to putative therapeutic actions of the ligands.
Materials and Methods
Ethics Statement
Experiments conformed with the U.K. Animals (Scientific Procedures) Act 1986, European
Communities Council Directive 1986 (86/609/EEC) and were subject to conformity with the
University of Bath ethical review document. The research reported in this study is not directly
regulated by Home Office procedures, as it was all conducted using Schedule 1 procedures.
Nevertheless, all experiments were subject to internal ethical review and were specifically
approved by the University’s Animal Welfare and Ethical Review Body Committee. This
Partial Co-Agonists at NMDA Receptors in Entorhinal Cortex
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ensures that the minimum number of animals is used and that every precaution is taken to
reduce suffering and stress. All research involving use of animal tissue at the University of
Bath requires a consideration of ethical implications by the principal investigator. A second
investigator, external to the research group, reviews this and signatory approval from both the
external reviewer and Head of Department, is required preceding further review by the
Departmental Research Ethics Officer. The Ethics Officer submits a report to the Animal Wel-
fare and Ethical Review Body Committee discussion with the investigator. These processes
ensure that ethical implications of the research have been adequately considered and that there
is a process in place for managing ethical issues. The Animal Users Committee monitors all
licenced and Schedule 1 procedures at quarterly meetings.
Slice preparation
Combined hippocampal-entorhinal brain slices from male or female juvenile Wistar rats (50–
100g; P28–38) were prepared as described previously [34]. Following cervical dislocation, rats
were decapitated and the brain rapidly removed into oxygenated artificial cerebrospinal fluid
(aCSF; see below for composition) at 4°C. Slices (300 μm thick) were cut (Campden Vibroslice
or Model 7000smz microtomes) at 4°C and transferred to a storage chamber containing oxy-
genated aCSF maintained at room temperature. They were allowed to recover for 1 hour before
being used for electrophysiological recording. The aCSF contained (in mM) NaCl (126), KCl
(4), MgSO4 (1.25), NaH2PO4 (1.4), NaHCO3 (24), CaCl2 (2), D-glucose (10), ascorbic acid
(0.57), sodium pyruvate (5) and creatinine monohydrate (5). Ketamine (4 μM), indomethacin
(45 μM), aminoguanidine (25 μM) and Coomassie Brilliant Blue (250 nM) were included in
the cutting solution, and both cutting and storage solutions also contained the antioxidants, n-
acetyl-L-cysteine (2 μM) and uric acid (100 μM), to aid neuronal survival and viability. We
have previously established that the use of these additives facilitates production of robust and
viable slices, but does not affect the pharmacology of glutamate transmission. Of particular
concern is the possibility that residual ketamine may compromise studies of NMDAr responses
in the experiments. However, we have used ketamine as a neuroprotectant, both as an anaes-
thetic prior to decapitation and in cutting solutions for over 20 years, and before introducing it
into routine use investigated this extensively, finding no evidence that this was an issue. In our
current protocols, slices are kept in a ketamine-free storage chamber for a minimum of 1 hour
(in reality most are stored for 2 hours plus) before transfer and then washed in the recording
chamber for a further 30–40 minutes before recording. The storage chamber has a large-sink
circulating volume of around 40 ml and the recording chamber is perfused at 2 ml/min. The
very high reverse rate constant for ketamine means that its dissociation from the receptor
channel is likely to be rapid and complete before actual recording commences. The ability to
elicit large repeatable NMDAr responses in the tissue suggests that residual ketamine is
unlikely to be an issue.
Whole-cell patch clamp recordings
After recovery, individual slices were transferred to a chamber on an Olympus BX50WI micro-
scope and perfused (~2 ml/min) with oxygenated aCSF at 31–32°C, where they were allowed to
further equilibrate before recording began. Neurones were visualised using differential interfer-
ence contrast optics and an infrared video camera.
Whole cell patch clamp recordings were made with an Axopatch 200A or 200B amplifier
using borosilicate glass pipettes pulled on a Flaming-Brown microelectrode puller. To record
AMPA receptor (AMPAr) mediated miniature excitatory postsynaptic currents (mEPSCs) we
used a Cs-gluconate based intracellular solution containing (in mM) D-gluconate (100),
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HEPES (40), QX-314 (1), EGTA (0.6), NaCl (2), Mg-gluconate (5), tetraethylammonium-Cl
(5), phosphocreatinine (10), ATP-Na (4), GTP-Na (0.3) and MK801 (5mM). The solution was
adjusted to pH 7.3 with CsOH and to 275–290 mOsm by dilution. Recordings were conducted
in the presence of TTX (1 μM) to eliminate activity-dependent glutamate release. To permit
recording of AMPAr-mediated responses in isolation, postNMDArs were blocked by inclusion
of MK-801 in the patch pipettes. This also allowed us to monitor activity at preNMDArs with-
out the complication of postsynaptic receptor activation/blockade. This approach was devel-
oped and validated in this laboratory [7,30–32], and has been used successfully by others
[35–40].
Miniature EPSCs were recorded at a holding potential of -60mV, filtered at 2 kHz, digitised
at 50kHz, and stored using AxoScope software. Access resistance was monitored at 5-minute
intervals throughout recording and if it varied by greater than 15% neurones were excluded
from analysis. Series resistance compensation was not used. Input resistances for the neurones
recorded in these studies were of the order 500–700 MO. Data recording commenced 15–20
minutes after gaining whole cell access and then continued for at least 15 minutes during con-
trol and each drug treatment condition. mEPSCs were analysed offline using a threshold-cross-
ing algorithm in Minianalysis software (Synaptosoft, Decatur) over stable 5-minute periods of
recording. Average frequency was compared before and after drug application. Amplitudes of
spontaneous currents were determined as median values for each neurone as these better
reflect the population distributions (normal distribution with a skew towards larger amplitude
events) than arithmetical means. Median values were then averaged for comparative illustrative
purposes. We have used this approach in previous studies [41]. The kinetics of mEPSCs were
compared via arithmetical means. Statistical comparisons of drug effects on mean frequency
and kinetics and mean median amplitudes within cells employed a two-tailed paired t-test.
Evoked postsynaptic responses were elicited by electrical stimulation using a bipolar tung-
sten electrode placed on the surface of the slice lateral to the recording site in the EC. Bipolar
pulses (10–30 mA, 100 ms duration) were delivered at intervals of 20 seconds. Again, record-
ings were made using whole cell patch clamp but without intracellular MK801 and extracellular
TTX. To isolate evoked NMDAr-mediated EPSCs (eNEPSCs), neurones were recorded at a
holding potential of +40 mV in the presence of NBQX (10 μM), bicuculline (20 μM) and picro-
toxin (50 μM). That NMDArs mediated the recorded responses was confirmed by abolition
with 2-AP5. After gaining whole cell access, no stimulation was applied for at least 20 minutes
to allow series resistance and cell activity to stabilise. Drugs were applied by addition to the per-
fusion aCSF, and each concentration was perfused for 10 minutes before increasing to the next
to construct cumulative concentration-response curves. The amplitude, rise time and decay
time of eNEPSCs were analysed off-line using Minianalysis software (Synaptosoft, Decatur). In
analysis of various treatments on decay time, this was calculated as the time taken to reach 37%
of peak amplitude.
To determine the effects of drug treatments on eNEPSCs, in each neurone the last five events
in each treatment epoch were averaged and the amplitude, rise time, decay time were determined.
The mean and standard error were then calculated for the group and are given for overall mea-
surements for data sets. The statistical significance of differences between control and drug treat-
ments was assessed using a two-tailed paired t-test. Normalised values were also calculated as
percentage change from control and these were used to calculate average percentage changes.
Materials
Salts used in preparation of aCSF were purchased from Fisher Scientific (UK). Indomethacin,
aminoguanidine, n-acetyl-L-cysteine, uric acid, Coomassie Brilliant Blue, and agents used in
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the preparation of the patch pipette solution, apart from QX-314 (Tocris UK) and MK801,
were purchased from Sigma (UK). Ketamine was supplied by Fort Dodge Animal Health Ltd
(Southampton, UK). Drugs were stored as frozen, concentrated stock solutions in distilled
water and applied by dilution in the aCSF perfusion immediately before use. The following
drugs were supplied by Tocris UK or Ascent Scientific UK: DCS, ACBC (1-aminocyclobutane-
1-carboxylic acid), DCKA (5,7-dichlorokynurenic acid), 2-AP5 (D,L-2-amino-5-phosphono-
pentanoic acid), MK801, D-serine, TTX, NBQX (6-nitro-7 sulphamoylbenzo[f]quinoxalone-
2,3-dione disodium), bicuculline methiodide and picrotoxin.
Results
Experiments were conducted on neurones in layer II of the medial EC. We did not attempt to
specifically identify neurones by dye injection. The selected neurones had identifiable pyrami-
dal or stellate cell morphology when viewed with DIC and are likely to be glutamatergic princi-
pal neurones.
Effects of DCS at presynaptic NMDArs
PreNMDArs tonically facilitate the spontaneous release of glutamate at excitatory synapses in
the EC [30,31]. In a recent study we showed that the co-agonist site of the receptor is endoge-
nously bound by D-serine. Thus, exogenous application of the full agonist, had little effect on
spontaneous release, but co-agonist site antagonists reduced it, suggesting a saturation of the
receptor/effect by endogenous D-serine [33].
In the first set of experiments we determined the effect of the partial agonist, DCS, using
the frequency of mEPSCs mediated by AMPAr as a reporter for glutamate release and, hence,
preNMDAr activity [30]. DCS (300 μM) had no observable effect on mEPSC frequency in 6
neurones (Fig 1A). In control conditions, mean frequency was 0.65±0.29 Hz and this was
almost identical in the presence of DCS (0.62±0.32 Hz). However, subsequent addition of
2-AP5 (50 μM) reduced the frequency of mEPSCs to 0.47±0.23 Hz, a decrease to 71.1±4.3%
of control (Fig 1A) confirming that preNMDArs were operative at these synapses to tonically
facilitate glutamate release. DCS failed to alter either the mean amplitude of mEPSCs (7.0±0.4
pA v 6.9±0.4 pA), or their frequency distribution (Fig 1B and 1C), and these parameters were
also unchanged with further addition of 2-AP5 (mean amplitude 6.9±0.4pA). Likewise, decay
kinetics (control 2.22±0.32 ms) were unaltered, either by DCS alone (1.98±0.30 ms) or DCS
plus 2-AP5 (2.00±0.28 ms). Finally, neither mEPSC rise time nor baseline holding current was
altered in any situation (not shown). The lack of effect on kinetics is clearly shown by the aver-
aged mEPSCs shown in Fig 1C. DCS was also tested, at a lower concentration (100 μM; n = 6)
and again had no observable effect on mEPSC parameters (e.g. frequency 0.55±0.14 Hz in con-
trol and 0.53±0.19 Hz in DCS; other data not shown). These data confirm that glutamate
release was subject to tonic facilitation by preNMDAr, but, at the concentrations tested, the
partial agonist at the co-agonist binding site did not alter the effects of presynaptic receptor
activation.
Postsynaptic NMDAr mediated EPSCs in the EC
In the presence of AMPAr and GABAA receptor blockers, stimulation in the EC lateral to
the recording site elicited large, slowly decaying EPSCs in layer II neurones voltage clamped at +40
mV. These were abolished by 2-AP5, confirming that they were mediated by postNMDArs
(Fig 2A; n = 3). In addition, we also tested the effect of a high concentration (100 μM, determined
to be close to Emax) of the co-agonist site competitive antagonist, DCKA (Fig 2B; n = 3). This
also rapidly (<5 minutes) abolished the eNEPSC and confirmed that the co-agonist site of the
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postNMDAr was endogenously activated. We have previously examined other aspects of the phar-
macology of these eNEPSCs in entorhinal neurones and determined that they are likely to be
mediated by triheteromeric GluN1-GluN2A-GluN2B receptors [8]. The slow decay of eNEPSC in
other neurones has been shown to be bi-exponential [42] so we looked at this possibility in our
neurones. We found that the decay of the eNEPSC in layer II was only marginally better described
by biexponential decay kinetics, compared to monoexponential (Fig 2C). The decay time constants
were variable from neurone to neurone, particularly in the case of the slow phase of decay, where
the variability precluded any meaningful analysis, so in all studies we have assumed monoexpo-
nential decay, and compared the time taken to decline to 37% of peak amplitude.
Effects of D-serine at postsynaptic NMDArs
As noted above, we have previously shown that the co-agonist site of the preNMDAr is essen-
tially saturated (or very close to it) by endogenous D-serine [33]. However this did not appear
to be the case with the postNMDArs at EC synapses. Thus, exogenous application of the full
Fig 1. Effects of DCS on preNMDAr activity. A. The histograms show average normalised changes in frequency of mEPSCs with DCS and 2-AP5 in six
neurones. DCS was without effect whereas subsequent, cumulative addition of 2-AP5 reduced frequency by ~30%.B. The graphs show that the frequency
distribution of amplitudes of mEPSCs was unaltered by either antagonist. C. Average mEPSCs (n = 20) in one neurone showing the lack of change in
amplitude, rise or decay time with either drug. * P<0.05.
doi:10.1371/journal.pone.0133548.g001
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Fig 2. eNEPSCs in entorhinal neurones. The traces show voltage clamp recordings of eNEPSCs evoked in
layer II neurones in the medial EC. Each response is the average of at least 5 events.A. The addition of the
competitive antagonist, 2-AP5 abolished the eNEPSC.B. Likewise, application of the co-agonist site
antagonist, DCKA, was also able to abolish the eNEPSC. C. The decay of n averaged (n = 8) eNEPSC was
fitted with either a mono- (top) or bi-exponential function. Whilst R2 values show an excellent fit to a
biexponential decay, the mono-exponential fit was almost as good. The slow decay corresponding to tau-2 in
the biexponential fit was extremely variable from neurone to neurone, and precluded meaningful analysis.
Since the mono-exponential fit was excellent, in all further studies we assumed a mono-exponential decay.
doi:10.1371/journal.pone.0133548.g002
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agonist, D-serine (100 μM, n = 6), increased the mean peak amplitude of eNEPSCs, from
205.5±40.7 pA to 240.3±50.1 pA (P<0.05), a normalised increase of 15.9±4.0% (Fig 3). The
averaged responses from one study are shown in Fig 3A, where an increase in peak amplitude
is evident. In addition, D-serine prolonged the decay time of the eNEPSC from 381.3±105.0
ms to 450.5±112.3 ms (Fig 3B). Scaling the traces to match control and drug treated amplitudes
Fig 3. D-serine increases the amplitude and decay time of eNEPSC in EC neurones. A. The traces show
averaged eNEPSCs recorded in one neurone. A small, but clear, increase in amplitude by D-serine can be
seen when the responses are overlaid. When control and D-serine responses were scaled to the same
amplitude and overlaid, the prolongation of decay time is also apparent.B. The histograms show pooled
normalised data for eNEPSC amplitude and decay times in the presence of D-serine in six neurones. * P<0.05.
doi:10.1371/journal.pone.0133548.g003
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shows this prolongation of decay. In contrast, the rise time of the eNEPSC in control record-
ings was 36.2±8.0 ms, and this was unaltered (33.4±6.3 ms) in the presence of D-serine.
Effects of DCS at postsynaptic NMDArs
We next examined the effect of DCS (1–30 μM), a partial agonist at the co-agonist site, on
eNEPSCs in 6 neurones. In contrast to D-serine, DCS did not significantly alter the amplitude
of eNEPSCs at any concentration tested, with a small reduction of around 8% recorded at the
highest concentration (30 μM) tested (190.9±53.8 pA v 160.6±35.3 pA; Fig 4A and 4B). Likewise,
DCS had no effect on rise time (44.7±9.3 ms v 52.3±15.1 ms at 30 μM) of eNEPSCs. However,
the drug elicited a clear, concentration-dependent decrease in decay time (Fig 4A and 4C). This
Fig 4. DCS decreases the decay time of eNEPSCs. A. Averaged traces for one neurone are shown for control and in the presence of 30 μMDCS. The
overlaid traces clearly show that the amplitude of the eNEPSC is unaffected whereas the response decay is substantially accelerated. The graphs show
pooled data of cumulative concentration response curves for normalised data in six neurones for peak amplitude (B) and decay time (C). DCS failed to
significantly alter peak amplitude at any concentration, but produced a concentration-dependent decrease in eNEPSC decay time. * P<0.05; ** P<0.01.
doi:10.1371/journal.pone.0133548.g004
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was evident and significant even at low concentrations and the effect had an IC50 of 2.1 μM. The
maximum normalised reduction (at 30 μM) was to 68.1±5.9% of control, corresponding to a
decrease in mean decay time from 593.8±94.6 ms to 417.4±78.7 ms (P<0.01). The exemplar
experiment shown in Fig 4A illustrates the lack of change in amplitude, but overlay of the records
reveals the much faster decay in the presence of DCS.
To confirm that DCS was exerting its effects at the co-agonist site of the NMDAr we deter-
mined the effect of combined administration of the co-agonist site antagonist, DCKA. We
showed earlier that DCKA applied at 100μM abolished eNEPSC and this is illustrated again in
Fig 5A. In the presence of the antagonist, subsequent addition of 1 mMDCS (n = 3) had no
restorative effects on the eNEPSC (not shown). However, at higher concentrations, DCS res-
cued eNEPSC amplitude in a concentration dependent manner (Fig 5A and 5B; n = 8). As
before, eNEPSCs were essentially abolished by DCKA, but in its continued presence the
Fig 5. DCS rescues the abolition of the eNEPSC from inhibition by DCKA. A. Averaged synaptic responses from one neurone show abolition of the
eNEPSC by the co-agonist site antagonist, DCKA. Subsequent addition of DCS at 2 mM partly restored the response; increasing the partial agonist
concentration to 10 mM had a substantially greater restorative action. The histograms show the pooled normalised data for amplitude (B) and decay time (C)
in 8 neurones. The restoration of the eNEPSCwas partial, but it is noteworthy that the peak amplitude with DCKA plus DCS at 10 mMwas not significantly
different to that in control conditions. * P<0.05; ** P<0.01.
doi:10.1371/journal.pone.0133548.g005
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amplitude of the evoked response was increased by the partial agonist to reach a mean of 42.4
±7.3% of control at 2 mM and 73.9±13.6% of control with cumulative addition to 10 mM (Fig
5A and 5B). The decay time of the restored responses was 26.1±2.9% of control (pre-DCKA) at
2 mM and 34.4±1.8% at 10 mM. Although the responses were not apparently fully recovered
with 10 mM DCS, the eNEPSC at this concentration had a mean absolute amplitude of 188.4
±101.9 pA, which was not significantly different to that before DCKA (217.6±64.5 pA). Thus,
it seems likely that the effects of DCS alone on eNEPSCs were due to agonistic actions at the
postNMDAr co-agonist binding site.
The effects of DCS are reversed by D-serine
To confirm whether the effect of DCS on eNEPSC kinetics was due to its partial agonist action
we examined whether it was reversible by the full agonist. In these experiments a sub-maximal
concentration (10 μM, n = 7) of DCS was applied, followed cumulatively by a saturating
concentration of D-serine (1 mM). As noted above, DCS elicited a selective and significant
decrease in decay time (to 84.7±2.9% of control). Following the addition of D-serine (Fig 6A
and 6B), the reduction of eNEPSC decay time by DCS was reversed and increased to beyond
control levels (109.8±2.1%; P<0.05). In addition, as with D-serine alone (see above), eNEPSC
peak amplitude also increased (to 126.6±4.0%) in the presence of DCS plus D-serine (Fig 6A
and 6C). The mean values for eNEPSC in control, DCS (10 μM) alone and DCS (10 μM) plus
D-serine (1 mM) conditions were 391.0±26.6 ms, 333.0±28.7 ms and 430.1±31.5 ms, respec-
tively, for decay time, and 123.5±23.9 pA, 124.8±26.2 pA and 160.1±34.3 pA, respectively, for
amplitude.
These results indicated that the actions of DCS were indeed readily reversible by a full-ago-
nist and indicated that the effects of DCS are likely to be due to a partial agonism at the co-ago-
nist site.
Effects of ACBC at presynaptic NMDArs
DCS has a relatively high efficacy at the co-agonist binding site (~85%). To determine if
efficacy was an important determinant of the actions of DCS we tested the effects of a partial
agonist, ACBC, with a much lower efficacy (~40%; [43]) on both the preNMDAr and the post-
NMDAr (see below). ACBC (1 mM) decreased the frequency of mEPSCs to 69.4±3.9%, from
1.7±0.3 Hz in control conditions to 1.2±0.2 Hz in the presence of the drug (P<0.05; n = 5; Fig
7A). Concurrently, there was no change in frequency distribution of event amplitudes (Fig 7B)
or in mean amplitude (6.9±0.3 pA v 6.5±0.3 pA; see Fig 7C). Likewise, neither mEPSC rise
time (2.18±0.14 ms v 2.38±0.06 ms) nor decay time (2.85±0.26 ms v 3.27±0.23 ms) was altered
by ACBC, exemplified by the averaged (n = 20) events illustrated from one cell in Fig 7C.
Effects of ACBC at postsynaptic NMDArs
Like DCS, ACBC (0.03–1 mM, n = 7) substantially reduced the decay time of eNEPSCs (Fig 8A
and 8C). The effect of ACBC was approaching maximal at 1 mM, where we recorded a mean
reduction in eNEPSC decay time to 57.5±12.4% of control, with a change in mean from 524.8
±102.96 ms to 249.0±26.5 ms (P<0.05). In contrast to DCS, however, ACBC also reduced the
amplitude of eNEPSCs in a concentration-dependent manner (Fig 8A and 8B). The mean
change in peak amplitude at 1 mM was to 62.0±5.9% of control (239.4±47.3 pA v 141.5±21.2
pA; P<0.05). Rise time was unaltered (31.3±4.2 ms v 30.3±5.3 ms). The averaged responses
shown for one neurone in Fig 8A clearly show the change in amplitude, and when the
responses were amplitude scaled and superimposed the reduced decay time was also obvious.
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Fig 6. The effect of DCS on the eNEPSC is reversed by D-serine. A. Averaged responses in one neurone show little effect of DCS on amplitude but a
decrease in decay time. Cumulative addition of D-serine reverses the effect of DCS and increases both parameters to beyond control levels. B and C show
pooled data for the two parameters in 7 neurones. * P<0.05.
doi:10.1371/journal.pone.0133548.g006
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Discussion
DCS, the partial agonist at the NMDAr glycine/D-serine co-agonist binding site, had no detect-
able effect on the preNMDAr mediated tonic facilitation of glutamate release, whereas ACBC
did induce a decrease in mEPSC frequency. This is explicable in terms of differences in efficacy
of the two partial agonists. The preNMDAr is saturated, or very close to it, by endogenous D-
serine [33], so the binding of a low efficacy partial agonist, ACBC, will substantially compete
with the endogenous activation of the site. Since activation of the co-agonist site is obligatory
for the receptor activation, ACBC will have a similar effect to a competitive antagonist at the
site [33], and thereby reduce its activation by ambient glutamate. Thus, the tonic facilitation of
glutamate release mediated by the preNMDArs will be reduced and mEPSC frequency will
decline. DCS has a much higher efficacy (85%) than ACBC (40%), which means that its
Fig 7. ACBC reduces preNMDAr activity. A. The histogram shows normalised frequency data for 5 neurones and indicates a significant decrease in
frequency in the presence of the low-efficacy partial agonist. B. There was no concurrent change in frequency distribution of event amplitudes. C. The
averaged mEPSCs recorded in one neurone illustrate that peak amplitude, rise and decay times of events was unaltered by ACBC. * P<0.05
doi:10.1371/journal.pone.0133548.g007
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competition with endogenous D-serine will have a less deleterious effects on activation of the
preNMDArs. Even complete blockade of preNMDAr activation with a competitive glutamate
or co-agonist site antagonists only results in around 25–30% reduction in mEPSC frequency
[30,31,33] it is not surprising that DCS did not elicit an obvious reduction in release.
It could also be that subunit specificity of the two partial agonists iis involved in the differen-
tial presynaptic effects of DCS and ACBC. There is evidence that although the action of partial
agonists is due to binding at the co-agonist site on GluN1 subunits, efficacy may be determined
by the identity of the GluN2 subunit. This certainly seems to be the case for DCS, which has a
higher efficacy at GluN1-N2A (90%) than GluN1-N2B (65–70%) receptors [44]. PreNMDAr
are comprised predominantly of GluN1-N2B diheteromers [31], whereas the postNMDAr are
likely to be GluN1-N2A-N2B triheteromers [8]. Although the overall efficacy of ACBC is
around 40% [43], comparative data at GluN1-N2A v GluN1-N2B receptors is not available. It
is not inconceivable that it may have a much lower efficacy at the latter, and that this could
contribute to why it is able to observably diminish the tonic facilitation of release whereas DCS
does not.
In contrast to the preNMDAr, both partial agonists had significant effects on the response
to postNMDAr activation. Following release, glutamate in the synaptic cleft rapidly peaks at
approximately 1 mM, which is saturating at the postNMDAr, and is then cleared by reuptake
with a time constant of 1 ms, approximately [45]. Activation of an NMDAr induces a series of
openings that persist for a relatively long period due to a slow rate of glutamate unbinding.
Fig 8. ACBC decreases both the amplitude and the decay time of the postsynaptic eNEPSC. A.
Averaged responses for one neurone show a clear decrease in amplitude in the presence of ACBC, and the
overlaid traces also indicate a substantial decrease in decay time. Amplitude scaling shows the latter effect
very clearly.B and C. The graphs show pooled data for 7 neurones and illustrate the clear concentration-
dependency for effects of ACBC on both parameters. * P<0.05.
doi:10.1371/journal.pone.0133548.g008
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Glutamate rebinding does not occur [42,45] indicating that the time course of postNMDAr
currents is determined only by receptor gating between bound/open, bound/closed and
unbound/closed conformations [46]. Several gating mechanisms have been proposed for
NMDAr, commonly with at least 10 transitions, though these are not resolvable from macro-
scopic currents [47].
Partial agonists at ligand-gated ion channels characteristically elicit submaximal synaptic
currents even at full occupancy due to a decrease in receptor open probability that results from
a reduction in the efficiency of receptor gating. However, partial agonists of NMDAr also alter
the decay of NMDAr synaptic currents. These properties were extensively studied by Priestley
and Kemp [48] who demonstrated that relative to a full agonist, partial agonists at either the
glutamate or the co-agonist binding site decrease the decay time in an extent proportional to
their efficacy. The kinetic analysis of Kussius and Popescu [49] has indicated that inter-subunit
coupling is central to the NMDAr gating process and that partial agonism at either site occurs
through broad effects on multiple gating transitions which results in receptors spending more
time in bound/closed states. Therefore, the reason why eNEPSC peak amplitude and decay
time are both determined by agonist efficacy is likely to simply be that both are determined by
the efficiency of gating transitions. This model also accurately predicts that partial agonists
accelerate the decay of macroscopic currents resulting from prolonged glutamate application
by increasing the time spent in bound/closed states, which can also transition to long-lived
bound/closed (desensitized) states. More recently this kinetic scheme was seen to accurately
predict changes in the decay time of synaptic-like macroscopic currents resulting from struc-
tural changes in NMDAr induced by site-directed mutagenesis [50]. These studies suggest that
the faster decay time induced by NMDAr partial agonists in comparison to full agonists could
result from the same broad reductions in channel gating efficiency that underlie lower ampli-
tude responses, providing a simple explanation of why both are determined by efficacy.
In the current study we found that partial agonists at the co-agonist binding site had differ-
ent effects on parameters of eNEPSCs in native tissue that may be related to efficacy. DCS
selectively decreased the eNEPSC decay time without affecting peak amplitude whereas ACBC
decreased both decay time and peak amplitude. A parsimonious explanation for the lack of
effect of DCS on amplitude is that the postsynaptic receptor co-agonist site is bound by the
endogenous full agonist (probably D-serine; e.g. [51]), which has a higher efficacy than DCS,
but is present at a concentration such that the number of co-agonist sites bound and, hence,
endogenous activation of these sites is matched to the efficacy of DCS. Thus, when DCS is pres-
ent, the number of glutamate receptors activated in response to stimulation is essentially
unchanged but the macroscopic decay is altered.
In contrast, ACBC decreased both amplitude and decay time. This result would support
the above scheme, since the low efficacy (~40%) would mean that there was a mismatch
between efficacy and number of sites bound by the endogenous agonist, so that when the par-
tial agonist is added it would be predicted to reduce amplitude as well as the decay of the mac-
roscopic response. The increase in amplitude seen with exogenous D-serine, alone or in
combination with DCS, indicates that the co-agonist sites at these synapses are probably not
saturated. A saturating concentration of D-serine elicited an increase in amplitude of 15–25%,
which suggests a tonic activation of around 80–85%. This agrees with the efficacy of DCS
reported by Priestly and Kemp [48] who also studied eNEPSCs (although in rat neuronal cul-
tures). Subsequently, Dravid et al. [52] have showed that inter-subunit coupling is a key deter-
minant of the efficacy of DCS at different NMDAr subtypes observing that the efficacy of DCS
is 90% and 65% of maximum for GluN2A and GluN2B containing NMDA receptors, respec-
tively. Interestingly, we have previously demonstrated that the postNMDAr in the EC is likely
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to be a GluN1-N2A-N2B triheteromer [8]. In light of the findings of Dravid et al. [52] such a
heterodimer could be anticipated to have the efficacy calculated by Priestly and Kemp [48].
Our data showing that D-serine increases the decay time of eNEPSCs warrants further dis-
cussion in light of evidence that D-serine is the endogenous co-agonist at synaptic NMDAr
and, thus, already binding the receptor [51]. One explanation is the existence of partially-
liganded NMDAr openings, which could cause a submaximal decay in the control condition
but not when all sites are saturated by exogenous D-serine. Currently, partially-liganded
NMDAr openings are not thought to occur, though evidence for this idea is largely reliant on
expression systems, where regulation of the NMDA receptor may well be different. Our results
with DCKA and DCS, where DCS rescued eNEPSC amplitude to a greater extent than decay
time, may also support the existence of partially-liganded openings. A second explanation is
that D-serine is not the sole endogenous ligand of the co-agonist site. Indeed, evidence for D-
serine being the endogenous agonist at these receptors has been based on enzymatic depletion
of D-serine, and typically this only produces a partial reduction of synaptic NMDAr currents
[51]. Recently, endogenous activation of the postNMDAr coagonist site at hippocampal synap-
ses has been shown to be due to a combination of both glycine and D-serine [53]; these may
have different efficacies at the receptors in the EC, and this could account for a change in decay
time when receptors become bound primarily by the exogenously applied D-serine. A further
explanation is that D-serine is alters the contributions of different gating modes, which are
argued to underlie the shape the synaptic response (see [54]). However, it would still be diffi-
cult to offer a molecular basis for this without either partially-liganded gated openings or the
presence of another endogenous ligand.
An alternative explanation for the kinetic effects observed in this study is that the post-
NMDAr population present consists of two or more subtypes with varying decay time. A
change in kinetics could then occur through biased agonist effects on these subtypes, altering
the contributions of the subtypes to the overall response and, thus, the kinetics. Our results
with DCS, where a kinetic change was seen independent of a change in amplitude, are not con-
sistent with such a scheme and may argue against this explanation. However, for the results
with ACBC and D-serine this remains a plausible basis for the observed kinetic effects. Previ-
ous studies have indicated that the receptors underlying these responses are predominantly a
GluN1-N2A-N2B triheteromer [8], though without the use of knockout animals it is difficult
to conclusively rule out the possibility of multiple contributing receptor subtypes.
In contrast to effects at postNMDAr the lack of effect of DCS on frequency of mEPSCs indi-
cates that the partial agonist does not noticeably modulate preNMDAr function. The lack of
presynaptic effect could be related to the difference in subunit composition of the pre and post-
NMDAr, as noted above. On the other hand, the preNMDAr appear to be saturated by endoge-
nous D-serine [33], and even if this binding was completely replaced by DCS, we might expect
only around a 20% reduction in function (see [52,54]), which may not be experimentally
observable using the indirect reporting of receptor activity employed. This is supported by
results with ACBC, which has a much lower efficacy and did decrease mEPSC frequency. Acti-
vation of preNMDArs does not appear to be restricted by saturation of the glutamate binding
site, since blocking reuptake an increase the frequency of AMPAr mEPSCs [55]. Thus, extrapo-
lating back from the postsynaptic site to presynaptic, it is possible that an unchanged strength
of the current through the preNMDArs coupled with a moderately increased rate of closure in
the presence of DCS would not affect physiological utility, as re-opening could quickly occur,
and the tonic facilitatory effect would persist. With ACBC, both current strength and duration
would be reduced and, thus, the facilitation would be compromised. Thus depending on the
partial agonist, we may be able to differentially modulate the postsynaptic responses, but also
exert site-specific (pre v post) modulation of NMDAr-mediated transmission.
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In this study we have documented what is, superficially at least, a diminishing of post-
NMDAr-mediated transmission by partial agonists, be it a decrease in duration alone or in
both amplitude and duration; in the case of ACBC, we also report a decline in preNMDAr
facilitation of glutamate release. However, there is good evidence for cognitive enhancement
with DCS [16–25] and other co-agonist site partial agonists (e.g. GLYX-13 [56]). Cognitive
enhancement is generally targeted at elevating NMDAr function (e.g. [57]), so these results
would seem counterintuitive. However, in preliminary studies (Lench A.M. and Jones R.S.G.,
see S1 Fig) we have examined the effect of DCS on synchronized local field potential discharges
induced by block of GABA-inhibition in EC slices. The effects were complex but generally
characterised by increased inter and intra burst frequencies and amplitude of discharges with
low doses of DCS. We have not yet investigated the cellular basis of this in detail. However,
since DCS only increases the rate of closure of postNMDAr, at synapses where NMDAr-medi-
ated transmission is operative this could permit more rapid and frequent reopening concurrent
with a maintained peak amplitude of the signal. Conceptually, this could result in enhanced
synchrony. As synchronous network oscillatory activity is likely to underlie many forms of cog-
nitive processing [58–60], this could be a basis for cognitive enhancement. We are currently
investigating the cellular basis for the prosynchronous effects of DCS and other partial
agonists.
In this regard, it is interesting that low doses of DCS have been suggested to be a useful
adjunct or treatment to enhance cognitive processing in schizophrenics through enhancement
of NMDAmediated transmission [61,62]. Based originally on the observations that ketamine
and phencyclidine can induce a schizophrenia-like psychosis [63,64], the disorder is increas-
ingly being seen as involving a hypofunction of glutamatergic, particularly NMDAr-mediated,
transmission [65–67]. There is also increasing evidence that the cognitive disruption associated
with schizophrenia may involve alterations in the oscillatory activity (particularly gamma-
oscillations) in cortical networks (see [68]) and experimental studies have shown that NMDAr
dependent gamma rhythms [69] may be substantially decreased in the entorhinal cortex in
schizophrenia and related animal models [68,70]. Thus, it may be tempting to suggest that the
counterintuitive prosynchronous effect of DCS that we propose here may be a basis for restor-
ing normal oscillatory effects in the EC in schizophrenia and amelioration of cognitive deficits
associated with it.
It is also interesting to note that the non-competitive NMDAr antagonist, memantine,
mildly enhances cognitive processing in people with Alzheimer’s disease. This has been sug-
gested to involve an increase in signal to noise ratio in cortical excitatory transmission signal,
as a result of a reduction in NMDAr-mediated synaptic noise [71]. However, it is also the case
that memantine can enhance both theta and gamma oscillations in cortical networks and
reverse the deleterious effects on these rhythms induced by scopolamine [72]. We are not pro-
posing that memantine and DCS share a common cellular mechanism for their prosynchro-
nous effects, but it is clear that a negative effects on NMDAr mediated responses does not
preclude a role as a cognitive enhancer, and the temporal and spatial location of these effects in
network activity are likely to be determinant factors.
Supporting Information
S1 Fig. DCS enhances synchronised activity. Synchronised epileptiform bursts recorded
extracellularly as local field potentials, were elicited in entorhinal slices by perfusion with bicu-
culline methiodide (20 μM), picrotoxin (50 μM) and strychnine (2 μM) to block both GABAA
and glycine receptors. Application of DCS at 30 μM, increased burst frequency and increased
the duration of individual bursts as well as the frequency of discharges within the bursts. In
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some instances overall burst amplitude also increased. During washout, most parameters were
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